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Abstract: A fundamental aspect of living organisms is the accurate replication and maintenance of the
genome to ensure the high-fidelity inheritance of genetic information throughout many cell generations.
The molecular machinery that replicates the DNA – acting at the so-called replication fork – can be
frequently hindered by obstacles of both extracellular and intracellular origin, such as chemicals or UV
radiations on one hand, and collision with other processes occurring on the DNA, like gene transcription,
on the other. These challenges to DNA replication may lead to transient slowing or stalling of replication
forks: we refer to this as replication stress. Cells evolved a variety of mechanisms, which fall under the
definition of DNA damage response, that allow them to respond to replication stress. Failure of these
mechanisms can lead to DNA damage, and ultimately result in genomic instability, a major driving force
of cancer. On the other hand, many chemotherapeutic compounds are designed to induce replication
stress, exploiting the stringent requirement of highly replicating cancer cells to continuously replicate
their genome. Therefore, investigating the mechanisms underlying replication stress has emerged as a
key tool to both understand cancer onset, and to develop new therapeutic approaches. Our laboratory has
recently reported that, upon cellular exposure to genotoxic treatments, replication forks slow down and
are frequently remodeled to form a detectable four-way junction at the replication fork, called reversed
fork. This transient molecular transaction is considered to be a protective response, required to limit
fork breakage in conditions of replication stress. In addition, our laboratory reported that, besides
exogenous genotoxic treatments, fork reversal frequently occurs also in response to endogenous molecular
processes, which are known to undermine genomic integrity, such as the activation (overexpression or
amplification) of cellular proto-oncogenes. In the current thesis, I will present our efforts to understand
what triggers reversed fork formation in different contexts, and what are the factors that contribute to
its formation and stability. In the first part, I describe strategies we designed for the generation of new
inducible oncogene overexpression systems in different cellular models, with the aim of describing the
common or different molecular consequences downstream of aberrant activation of different oncogenes.
This part has led to date to inconclusive results, mainly due to technical difficulties in establishing an
efficient and robust oncogene induction system. The importance of this question (oncogene- induced
replication stress in cancer) demands additional future work, and fine-tuning of the techniques for a
time-controlled oncogene overexpression. In the second part, I successfully investigated the function
in replication fork remodeling of the proteins involved in homologous recombination, with particular
attention on the tumor suppressors RAD51 and BRCA2. Besides their established role in double strand
break repair via homologous recombination, RAD51 and BRCA2 were in fact known to protect stalled
replication forks from extensive nucleolytic degradation. Underlying the importance of this alternative
function for these genes, defects in fork protection lead to chromosomal instability, and contribute to the
sensitivity of BRCA2-defective tumors to chemotherapeutics by yet-unknown mechanisms. Our results
showed that RAD51 contributes to reverse fork formation. Moreover, we found that these structures are
progressively degraded in the absence of BRCA2 (loss-of-function mutations in BRCA2 are a common
feature of many cancer types). Inhibiting MRE11 nuclease activity or its recruitment to the reversed
fork can restore fork integrity and prevent chromosomal breakage. On the contrary, preventing fork
degradation by impairing the formation of reversed forks, leads to increased chromosomal breakage in
BRCA2-defective cells, being thus detrimental for genome stability. Collectively, our study reveals that
fork reversal has a crucial physiological relevance in protecting genome stability upon replication stress,
and that a complex interplay of HR factors co- operate to remodel and stabilize stalled DNA replication
forks.
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Zusammenfassung 
 
Eine fundamentale Eigenschaft des lebenden Organismus ist die akkurate Replikation des 
Genoms, um die exakte Weitergabe der genetischen Information über mehrere Zellteilungen zu 
gewährleisten. Die molekulare Maschinerie, die für die Replikation der DNA verantwortlich ist und 
an der sog. Replikationsgabel agiert, kann des Öfteren gestört werden durch sowohl 
extrazelluläre als auch intrazelluläre Hindernisse; dazu gehören zum einen Chemikalien oder UV-
Strahlung, zum anderen Kollisionen der Replikationsmaschinerie mit anderen zellulären 
Prozessen wie zum Beispiel der Transkription. Diese Komplikationen können zur Verlangsamung 
oder zum Pausieren der Replikationsgabel führen, ein Phänomen, das wir Replikationsstress 
nennen.  
Zellen haben eine Vielzahl von Mechanismen - definiert als Teil der sog. DNA Damage Response 
(DDR) - entwickelt, die ermöglichen, auf diesen Replikationsstress zu reagieren. Versagen dieser 
DDR Antwort kann zu DNA Schäden und letztendlich zu genomischer Instabilität führen, eine der 
treibenden Kräfte der Tumorgenese. Des Weiteren kann Replikationsstress gezielt durch 
Chemotherapeutika induziert werden, um die absolute Abhängigkeit der schnell replizierenden 
Zellen vom eigentlichen Replikationsprozess auszunutzen. Die Untersuchung der Mechanismen 
hinter dem Phänomen Replikationsstress hat sich deshalb als einer der Schlüsselansätze 
entwickelt, die Hintergründe der Krebsentstehung zu verstehen und neue therapeutische Ansätze 
zu entwickeln.  
Unser Labor hat vor kurzem gezeigt, dass die Behandlung von Zellen mit genotoxischen 
Substanzen zu einer Verlangsamung, sowie zu einer Umgestaltung der Replikationsgabeln hin zu 
einer Four-way-Junction, einer sog. Reversed Fork, führt. Diese transiente molekulare 
Transaktion wird als eine Schutzreaktion angesehen, die den Bruch der Replikationsgabel in 
Stresssituationen verhindern kann. Des Weiteren hat unser Labor gezeigt, dass diese 
Umgestaltung der Replikationsgabel nicht nur durch exogene genotoxische Einflüsse ausgelöst 
werden kann, sondern auch durch endogene molekulare Prozesse, die bekanntlich die 
genomische Integrität gefährden, wie z.B. die Aktivierung (Überexpression oder Amplifikation) 
von zellulären Proto-Onkogenen.   
In dieser Thesis präsentiere ich unsere Bemühungen zu verstehen, was die Umgestaltung der 
Replikationsgabel hin zur Reversed Fork in verschiedenen Kontexten auslöst und welches die 
Faktoren sind, die zu dieser Umgestaltung beitragen.  
Im ersten Teil beschreibe ich unsere Strategien, neue induzierbare Überexpressionsystemen für 
Onkogenen in verschiedenen zellulären Modellen zu etablieren, mit dem Ziel, die Konsequenzen 
der Aktivierung verschiedener Onkogene auf ihre Gemeinsamkeiten und Unterschiede zu 
vergleichen. Auf Grund von hauptsächlich technischen Schwierigkeiten in der Etablierung von 
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effizienten und robusten Induktionssystemen für Onkogene hat dieser Teil der Arbeit bis jetzt 
nicht zu eindeutigen Ergebnissen führen können. Die Wichtigkeit dieser Frage (Onkogen-
induzierter Replikationsstress in der Tumorgenese) bedarf einer Fortführung der Arbeit, mit 
besonderem Augenmerk auf dem Fine-tuning der Techniken, die eine zeitlich kontrollierbare 
Onkogen-Überexpression ermöglichen.  
Im zweiten Teil dieser Thesis konnte ich erfolgreich erarbeiten, welche Funktion Proteine aus der 
homologen Rekombination (HR), vor allem die Tumorsuppressoren RAD51 und BRCA2, in der 
Umgestaltung der Replikationsgabel erfüllen. Neben ihrer bereits etablierten Rolle in der 
Reparatur von Doppelstrangbrücken (DSB) via HR sind RAD51 und BRCA2 bekannt dafür, 
pausierende Replikationsgabeln vor umfangreichem nukleolytischen Abbau zu schützen. Die 
Bedeutung dieser alternativen Funktion dieser Proteine wird durch die Beobachtung untermauert, 
dass Defekte im Schutz der Replikationsgabel zu chromosomaler Instabilität führen und, über 
einen unbekannten Mechanismus, zur Sensitivität von BRCA2-defekten Tumoren gegenüber 
Chemotherapeutika beitragen.  
Unsere Ergebnisse zeigen, dass RAD51 an der Umgestaltung hin zur Reversed Fork beteiligt ist. 
Zudem haben wir erarbeitet, dass diese Strukturen in Abwesenheit von BRCA2 (BRCA2 
Mutationen, die zum Funktionsverlust führen, sind eine Gemeinsamkeit vieler Tumorarten) 
zunehmend abgebaut werden. Inhibierung der Nukleaseaktivität oder ihre Rekrutierung zur 
Reversed Fork kann die Integrität der Reversed Fork wiederherstellen und den chromosomalen 
Abbau verhindern. Wird der Abbau der Reversed Fork jedoch dadurch verhindert, dass die 
Umgestaltung der Replikationsgabel an sich blockiert ist, führt dies zu einer Häufung an 
chromosomalen Brüchen in BRCA2-defekten Zellen, die die genomische Stabilität gefährden. 
Zusammenfassend zeigt unsere Studie, dass die Umgestaltung der Replikationsgabel hin zur 
Reversed Fork eine bedeutende physiologische Rolle im Schutz der genomische Stabilität gegen 
Replikationsstress spielt, und dass ein komplexes Zusammenspiel von HR Faktoren benötigt 
wird, um die DNA Replikationsgabel umzugestalten und zu stabilisieren.  
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Summary 	  
A fundamental aspect of living organisms is the accurate replication and maintenance of the 
genome to ensure the high-fidelity inheritance of genetic information throughout many cell 
generations. The molecular machinery that replicates the DNA – acting at the so-called 
replication fork – can be frequently hindered by obstacles of both extracellular and intracellular 
origin, such as chemicals or UV radiations on one hand, and collision with other processes 
occurring on the DNA, like gene transcription, on the other. These challenges to DNA replication 
may lead to transient slowing or stalling of replication forks: we refer to this as replication stress. 
Cells evolved a variety of mechanisms, which fall under the definition of DNA damage response, 
that allow them to respond to replication stress. Failure of these mechanisms can lead to DNA 
damage, and ultimately result in genomic instability, a major driving force of cancer. On the other 
hand, many chemotherapeutic compounds are designed to induce replication stress, exploiting 
the stringent requirement of highly replicating cancer cells to continuously replicate their genome. 
Therefore, investigating the mechanisms underlying replication stress has emerged as a key tool 
to both understand cancer onset, and to develop new therapeutic approaches. 
Our laboratory has recently reported that, upon cellular exposure to genotoxic treatments, 
replication forks slow down and are frequently remodeled to form a detectable four-way junction 
at the replication fork, called reversed fork. This transient molecular transaction is considered to 
be a protective response, required to limit fork breakage in conditions of replication stress. In 
addition, our laboratory reported that, besides exogenous genotoxic treatments, fork reversal 
frequently occurs also in response to endogenous molecular processes, which are known to 
undermine genomic integrity, such as the activation (overexpression or amplification) of cellular 
proto-oncogenes.  
In the current thesis, I will present our efforts to understand what triggers reversed fork formation 
in different contexts, and what are the factors that contribute to its formation and stability. 
In the first part, I describe strategies we designed for the generation of new inducible oncogene 
overexpression systems in different cellular models, with the aim of describing the common or 
different molecular consequences downstream of aberrant activation of different oncogenes. This 
part has led to date to inconclusive results, mainly due to technical difficulties in establishing an 
efficient and robust oncogene induction system. The importance of this question (oncogene-
induced replication stress in cancer) demands additional future work, and fine-tuning of the 
techniques for a time-controlled oncogene overexpression.  
In the second part, I successfully investigated the function in replication fork remodeling of the 
proteins involved in homologous recombination, with particular attention on the tumor 
suppressors RAD51 and BRCA2. Besides their established role in double strand break repair via 
homologous recombination, RAD51 and BRCA2 were in fact known to protect stalled replication 
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forks from extensive nucleolytic degradation. Underlying the importance of this alternative 
function for these genes, defects in fork protection lead to chromosomal instability, and contribute 
to the sensitivity of BRCA2-defective tumors to chemotherapeutics by yet-unknown mechanisms. 
Our results showed that RAD51 contributes to reverse fork formation. Moreover, we found that 
these structures are progressively degraded in the absence of BRCA2 (loss-of-function mutations 
in BRCA2 are a common feature of many cancer types). Inhibiting MRE11 nuclease activity or its 
recruitment to the reversed fork can restore fork integrity and prevent chromosomal breakage. On 
the contrary, preventing fork degradation by impairing the formation of reversed forks, leads to 
increased chromosomal breakage in BRCA2-defective cells, being thus detrimental for genome 
stability. Collectively, our study reveals that fork reversal has a crucial physiological relevance in 
protecting genome stability upon replication stress, and that a complex interplay of HR factors co-
operate to remodel and stabilize stalled DNA replication forks.  	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1. Introduction 
 
The year 2015 was a very exciting year for the DNA repair field. Three scientists - Tomas Lindahl, 
Paul Modrich, and Aziz Sancar - were awarded the Nobel Prize in Chemistry for their pioneering 
studies on biochemical mechanisms in three of the major DNA repair pathways: base excision 
repair, mismatch repair and nucleotide excision repair, respectively. Moreover, the prestigious 
Albert Lasker Basic Medical Research Award honored Evelyn M. Witkin and Stephen J. Elledge 
for their discoveries concerning the DNA damage response, the mechanism that protects the 
genomes of all living organisms.  
The importance of these discoveries is emphasized by the fact that every human cell faces the 
daunting task of faithfully replicating the 6×109 nucleotides of genomic information which is stored 
into DNA molecules and packaged as chromatin. However, during the life of any organism, the 
genome is constantly challenged by exogenous and endogenous factors, which can damage 
DNA, generating approximately 104-106 lesions per day. Although genetic variation is important 
for evolution, the survival of the individual demands genetic stability.  
Mistakes in DNA replication introduce mutagenic DNA lesions or genomic instability, both of 
which have been linked to the onset of many diseases, including cancer. Cells respond to DNA 
lesions by activating the DNA damage checkpoint and by using different repair pathways. The 
coordinated action of both processes is known as the DNA damage response (DDR). 
 
1.1 DNA Replication in Eukaryotes 
 
Cellular proliferation is an essential process during the development and maintenance of an 
organism. Every cell division cycle requires the faithful duplication of the entire genome to assure 
high-fidelity transmission of genetic information from parental cell to daughter cells. Therefore, it 
is of prime importance that the genome is replicated once and only once and then segregated 
equally to the daughter cells. This mechanism, conserved from prokaryotes to eukaryotes, is 
known as semiconservative DNA replication and it is broken down into separate steps - initiation, 
elongation, and termination - that are carried out at distinct cell cycle stages and depend on a set 
of tightly regulated factors.  
 
DNA replication starts with the assembly of the replisome complex at genomic sites that are 
termed origins of replication (Ori)1. Origins are selected through binding of the origin recognition 
complex (ORC), which consists of six proteins ORC1-ORC6. During G1 phase, DNA replication 
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factor 1 (CDT1) and cell division cycle 6 (CDC6) proteins associate with Ori sites throughout the 
genome and facilitates the recruitment and loading of inactive double-hexameric mini-
chromosome maintenance 2–7 (MCM2-7) helicase. This results in the generation of a 
prereplication complex (pre-RC), which licenses the origin to fire in the following S phase. Many 
of the licensed origins will not fire during normal replication but provide backup origins in case of 
replication slow down or failure (Figure 1). 
At the onset of S phase, origin firing is brought about by the activity of cyclin-dependent kinase 2 
(CYCE-CDK2) and Dbf4/Drf1-dependent CDC7 kinase (DDK). DDK and CDKs phosphorylate 
several replication factors like CDC45, GINS and DNA polymerase ε (POL ε) to promote their 
loading on origins2. MCM2–7 double hexamer is also phosphorylated and together with CDC45 
and GINS form the active helicase (CMG) required for DNA unwinding. At this point, replication 
protein A (RPA) binds to single strand DNA (ssDNA) to stabilize the replication fork3. The 
topological tension generated by DNA helix unwinding is released by topoisomerase, which cuts 
either one (topoisomerase I, TOP1) or both (topoisomerase II, TOP2) strands of DNA double 
helix and re-anneals them. DNA polymerases must use a 3'-OH of a nucleoside as a primer and 
synthesize DNA in the 5'-3' direction. Since DNA consists of antiparallel strands, they are copied 
differently, with one strand synthesized continuously (leading strand) and the opposite strand 
copied in short segments (Okazaki fragments), which are joined together postreplicatively 
(lagging strand). Both the leading strand and every Okazaki fragment on the lagging strand are 
primed by a short RNA primer synthesized de novo by polymerase α-primase. The latter is 
replaced by DNA polymerase δ and ε to continue synthesizing the complementary strand of DNA 
in the lagging strand and the leading strand respectively. Replication factor C (RFC) and 
proliferating cell nuclear antigen (PCNA) regulate the switch between polymerase α-primase and 
Figure 1 Schematic representation of 
replication initiation, origin firing and 
elongation. Origin recognition and formation 
of pre-RC complex implicates binding of 
ORC to DNA and subsequent loading of 
MCM2-7 helicase complex via the action by 
Cdc6 and CDT1. CDK and DDK-dependent 
activation of pre-RC components leads to 
Cdc45 loading, resulting in origin firing. 
Helicases and associated proteins unwind 
DNA. ORC, Cdc6 and Cdt1 dissociate from 
DNA and the chain elongation starts. 
Modified from (Claus Storgaard Sørensen, 
2011). 
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replicative polymerases δ and ɛ and act as loading platform for DNA ligase I and flap 
endonuclease I (FEN-1) for maturation of Okazaki fragments4. 
Little is known about termination process of DNA synthesis. Since multiple origins are fired on 
each chromosome, termination of replication occurs when two opposing replication forks meet 
and the nascent DNA from the two forks is ligated together. This process involves completion of 
DNA synthesis, decatenation of daughter molecules and replisome unloading. Resolution of steric 
hindrances of the merging forks and topological constrains requires TOPII5. The mechanism of 
replisome disassembly is still under investigation. Recent studies have identified factors that 
regulate unloading of MCM2-7: MCM-BP6 or p97/VCP/CDC48 protein remodeler7,8. 
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1.2. Replication stress and DDR 
 
Even before the discovery of the DNA structure in 1953, researchers have showed that 
exogenous agents, such as irradiations or chemicals can cause genetic alterations that might 
lead to cancer9. Many years after DNA structure has been defined, researchers discovered that 
DNA could be damaged also from endogenous sources during normal metabolism like reactive 
oxygen species (ROS)10 or stochastic misincorporation of nucleotides. In addition to these 
lesions, intrinsic replication-fork obstacles such as unusual DNA structures or transcription 
complex can interfere with the progression of DNA replication, thereby causing the forks to slow 
down or stall. This phenomenon is defined as replication stress and is among the primary cause 
of genome instability and tumorigenesis. 
To preserve genome integrity, cells have evolved sophisticated mechanisms, collectively known 
as DDR11. Via these mechanisms cells can detect DNA lesions and promote cell cycle arrest. 
This allows the cells to either repair or bypass the damage. When the repair of the lesion is not 
possible or is incomplete, DDR triggers senescence or programmed cell death. 
In 2005, work from Halazonetis12 and Bartek13 groups showed that most cancers, in their early 
state, display varying degrees of replication stress, accompanied by activation and increased 
expression of various DDR components. A failure in DDR activation, or mutations in DDR factors, 
causes tumor progression. These findings established replication stress as a causative event in 
cancer and the DDR as an important barrier against tumor formation and progression. 
It is important to note that, even though replication stress can be a prominent cause of 
tumorigenesis, it also has the potential of being a target for cancer therapy. In fact, when 
replication stress occurs at low to mild levels, it can fuel tumorigenesis. Conversely, current 
cancer chemotherapies are meant to induce high levels of replicative stress, which causes cancer 
cell death through mitotic catastrophe, thereby counteracting cancer progression. 
 
1.2.1 Sources of replication stress 
 
Faithfull DNA replication requires processive and stable replication forks, which however 
encounter many obstacles on their path14. Template unwinding by helicases can be impaired by 
topological constraints, such as DNA secondary structures like hairpins or G-quadruplexes, intra-
strand crosslinks or tightly DNA bound proteins. Progression of DNA polymerases can be directly 
impaired by unrepaired DNA lesions (nicks and gaps, misincorporated ribonucleotides, DSB or 
bulky base-adducts) or by shortage of replication machinery components and nucleotides. 
Additionally, during S phase DNA polymerases compete for the same template with other 
enzymes like RNA polymerases. Although cells have evolved a spatio-temporal segregation to 
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minimize replication-transcription conflict, certain conditions like RNA polymerase blockage or 
unresolved R-loops can cause these two machineries to collide, thus inducing replication stress15. 
Finally, overexpression or constitutive activation of oncogenes increases origin firing, which 
depletes nucleotide pools and decreases replication speed, resulting in replication fork collapse. 
As described in more details below, by perturbing the timing of replication initiation and 
progression, oncogenes can disrupt spatio-temporal separation that normally prevents collision 
between transcription and replication (Figure 2). 
 
Oncogene activation. Many oncogenes have been reported to cause replication stress when 
activated12,13,16. In pre-neoplastic lesions, the DDR signaling is constitutively activated, providing 
a natural barrier that delays or prevents malignant transformations through the induction of 
senescence or apoptosis. Interestingly, analogous constitutive DDR activation can be 
recapitulated in vitro by overexpression of various oncogenes such as CYCE, E2F1 and cell 
division cycle 25 homolog A (CDC25A), linking oncogene-induced replication stress and 
tumorigenesis13,17,18. The DDR activation has been attributed to unspecified alterations of bulk 
DNA replication and DSB accumulation, particularly in regions intrinsically difficult to replicate19,20. 
Despite the accumulated evidence indicating that oncogene-induced replication stress is a major 
driving force in the early stages of tumorigenesis, its molecular basis is still largely unclear. A 
widespread consequence of oncogene activation is the overriding of cell-cycle checkpoints before 
the S phase, thereby forcing cell proliferation. Two opposite mechanisms have been proposed: 
insufficient or excessive usage of replication origins21. Overexpression of CYCE can impair 
MCM2-7 binding to the chromatin resulting in a reduced number of replication origins that are 
licensed during G1. Consequently, replication stress increases in S-phase due to the shortage of 
back-up origins to cope with stalled forks22. In contrast, the overexpression of certain oncogenes 
(c-MYC, H-RAS, CYCE, CYCD2) can have the opposite effect and generally increase the origin 
Figure 2 Sources of replication stress. Schematic representation of obstacles that can impair replication 
fork progression and induce replication stess. Modified from (Zeman and Cimprich, 2014). 	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firing or origin reactivation within the same cycle of replication by deregulating CDK activity or 
gene expression of origin licensing factors like CDT1 or CDC6. In particular c-MYC has been 
found to transcriptionally regulate the expression of cell-cycle-related genes and to directly 
interact with components of pre-RC at DNA replication origins. Increase in origin firing can drive 
an unscheduled proliferative burst and/or re-replication of the DNA that result in replication slow 
down and stalling, due to increased replication-transcription collisions and/or the depletion of 
nucleotides pool23,24. This is supported by the fact that supplementing cancer cells with 
exogenous nucleotides or inhibiting transcription helps preventing genomic instability. However, it 
remains unclear how these perturbations at the replication forks results in DSB formation that 
promotes chromosomal rearrangements. 
In our laboratory, we studied the molecular basis of the oncogene-induced replication stress and 
the DNA breakage, focusing on the conditional overexpression of two well-characterized 
oncogenes: i) CYCE, the regulator of replication initiation in complex with CDK2, and ii) CDC25A, 
a phosphatase involved in DNA damage response and activation of CDKs throughout the cell 
cycle25. Both oncogenes substantially slowed down replication fork progression as reported 
earlier, and surprisingly also induced the accumulation of reversed forks (four-way junction 
structures discussed in detail in section early after their activation). Despite similar rapid effects 
on the replication process, the two oncogenes induced DNA damage with different kinetics and 
penetrance. CYCE-expressing cells showed slow and mild accumulation of DSBs because they 
could transiently delay mitotic entry and resolve the unusual replication structures. Cells 
overexpressing CDC25A, on the other hand, entered mitosis prematurely and rapidly 
accumulated massive DNA breakage and activated full DDR due to unscheduled processing of 
reversed forks by MUS81.  
In another study in our laboratory, we deregulated origin licensing by early mitotic inhibitor 1 
(EMI1) depletion to induce and study DNA re-replication, a specific alteration of DNA replication 
frequently found upon oncogene activation26. By directly visualizing replication intermediates at 
electron microscopy (EM), we observed DDR-blind accumulation of ssDNA during the first 
replication round. Uncontrolled reactivation of replication origins, in this context, triggered 
chromosomal breakage when re-replication forks approached discontinuities on the template.  
It is currently unknown whether the molecular events described for CYCE and CDC25A can be 
proposed as a general model for other oncogenes that induce replication stress through different 
mechanism of action and can be correlated with their diverse tumorigenic potential, in particular 
H-RAS and c-MYC. H-RAS is a G protein whose activity is regulated by the binding of guanine 
nucleotides. Following activation by upstream receptor tyrosine kinases, RAS proteins exchange 
GDP with GTP and activate several effector pathways involved in cell cycle regulation and 
transcription, the best characterized of which are rapidly accelerated ribrosarcoma (RAF), 
Phosphoinositid-3-Kinasen (PI3K) and RAL guanine nucleotide exchange factors (RAL-GEFs). 
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Cancer-associated mutations in H-RAS genes generally act by locking the RAS proteins in the 
GTP-bound constitutively active state, and such mutations are frequently found in human 
cancers27,28. C-MYC is a transcription factor of the helix-loop-helix/leucine zipper class of proteins 
that heterodimerize with myc-associated factor X (MAX) protein and bind specific DNA 
sequences known as E-boxes29. MYC regulates a complex biological program by transcriptionally 
activating and repressing its numerous target genes. As such, MYC is a master regulator of key 
cellular functions, including cell cycle entry, DNA replication, ribosome biogenesis, and 
metabolism30,31. Additionally, c-MYC has also a non-transcriptional control of DNA replication by 
interacting with pre-replicative complex32. The MYC oncogene was first implicated in Burkitt's 
lymphoma33 and later showed to be mutated in nearly all types of human cancers34. 
 
1.2.2 Cellular response to replication stress 
 
DDR is a complex arsenal of interacting pathways that, similarly to developmental molecular 
cascades, has signal sensors, transducers, and effectors11. 
Contrary to the signaling pathways that are triggered by ligands of receptor kinases, the DDR is 
activated by unusual DNA structures formed in response to DNA damage or DNA replication 
stress. The main regulators of the DDR belong to the family of the phosphatidylinositol 3-kinase-
like protein kinase (PIKK), which includes, in particular, ataxia-telangiectasia mutated (ATM), and 
ATM-and-RAD3-related (ATR). ATM triggers a response to various stimuli, but most prominently 
to DNA double strand breaks (DSBs). In contrast, ATR is activated upon ssDNA and is therefore 
the major kinase mediating the response to replication stress14. 
Impediments on the DNA that specifically stall the DNA polymerase lead to physical uncoupling of 
the polymerase from the replicative helicase, which continues unwinding and generates extended 
ssDNA at the replication fork. ssDNA is also generated during DNA repair, as a of controlled 
nuclease-dependent resection of DSBs during the S- and G2-phase. In both cases, the ssDNA is 
readily coated by RPA, which recruits and activates ATR through the action of its associated 
factor ATR-interacting protein (ATRIP). The importance of this mechanism is emphasized by the 
fact that loss of ATR and other components of the pathway is embryonically lethal, while 
hypomorphic mutations cause developmental disorders, like ATR-Seckel syndrome35. Once 
activated, ATR amplifies the DNA damage signal by phosphorylating several repair and 
checkpoint proteins at Ser/Thr-Glu motifs. Among the latter are checkpoint kinase 1 (CHK1), 
histone H2AX and tumor protein p53. CHK1 himself triggers a second wave of phosphorylation 
events aiming to promote resolution of the stress and to ensure the completion of DNA synthesis. 
Locally, ATR-CHK1-mediated signaling regulates different components of the replisome to slow 
DNA synthesis, stabilize and restart stalled forks, and suppress recombination. Globally, the 
ATR-CHK1 pathway inhibits cell-cycle progression and prevents late origin firing36. 
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ATM is activated upon DSB formation. ATM mutations lead to a neurodegenerative and cancer-
prone disorder called ataxia telangiectasia37. Its effector kinase is checkpoint kinase 2 (CHK2), 
which similarly to CHK1 phosphorylates proteins that regulate cell cycle and DNA damage repair. 
Mild cancer-relevant replication stress has been largely uncoupled from DSB formation25,26,38–40, 
therefore ATM is considered to have a less prominent role during replication. Nevertheless, ATM 
pathway also slows DNA replication in response to DNA damage, stabilizes and repairs damaged 
replication forks11.  
It must be noted that not all sources of replication stress lead to long ssDNA formation. Along the 
same line, replication stress is not necessarily associated with detectable checkpoint activation. 
There is not yet a well-defined set of cellular markers that characterize all types of replication 
stress and the outcomes in the cell are not entirely understood. As a result the definition of 
replication stress is still evolving14.  
 
Stabilization of the stalled replication forks. In eukaryotic cells, replication fork breakdown 
constitutes a major source of genomic instability and it is therefore important to preserve its 
integrity, especially during replication stalling. Immunoprecipitation experiments in yeast showed 
that ATR-CHK1 pathway stabilizes the replisome at stalled forks41, but this view has been later 
challenged by biochemical studies showing that replisome stability upon fork stalling is 
independent from checkpoint kinases42. One way to interpret these conflicting data is to postulate 
that the replisome does not disassemble, but moves away from the site of DNA synthesis, and 
that the role of ATR-CHK1 pathway is to control exonuclease and endonuclease activities that 
potentially process unprotected DNA at stalled forks.  
In addition to checkpoint factors, also homologous recombination (HR) proteins appear to be 
involved in the protection of arrested forks. Studies in vertebrates have shown that breast cancer 
1 and 2 (BRCA1/2) and Fanconi Anemia (FA) proteins stabilize RAD51 filaments at stalled forks, 
thereby protecting nascent strands from excessive Meiotic recombination 11 (MRE11)-dependent 
degradation39,40,43. This process will be extensively discussed in the section 1.3.3.  
 
Mechanisms of replication fork processing and restart. Several cellular mechanism have 
been described to explain the processing and the restart of stalled replication forks and their 
relevance vary depending on the cause of fork arrest and genetic background44 (Figure 3):  
(i) unreplicated regions caused by the stalling of a fork can be synthesized by the neighboring 
active replication fork; (ii) activation of the dormant origins in the proximity of stalled forks further 
promotes replication completion; (iii) re-priming DNA synthesis downstream of an obstacle and 
filling the ssDNA gap left behind; (iv) activating the DDT pathway that permits bypassing the 
lesion by recruiting specialized DNA polymerases (also known as ‘translesion DNA synthesis’) or 
by using the sister chromatid as alternative template via recombination-based and post-replicative 
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repair mechanisms (template switch); (vi) structure-specific endonucleases such as MUS81 and 
Essential Meiotic Structure-Specific Endonuclease 1 (EME1) can generate one-ended DSB and 
the DNA synthesis is then reinitiated by a HR variant called break induced replication (BIR); (vii) 
the replication fork can be remodeled to form a more stable four-way junction structure called 
reversed fork. 
Despite the relative importance of each of the above-mentioned pathways, investigating the 
molecular events underlying the replication fork reversal constitutes the founding rationale of the 
work presented in this thesis.	  
 
1.2.3 Replication fork reversal 
 
Besides replication slowdown, ssDNA gaps and γH2AX foci, there is a peculiar feature that 
accompanies replication stress at the DNA level: replication fork reversal45.  
Replication fork reversal is defined as the conversion of the replication fork into a stable paused 
four-way junction structure by the unwinding of newly synthesized strands from their template, the 
re-annealing of the parental strands and the annealing of the newly synthesized strands to each 
Figure 3 Mechanisms of replication fork processing and restart. (A-B) Replication-fork uncoupling 
through functional dissociation of helicase from polymerase leads to ssDNA accumulation at the fork. 
Alternatively, ssDNA may result from nuclease-mediated resection of stalled forks. ssDNA is rapidly coated 
by RPA (yellow spheres). (C) DNA synthesis can be re-primed (green arrow) and reinitiated ahead of the 
lesion. The resulting gaps are repaired post replicatively by a recombination-based mechanism or by 
specific translesion synthesis (TLS) polymerases. (D) RAD51 (orange spheres) binds to ssDNA at stalled 
forks and drives fork reversal. (E) Fork reversal prevents collisions between the moving fork and the lesion, 
allowing the time for the repair of the lesion. (F) Prolonged fork stalling promotes fork cleavage by structure-
specific endonucleases. Broken forks resume DNA synthesis by the error-prone BIR mechanism. Modified 
from (Berti and Vindigni, 2016).  
A B 
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other, to form a fourth regressed arm at the fork elongation point (Figure 4). This DNA transaction 
structure was first proposed in 197646, and for a long time it was found only in prokaryotes and 
specific yeast mutants47.  
 
First piece of evidence that supported the physiological relevance of the replication fork reversal 
during replication stress in human cells arose from studies in our lab using TOP1 inhibitors like 
camptothecin (CPT)38. Here, it was shown that, upon TOP1 inhibition, replication forks undergo 
rapid slowdown and frequent reversal to prevent the collision with the damaged DNA ahead of 
the fork, thereby limiting DSB formation. Further studies identified replication fork reversal in 
response to oncogene activation25, deregulated origin licensing26, secondary DNA structures48 
and to a full set of chemotherapeutic treatments49, suggesting fork remodeling in eukaryotes as a 
general physiological strategy to cope with different types of replication stress. Poly (ADP-ribose) 
polymerases (PARP) inhibition, one of the most promising chemotherapy treatment for breast 
cancer and ovarian cancer50,51, was the first condition found to impair effective fork reversal38, 
suggesting that the molecular determinants orchestrating fork remodeling may be novel attractive 
target for combinatorial cancer chemotherapy. 
Extensive effort from our laboratory, in collaboration with other groups, allowed the identification 
of an initial set of human factors involved in the formation, processing or restart of reversed 
replication forks. Although many DNA translocases, like SWI/SNF-related matrix-associated 
actin-dependent regulator of chromatin subfamily A-like protein 1 (SMARCAL)52 or helicase like 
transcription factor (HLTF)53, can drive fork reversal in vitro, a clear in vivo function has been so 
far confirmed by direct visualization of reversed forks only for the helicases F-box DNA helicase 1 
(FBH1)54 and zinc finger RANBP2-Type containing 3 (ZRANB3)55. 
Moreover, increasing evidence suggests that several HR factors possess a DSB repair-
independent role in replication stress response. In particular, the recombinase RAD51 is required 
to drive fork reversal in response to mild genotoxic treatments49. Thorough analysis of the 
replication intermediates isolated from challenged cells revealed accumulation of extended 
ssDNA at the fork junctions, reflecting uncoupling between DNA polymerase and the helicases 
involved at the fork. Importantly, there is a marked correlation between the frequency of fork 
Figure 4 The process of replication fork 
reversal. During fork reversal, the three-
way junction at the replication fork is 
converted into a four-way junction and is 
backtracked along the replicating DNA 
molecule. This includes the unwinding of 
newly synthesized strands, annealing of 
the parental strands and annealing of the 
newly synthesized strands. Modified from 
(Neelsen and Lopes, 2015). 
	   15 
reversal and the extent of ssDNA regions at the fork49. By analogy to DSB repair (see Chapter 
3.2), the recombinase RAD51 is proposed to be recruited to the extended ssDNA where, by 
recombinational strand exchange, contributes to the conversion of uncoupled forks into reversed 
forks. Intriguingly, this appears to be true not only for treated cancer and primary cell lines, but 
also for unperturbed mouse embryonic cells56. In these cells fork reversal is very frequent, and it 
is possibly required for coping with high levels of replication stress caused by fast cell cycle 
progression. Also in this context RAD51 is required for fork remodeling and its loss leads to 
marked chromosomal breakage. These findings implicate that such fork remodeling function, 
rather than its well-known role in DSB-repair, may represent the essential role of RAD51 during 
early embryogenesis. We speculate that this might possibly be the case for other HR factors.  
However, our mechanistic understanding of the role of HR factors in replication fork remodeling is 
still very limited. In principle, HR-mediated transactions can be envisaged in both steps of fork 
remodeling, fork reversal and fork restart45 (Figure 5 a).  
	  
Figure 5 Role of homologous recombination factors in replication fork remodelling. (a) The top panel 
shows that following replication stress and fork uncoupling, RAD51 binds to extended ssDNA regions at the 
fork. Assisted by ZRNB3 and FBH1, RAD51 mediates fork reversal. Once reversed fork is formed, the 
regressed arm is processed by the controlled action of DNA2 and WRN to recruit RAD51 (bottom panel), 
promote homology-driven invasion of the re-annealed template strands and drive recombination-mediated 
fork restart. (b) RECQ1 binds to reversed fork and primes the restart through branch migration mechanism. 
PARP1 stabilizes reversed forks by transiently inhibiting RECQ1. When the DNA is repaired and replication 
stress released, PARP is inactivated. RECQ1 binding at the reversed forks inhibits the fork restart via 
DNA2/WRN mechanism. The resected regressed arm may recruit and alternative branch migration factors, 
or promotes homologous recombination-dependent restart. Modified from (Neelsen and Lopes, 2015). 
 
A 
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While strand exchange events are indeed required to drive fork reversal, controlled resection of 
the regressed arm – remarkably similar to a DSB - may also prime RAD51-dependent homology 
search and strand exchange reactions with the duplex ahead of the fork and provide one of the 
mechanisms to restart reversed forks once the stress is released. In condition of RecQ-like 1 
(RECQ1) loss, the nucleolytic resection of the regressed arm to form a 3' overhang is mediated 
by the combined activity of Werner (WRN) and DNA replication ATP-dependent helicase-like 
homolog (DNA2). Here, the role of DNA2 is independent of the DSB resection activities of 
proteins such as (CTBP interactin protein) CtIP, MRE11 or exonuclease 1 (EXO1)57. Further 
mechanisms of regressed arm processing in pathological conditions, like upon BRCA2 mutation, 
are extensively discussed in the section 1.3.3. Resection of the regressed arm in physiological 
conditions is still largely unknown.  
Several important questions are still open: which co-factor assist RAD51 loading at stalled forks 
upon replication stress? Is loading of RAD51 different during formation and restart of reversed 
forks? What is the role of HR factors that are involved in maintaining the stability of the stalled 
forks, like BRCA1 and BRCA2, in fork remodeling? These questions need to be tackled to fully 
understand the events underlying fork remodeling, especially considering that many of these 
factors involved are tumor suppressor genes often mutated in human syndromes displaying 
genomic instability.  
Besides a recombination-mediated fork restart, a branch migration-assisted reestablishment of a 
functional replication fork has been described. Here, the human RECQ1 helicase drives the 
restart of reversed forks, and its activity is strictly limited by PARP1-mediated ADP ribosylation, 
until the damage is repaired58 (Figure 5 b)  
When the damage persists and the fork fails to resume, the reversed forks might represent a 
preferred substrate for structure-specific nucleases. Indeed, MUS81 is linked to chromosomal 
breakage after prolonged fork stalling, and more recently it was shown to cleave reversed forks 
upon oncogene-induced replication stress25,59. Similarly, SLX4 targets replication forks regressed 
by SMARCAL1 following nucleotide depletion60. Normally, these nucleases act in late-S or G2 
phases of cell cycle, thus their activation could represent the last attempt to complete the 
replication before the cell division.  
How cells choose between these apparently redundant mechanisms of replication fork processing 
and restart is still unknown. Moreover, mechanistic understanding of the turnover and position of 
the replisome components and specific chromatin marks during fork reversal is currently very 
limited. 
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1.3. BRCA2: from DNA damage repair to replication fork protection 
 
BRCA1 and BRCA2 are tumor suppressors that participate in a variety of DDR and genome 
stability processes - in particular DSBs repair, interstrand DNA crosslink repair via the FA 
pathway, DNA damage checkpoint activation and protection of DNA replication forks upon 
replication stress61.  
BRCA1 and BRCA2 were identified as genes mutated in hereditary breast and ovarian cancer in 
199462 and 199563, respectively. The average cumulative risks by age 70 years for BRCA1 
carriers is estimated to be 60% for breast cancer and 59% for ovarian cancer. For BRCA2 
carriers, the corresponding risks are 55% for breast cancer, 16.5% for ovarian cancer64. The 
numbers are frighteningly high. 
BRCA-mutated tumors are defective in DNA repair and display genetic instability. This opens a 
therapeutic window by making tumor cells exquisitely sensitive to DNA damaging drugs, like 
crosslinking agents (e.g.cisplatin) and PARP inhibitors65. In the latter case it is exploited the 
genetic concept of synthetic lethality66. It describes the situation in which defects in either one of 
two genes individually is compatible with life, but simultaneous loss of both genes results in cell 
death. Inhibition of PARP1 has been shown to be synthetically lethal with deficiency of BRCA 
genes. PARP1 is involved in various DNA repair pathways, including ssDNA repair pathway67. It 
was proposed that PARP inhibitors caused an increase of single-strand breaks, which are 
converted to DSBs during replication. Replication-associated DSBs are irreparable in the 
absence of HR, and are therefore toxic in the context of BRCA deficiency. Cells carrying BRCA 
mutations are up to 1,000 times more sensitive to PARP inhibitors than wild-type cells, therefore 
PARP inhibitors such as Olaparib continue to be among the most promising and attractive 
treatment options for BRCA-deficient tumors50,51,66. 
Given the malleable nature of cancer cells, unfortunately even tumors carrying mutations in 
BRCA genes acquire resistance. Understanding the fine mechanistic detail of BRCA functions 
and mechanisms that drive chemoresistance in mutant tumors will open new opportunities for 
clinical applications. 
The work presented in this thesis is focused on the role of the BRCA2 protein. 
 
1.3.1 BRCA2 functional domains 
 
BRCA2 is a large protein of 384 kDa, composed of 27 exons and exist predominantly as a 
homodimer 61. Several key domains have been identified in BRCA2 in the past two decades 
(Figure 6). Through these domains, BRCA2 forms complexes with several proteins, implicating 
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BRCA2 in multiple cellular functions such as DNA repair, DNA replication, telomere homeostasis 
and cell cycle progression. N-terminus interaction with partner and localizer of BRCA2 (PALB2) 
connects BRCA2 to BRCA1: the formation of this tripartite complex is critical for its role in HR 
(see paragraph 1.3.2). The central part contains eight conserved BRC repeats, required for 
RAD51 binding. Interactions between the BRC repeats and RAD51 occur through the ATPase 
core of RAD51, and these interactions maintain RAD51 in a form that is mostly monomeric. 
Downstream of the BRC repeats there is a DNA-binding domain (DBD), which consists of a 
helical domain (H), three oligonucleotide binding (OB) folds, and a tower domain (T). Their 
combined action facilitates BRCA2 binding to both single-stranded DNA and double-stranded 
DNA. The C-terminal part of BRCA2 contains a nuclear localization signal (NLS) critical for its 
cellular localization and a TR2 domain, an additional RAD51 binding site. This binding is crucial in 
response to DNA damage, when RAD51 is delivered to sites of DNA damage and interaction 
between the C-terminal region of BRCA2 and RAD51 serve to stabilize the filaments on ssDNA. 
Of note, BRCA2 is post-translationally modified by CDK and other DNA Damage dependent 
kinases (ATM/ATR, CHK1/2) in a cell cycle-dependent fashion. Among the multiple 
phosphorylation sites there is S3291, whose phosphorylation abrogates BRCA2-RAD51 
interaction at G2/M68. 
 
 
 
 
 
 
1.3.2 BRCA2 is a key factor in DSB repair by HR 
 
Among DNA types of damage, DSBs are the most menacing lesions for a cell. If left unrepaired, 
they may cause mutations or broader chromosomal aberrations, both of which are hallmarks of 
cancer11.  
DSB are induced by DNA-damaging agents such as irradiation (IR) and DNA topoisomerase 
inhibitors (e.g. CPT), or arise spontaneously due to endogenously generated reactive oxygen 
species or collapsing DNA replication fork. Although most DSBs are not desirable, cells possess 
	  
Figure 6 Structure of BRCA2. The N terminus of BRCA2 mediates PALB2 binding. Its central BRC repeats 
and C-terminal domain interact with RAD51. The BRCA2 DNA binding domain contains oligonucleotide 
binding (OB) domain, helical domain (H) and a tower domain (T) and mediates BRCA2 interaction with 
ssDNA and dsDNA. This region also binds deleted in split-hand/split-foot syndrome (DSS1). CDK 
phosphorylation site at S3291 is indicated.  
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specific enzymes that can introduce breaks in important physiological processes, like meiotic 
recombination or maturation of the immune system (e.g. the class-switch and V(D)J 
recombination in B- and T-lymphocytes). 
In higher eukaryotes, classical nonhomologous end joining (c-NHEJ) and HR are the main DSB 
repair pathways. Importantly, while the first acts throughout the cell cycle and rely on rapid 
ligation of the two ends with little-to-no DNA end processing, the second is restricted to the S/G2 
phase and requires extensive DNA resection. The regulation of DSB resection, therefore, acts as 
the key determinant in committing the repair of DSB to C-NHEJ or to HR pathway. These two 
pathways are described in more detail in the sections below. 
Which pathway to choose is a critical step for repairing DSBs69. Two fundamental regulators of 
this choice have been identified: tumor suppressor p53 binding protein 1 (53BP1) and BRCA1. 
53BP1 promotes NHEJ by antagonizing resection of DSBs, whilst BRCA1 channels DSB repair 
into HR70. In G1 phase, 53BP1 inhibits the resection of DSBs by recruiting the two effectors Pax 
transactivation domain-interacting protein (PTIP), and RAP1-interacting factor 1 (RIF1). PTIP and 
RIF1 bind to sites of 53BP1 that are phosphorylated by ATM. 53BP1-RIF1 complex acts under 
both physiological (Class switch recombination) and pathological conditions, while 53BP1-PTIP 
pathway functions only under pathological conditions to promote NHEJ71,72. These interactions 
repress the recruitment of the pro-resection factor BRCA1. Indeed, in RIF1- or 53BP1-depleted 
cells, BRCA1 can form foci in G1. Antagonistically, in coordination with CtIP during S/G2 phase, 
BRCA1 prevents the accumulation of 53BP1, RIF1 and PTIP at the break sites. There are 
additional layers of control that regulate the choice of the repair pathway at DSBs. Some 
examples are the DNA end protection by Ku heterodimer73, which blocks resection in G1, or the 
TONSL-MMS22L complex, which recognizes de novo loaded histone H4 during replication to 
mark post-replicative chromatin, and favor HR74. HR is further supported by CDK activity, which 
targets multiple end processing factors, such as CtIP and EXO1 to stimulate end resection75. 
 
Classical nonhomologous end joining. Shortly, during NHEJ, DSBs are rapidly recognized and 
bound by the Ku heterodimer (Ku70 and Ku80), as a consequence of its extremely high affinity for 
DNA ends76. The most prominent function of Ku is to protect DSB and recruit DNA-dependent 
protein kinase (DNA-PK)77. DNA-PK phosphorylates an array of DDR proteins and most 
importantly auto-phosphorylates itself on two distinct regions: the so-called PQR and ABCDE 
phosphorylation clusters. Auto-phosphorylation of the ABCDE residues dampens the interaction 
between DNA-PK and the DNA ends, thereby facilitating end joining. In contrast, auto-
phosphorylation at PQR cluster inhibits DSB processing, which in turn blocks DSB repair via 
HR78. At this point, a nuclease called ARTEMIS is recruited at the DNA ends, resulting in 
nucleotide gaps subsequently filled by DNA polymerases µ, λ and TdT. DNA ends ligation can 
then be executed by the essential DNA ligation complex DNA ligase IV/XRCC4/XLF. In C-NHEJ 
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the sequence at DSB might not be faithfully restored: this could lead to loss of information and/or 
chromosomal rearrangements79. 
 
Homologous recombination. HR has a primary role in the S/G2 phases, when the sister 
chromatids are available as template. HR can therefore promote error-free DSB repair. HR can 
be divided into 3 stages: presynapsis, synapsis and post synapsis11. Presynapsis is initiated by 
the MRE11-RAD50-NBS1 (MRN) complex that recognizes the breaks and, together with CtBP-
interacting protein (CtIP), starts the short-range DNA end resection. Subsequently, extensive 
resection is carried out by the combined action of EXO1, DNA2, and the Bloom syndrome 
helicase (BLM). However, MRE11, the nuclease within the MRN (MRE11-RAD50-NBS1) 
complex, exhibits 3′-5′ exonuclease activity, which is the exact opposite of what is required to 
generate 3′ ssDNA overhangs for HR promotion. Emerging evidence indicates that CtIP activates 
MRN endonuclease activity to generate an incision in a single strand close to the DSB. This is 
followed by bidirectional resection catalyzed by MRN, in the 3′ to 5′ direction, and EXO1, in the 5′ 
to 3′ direction80,81. As the degradation occurs, the ssDNA is promptly coated by the ubiquitous 
and abundant RPA. At this step, BRCA1 recruits PALB2 and BRCA2 to the DSB. BRCA2, in turn, 
binds and dismantles native RAD51 heptamers and facilitates the loading of RAD51 monomers 
onto ssDNA, replacing RPA. In mammalian cells this process is assisted by other factors, like 
RAD52 and RAD51 paralogs.  
Once the RAD51-ssDNA nucleoprotein filament is formed, RAD51 initiates the search for an 
homologous DNA template by invading the sister chromatid, and resulting in the formation of a D-
loop structure called synapsis. Here, the invading 3' end acts as a primer for DNA polymerization. 
Finally, in the postsynapsis phase, the D-loop is resolved by different mechanisms, all yielding to 
intact and repaired DNA molecules. In mitotic cells, most frequently, the D-loop is resolved by 
anti-recombinases helicases, such as regulator of telomere elongation helicase 1 (RTEL1). The 3' 
invading strand is disengaged after DNA synthesis and re-annealed to the second end of the 
break in a pathway called synthesis-dependent strand annealing (SDSA). In meiotic cells instead, 
the second end of the break is captured by the D-loop to form a double Holliday junction (HJs) 
structure. The junction can then be processed by the activity of endonucleases MUS81-EME1, 
SLX1-SLX4 or GEN1 into either non-crossover or crossover products. Alternatively, HJs can be 
dissolved by the BLM-TOPIII- RMI1-RMI2 (BTR) complex, leading to either crossover (CO) or 
non-crossover (NCO) products82.  
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1.3.3 BRCA2 maintains genomic stability upon replication stress  
 
While our understanding of the exact mechanism by which resection contributes to the 
processing of stalled replication forks is limited, both its loss and its uncontrolled activity are 
detrimental for replication fork restart and genome stability. Controlling stalled fork resection 
therefore represents an important barrier to prevent genome instability.  
A role for BRCA2 in stabilizing stalled forks was firstly reported by Venkitaraman and colleagues 
in 200383. This study showed that Y-shaped DNA junctions  - stalled replication forks are detected 
in 2D gel electrophoresis - disappear during hydroxyurea (HU)-induced replication arrest in 
BRCA2-deficient mouse cells. The explanation for this puzzling observation came from a later 
study, showing that BRCA2 protects stalled forks from extensive MRE11-dependent 
degradation39. They used the so-called DNA fiber assay, in which the newly synthesized DNA is 
sequentially pulse-labeled for equal amount of time with different nucleotides analogues. These 
modified nucleotides are then recognized by fluorescently labelled antibodies. This setup allows 
measuring the stability of stalled replication forks based on the length of newly synthesized 
labeled DNA. By exploiting several BRCA2-deficient mammalian cell lines, the authors observed 
that the nascent strands were significantly shorter, demonstrating that BRCA2 protects nascent 
DNA at stalled replication forks. The nuclease responsible for this form of fork instability in 
absence of BRCA2 is MRE11. This conclusion could also confirm previous results obtained by 
EM analysis in RAD51-depleted Xenopus laevis extracts, that showed a high frequency of 
MRE11-dependent ssDNA gaps at replication forks43.	  
Mutational analysis revealed that BRCA2 does not prevent the degradation by directly binding the 
DNA, but through its ability to load and stabilize RAD51 filaments by its conserved C-terminus 
domain. Interestingly, BRCA2 mutants like Ser3291Ala that disrupt the C-terminal interaction with 
RAD51, are defective for protection against HU-triggered nascent strand resection, leave 
unperturbed BRCA2 role in repairing DSB via HR. These mutants provide strong evidence of 
genetically separated functions of BRCA2 in these two processes39. 
 
Additional factors blocking uncontrolled fork resection. FA is a disorder characterized by 
severe developmental abnormalities, bone marrow failure, cancer predisposition, and sensitivity 
to crosslinking agents. RAD51, BRCA1 and BRCA2 are part of the 18 genes of FA that encode 
for proteins that coordinate multiple repair processes and checkpoint signaling events necessary 
for the accurate removal of ICL lesions. The central event of FA pathway involves 
monoubiquitination of FANCD2 and FANCI proteins by the FA core complex, and promote ICL 
unhooking via DNA incision. The resulting lesion is then accurately repaired by translesion 
synthesis (TLS) and HR protein84. Interestingly, FA/BRCA protein network is also activated by 
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replication stalling agents (aphidicolin, HU) that do not require a physical removal of the lesion85. 
Moreover, FANCD2 and BRCA2/RAD51 functionally interact and co-localize in DNA damage-
induced foci86,87. These findings prompted the authors to extend their studies by examining the 
possible involvement, in fork stability, of other HR components and FA proteins40. Perhaps not 
surprisingly, they found that FANCD2- and BRCA1-defective cell show a dramatic MRE11-
dependent degradation of the nascent strand, and an increase in chromosomal aberrations upon 
replication fork stalling induced by HU treatment. These results unite breast cancer and FA 
susceptibility genes in one common pathway, whose function is to protect stalled replication forks 
from extensive degradation, thereby counteracting genomic instability.  
Many other proteins have been shown to protect nascent DNA by regulating the formation and 
the stabilization of RAD51 nucleofilaments. In particular, helicase/nuclease WRN88 and its binding 
partner Werner helicase interacting protein 1 (WRNIP1)89, TLS polymerase REV190 and RAD51 
paralogs91, were recently shown to promote resistance to replicative stress in BRCA-deficient 
cells.  
Intriguingly, it has been reported that high levels of RAD51 expression causes genome instability. 
Moreover, RAD51 appears to be frequently overexpressed in cancers92. Thus beside the 
mechanisms that support RAD51 activity, proteins must exist that will limit the genotoxic effect of 
RAD51 to promote the proper balance between its activities. Possibly via direct interaction with 
FANCD2 and BRCA2, a newly identified protein biorientation of chromosomes in cell division 1 
like (BOD1L) promotes stalled fork protection through the stabilization of RAD51 by suppressing 
the anti-recombinogenic and pro-resection activities of FBH1 and BLM93.  
Cells have additional ways of fine-tuning RAD51 function through negative regulation. Recently, a 
protein called RADX was shown to protect the stalled forks by antagonizing the activity of 
RAD5194. Indeed, its inactivation results in excessive RAD51 activity and fork collapse; on the 
other hand, in cancer cells lacking BRCA2, RADX deletion is sufficient to restore fork protection 
and genome stability. Thus, by modulating RAD51 binding at the fork, RADX provides a finely 
tuned regulatory mechanism to yield the right amount of nascent strand resection.  
 
Factors promoting stalled fork resection. MRE11, CtIP, DNA2, and EXO1 nucleolytic activity 
have been extensively studied in the context of DSBs processing. As discussed in the section 
3.2, MRE11 and CtIP start the short-range resection, while EXO1 and DNA2 act independently to 
execute extensive resection to facilitate RAD51 loading.  
These proteins have also been implicated in nucleolytic processing of stalled forks that leads to 
increased genome instability39,40,57,88,95. MRE11 was the first nuclease to be described acting at 
stalled forks, and its uncontrolled resection has been observed in the absence of many factors, 
including functional FA/HR pathways39,40. However, MRE11 has limited nucleolytic activity, and is 
unlikely to be the only nuclease responsible for degrading several kilobases of DNA in 
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pathological conditions. The proteins DNA2 and EXO1 are also implicated in fork over-resection. 
DNA2 downregulation, but not depletion of EXO1 or MRE11, has been shown to alleviate fork 
processing after HU administration57. Furthermore, DNA2 loss in FA/HR deficient cells rescues 
their hypersensitivity to ICLs and limits excessive over-resection of the DNA at stalled forks93,96,97. 
EXO1 knockdown reduced fork over-processing in WRN exonuclease mutant cells88. In addition, 
it has been recently shown that, together with MRE11, EXO1 contributes to extensive fork 
degradation in BRCA-deficient cells and that this process is initiated by CtIP98.  
The involvement of other proteins regulating resection of stalled forks adds an additional level of 
complexity. This group of proteins, while not directly possessing a nuclease activity, modulates 
the recruitment of nuclease enzymes at the stalled forks. PARP1 for example, has been 
implicated in various DNA repair pathways and in the maintenance of genomic stability67. High-
throughput analysis of protein dynamics at replication forks revealed the presence of PARP1 at 
normal and at stalled forks99. Beside its role in fork reversal, PARP1 has been shown to interact 
with and recruit MRE11 to stalled forks100,101. Indeed, in the context of BRCA deficiency, in which 
replication forks become highly unstable upon stalling, PARP1 inhibition prevents excessive fork 
degradation by limiting MRE11 access to the forks95,101,102. In addition, chromatin-remodeling 
factors, PTIP and Chromodomain Helicase DNA Binding Protein 4 (CHD4) mediate the 
recruitment of MRE11 to the DNA, thereby their downregulaton impairs MRE11 enzymatic 
nuclease activity at the forks102,103.  
The discovery of this multitude of factors that contribute to positively or negatively regulate the 
resection of stalled forks, suggests that this process is astonishingly more complex than initially 
anticipated. 
 
Clinical relevance of fork protection mechanisms. Resistance to drugs of BRCA-mutant 
tumors continues to be a major problem in oncology affecting the majority of cancer patients. 
Besides reduced uptake and increased efflux of drugs, the most well described mechanism that 
drives chemotherapeutic resistance in BRCA1/2-deficient tumors is through the re-establishment 
of HR due to secondary mutations104. Surprisingly, last year, André Nussenzweig and Shyam 
Sharan groups described a new mechanism for resistance to BRCA-targeted therapy101,102. They 
found that the central functions of BRCA1/2 in fork protection underlies the sensitivity of 
BRCA1/2-deficient cells to genotoxic drugs. In fact, loss of PTIP, PARP1 and CHD4 impair 
recruitment of MRE11 nuclease at stalled replication forks and confers resistance to a variety of 
DNA-damaging agents. Resistance to PARPi and cisplatin both in primary and in tumour cells 
grown in vitro or in vivo correlates with protection from replication fork degradation and is 
independent of the restoration of classical HR-dependent DSB repair. Clinically, these findings 
are of particular relevance, as the expression of these proteins appears to be an indicator of 
patient response to chemotherapy. 
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Loss of Brca2, as well as other HR factors like BRCA1, in ESCs is incompatible with cell 
survival105. By inactivating PARP1 or PTIP before BRCA2 loss, the above-mentioned groups 
were able to rescue the lethality of Brca2-/- mESC101,102. Importantly, these cells displayed stable 
replication forks compared to cells carrying Brca2 hypomorphic mutant, but lacked irradiation-
induced RAD51 foci, indicating that HR was not restored. Thus, suppression of uncontrolled 
degradation of stalled forks rescues the lethality of Brca2-/- ESCs without restoring HR repair. 
	   25 
2. Aims 
 
Oncogene-induced replication stress is as a crucial, early event in tumorigenesis. Despite its 
clinical relevance, the molecular bases of this process have been poorly characterized. 
Research in our laboratory has uncovered that overexpression of CyclinE and Cdc25A rapidly 
(after 8h) induced the formation of reversed forks in osteosarcoma cell line (U2OS), and 
uncontrolled processing of these structures leads to genomic instability. However, whether this is 
a general consequence of oncogene activation occurring in cancers, remains an important open 
question.  
The first aim of my doctoral research is to investigate the consequences of overexpressing two 
frequently mutated oncogenes, c-MYC and H-RAS. This, together with the previous work on 
CYCE and CDC25A, might enable us to uncover what are the conserved mechanisms occurring 
downstream of oncogene activation both in cancerous and in untransformed cells, possibly 
revealing future new therapeutics options to target oncogene-addicted cancer cells.  
 
Extensive work has contributed to our understanding of the mechanism and the factors involved 
in replication fork reversal. Replication fork reversal has emerged as a global, protective response 
to genotoxic stress in cancer and untransformed cells. Surprisingly, this transaction was recently 
found to be extremely frequent in unperturbed fast-replicating mouse embryonic stem cells 
(mESC). 
This molecular transaction at replication forks requires the central recombinase RAD51, 
suggesting a crucial genome protective role of HR factors in replication fork remodeling. 
In addition, several laboratories have uncovered a role for BRCA2, as well as other HR and FA 
factors, in protecting stalled replication forks from extensive nucleolytic degradation. This is 
important, as it represents an entirely new function of HR factors, that appears uncoupled from 
their classical role in double-strand break repair and - most importantly –underlies both the early 
embryonic lethality and the exquisite sensitivity to genotoxins (e.g. PARP inhibitors) associated 
with BRCA2 loss. 
In light of these recent findings, we have focused, in the second part of the research described in 
this thesis, on the role of the tumor suppress gene BRCA2. More specifically, we have planned to 
assess the contribution of BRCA2 to fork remodeling, monitoring fork stability and architecture - 
by fiber analysis and EM, respectively - upon BRCA2 loss in different cellular systems. We 
envisioned to unveil the structures that are protected by HR factors from extensive nucleolytic 
degradation, and that are fundamental to preserve genome stability. The elucidation of this 
mechanism will possibly explain the essential function of HR proteins during early embryogenesis 
and, more importantly, the specific sensitivity (and acquired resistance) to chemotherapeutic 
treatments of BRCA2-mutant tumors.  
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Of note, we initially planned to study the role of BRCA2 in fork remodeling upon oncogene 
activation. However, the experimental system we tested to overexpress c-MYC and H-RAS 
(tamoxifen-inducible expression of ER-oncogene fusions) still requires refinement and validation, 
in order to ascertain its suitability for these studies. Thus, inspired by recent publications, we set 
out to study the role of BRCA2 in fork remodeling, using mainly TOP1 inhibition (CPT) and 
nucleotide depletion (HU) (instead of oncogene overexpression) as a source of replication 
stress38,39,49.  
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3. Results 
 
3.1 Oncogene-induced replication stress 
3.1.1 Selection of the model system 
 
To study the molecular events during the early phases of c-MYC or H-RASV12-induced replication 
stress, the selection of two experimental parameters is of crucial importance: 1) an adequate set 
of cellular systems, and 2) the technology to timely control the overexpression of the genes.   
We analyzed the cell cycle distribution of two hTERT-immortalized cell lines, experiencing CPT-
induced replication stress: BJ cell line, derived from human foreskin, and RPE-1 cells derived 
from retinal pigment epithelium; U2OS cells have been used as control25 (Figure 7 a). As observed 
in U2OS, RPE-1 cells rapidly accumulated in S/G2 phase after CPT treatment, indicative of a 
relatively high fraction of cells undergoing S-phase. BJ cells in contrast, showed an accumulation 
in G1. We hypothesized that this could be due to a very low replication rate in the latter cell line, 
rendering it less suitable to study early events of replication stress. Therefore, we chose to 
overexpress c-MYC and H-RAS in U2OS and RPE-1 cells. 
Concerning the overexpression system, two different approaches have been previously exploited 
in our laboratory25: the tetracycline-controlled Tet-Off gene expression (Tet-off) and the transient 
transduction using retroviral vectors. Although the Tet-off system allows timely-controlled and 
efficient transcription of the gene of interest, it also involves a multi-step cloning process that can 
be time consuming and laborious. For this reason, a faster and simpler transient transfection was 
applied in the first place to rapidly assess the feasibility of the approach. However, IF assay 
showed that, upon transient transfection of the vector carrying CDC25A gene used as control, 
only 30% of the cells were expressing the protein, compared to the stably transfected 
tetracycline-inducible expression that yielded ca. 70% of cells positive for CDC25A (Figure 7 b-c). 
Moreover, besides low efficiency, transient transfection does not permit a precise temporal 
activation of the gene. 
Therefore, to obtain a fine control of the expression, we cloned the coding sequence of c-MYC 
and a constitutively active mutant of H-RAS (H-RASV12) in frame with the hormone-binding 
domain (HBD) of transcriptionally inactive mutant estrogen receptor (ER), referred to as ERTAM.  
The modified receptor does not bind estrogens, but retains normal affinity for the synthetic ligand 
4-hydroxy-tamoxifen (4-OHT). The fusion proteins are supposed to be expressed under the 
control of the retroviral 5’ long terminal repeats (LTR), and to remain inactivated by complexing 
with heat shock protein 90 (HSP90) until 4-OHT treatment. Following administration of 4-OHT, 
the fusion protein is released from HSP90 inhibitory complex, allowing translocation from the 
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cytoplasm to the nucleus and subsequent transcriptional activity106 (Figure 7 d).  
To achieve stable transgene integration we exploited a retroviral transduction. Here, the viruses 
are used as a vector to deliver the transgene within target cells. Antibiotic-treatment will 
subsequently allow selection of the transduced cells and the transgene integration it in the 
genome. Briefly, the retroviral plasmids carrying the fusion c-MYC-ERTAM or H-RAS-ERTAM were 
transfected in Phoenix amphotropic packaging cells, a 293T-based cell line that contains 
transgenes for the production of the viral capsid proteins gag, pol and env. Once the amphotropic 
Figure 7 Selection of the cell line and gene overexpression technique. (a) FACS analysis of cell cycle 
progression in U2OS, RPE-1 and BJ cell lines treated with 25 nM of CPT for indicated time points. The DNA 
content was detected by propidium iodide staining. (b) Immunofluorescence (IF) staining of U2OS cells for 
CDC25A and the DNA damage marker γH2AX cells. The overexpression of CDC25A was induced by 
removing tetracycline from the media (Tet-off system) in case of stable transfection or by transiently 
transfecting the vector carrying CDC25A gene.  (c) Quantification of double IF staining displayed in (b) in 
U2OS cells. A minimum of 130 cells was scored for each transfection system. (d) Schematic diagram of 
ERTAM-Tamoxifen based temporal control of oncogene overexpression. (e) Schematic representation of 
retroviral packaging and transfection, left (see Method section for more details).  Transfection of Phoenix-
AMPHO cells and transduction of RPE-1 and U2OS cells was followed with GFP reporter gene, right. The 
pictures of Phoenix-AMPHO cells were taken 24h after the calcium phosphate mediated transfection and 
RPE-1 and U2OS 48h after the first round of viral infection. 	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infectious particles are produced, the gene of interest is packaged within the viral genome. The 
viral particles can then be collected in large amounts and used to infect target cells. The activity 
of the viral integrase will stably integrate the gene in the cell and these will be selected with 
specific antibiotics. As an indirect readout for the efficiency of transfection and infection, we used 
a plasmidic vector encoding the reporter gene GFP (Figure 7 e). We observed a high infection 
efficiency of both target cell lines (40-50% in U2OS cells and ca. 80% in RPE-1 cells). In parallel, 
we were able to produce RPE-1 and U2OS cells carrying c-MYC-ERTAM transgene, and RPE-1 
(but not U2OS) cells with H-RASV12-ERTAM. This was probably due to a lower infection efficiency 
of U2OS cells compared to RPE-1 (Figure 7 e).  
 
3.1.2. Oncogenes overexpression and validation 
 
Upon activation of c-MYC and H-RASV12 by the ligand 4-OHT, the c-MYC-ERTAM and H-RASV12-
ERTAM fusion protein should translocate from the cytosol to the nucleus. To investigate the 
efficiency and the precision of the temporal control of the translocation, we studied the subcellular 
localization of the tagged proteins at different time intervals after 4-OHT administration. We 
focused on RPE-1 cells and isolated the nuclear and cytosolic proteins (Figure 8 a-b). The levels 
of both cytoplasmic and nuclear c-MYC and H-RASV12 significantly increased compared to 
parental cells and cells carrying the EV, which suggest a successful integration and 
overexpression of the genes. However, the nuclear levels of the proteins were high already at 0h 
of 4-OHT treatments. C-MYC levels in nuclear extract showed a slight increase upon longer 
exposure to 4-OHT (Figure 8 a), while there was no significant alteration of H-RASV12 localization 
(Figure 8 b). This observation suggests a “leakiness” in the nuclear translocation of the two 
proteins. Nevertheless, the controls that we used to monitor cytoplasmic (GAPDH) and nuclear 
(RPA and TFIIH) proteins showed a cross-contamination between the two fractions, not allowing 
to a full extent the quantification of the nuclear translocation of c-MYC and H-RAS in the absence 
of 4-OHT. Improved fractionation of cytoplasmic versus nuclear proteins will be an important next 
step.  
We also performed IF analysis, by staining with c-MYC and H-RAS specific antibodies and the 
DNA damage marker γH2AX, used as functional readout (Figure 8 c-d). Consistent with western 
blot data, IF detection of c-MYC was higher in transduced cells compared to parental or EV-
transduced cells. As before, the cells displayed increased nuclear levels of c-MYC in the absence 
of 4-OHT suggesting a leaky overexpression and nuclear translocation of the protein. As seen by 
western blot, prolonged treatment with 4-OHT increased the number of cells positive for nuclear 
c-MYC. Unfortunately, we were not able to detect significant increase of H-RAS levels in RPE-1 
cells carrying H-RASV12-ERTAM construct, compared to control cells. An outlook to solve this 
problem will include testing different antibodies and/or sequencing of the plasmidic contruct, with 
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particular attention on the H-RAS coding sequence and the promoter driving its expression. 
Undesired mutations in these regions could in fact explain the absence of H-RAS expression. In 
addition, a new cloning strategy will be set up to produce an alternative overexpression construct 
for H-RAS. 
Overall these results suggest that, particularly for c-MYC, we are able to efficiently overexpress 
the protein using retroviral transduction technique. The ERTAM - 4-OHT system, however in our 
hands, did not allow a precise temporal control of the oncoprotein nuclear translocation. 
  
3.1.3. Analysis of C-MYC-ERTAM overexpression in RPE-1 cells  
 
Encouraged by the increasing expression of c-MYC-ERTAM in the nuclear extract upon prolonged 
time of 4-OHT (Figure 8 a, c), we aimed to perform a more sensitive quantification assay to 
evaluate the basal nuclear levels of the protein at 0h of 4-OHT. We established a FACS-based 
method to quantify chromatin bound c-MYC-ERTAM and, performed a time course experiments 
upon 4-OHT treatment (Figure 9 a). FACS data clearly show a significant increase of c-MYC 
signal compared to the EV control, even in the absence of 4-OHT. The signal intensity remained 
unchanged upon prolonged 4-OHT treatments. This outcome was confirmed by analyzing the 
transcription levels of the known c-MYC target genes encoding eukaryotic translation initiation 
factor 4E (eIF4E) and nucleolin (NCL)107 using real-time quantitative RT-PCR assay (Figure 9 b). 
The amount of the eIF4A and NCL transcript was significantly higher in unstimulated RPE-1-c-
MYC-ERTAM cells in comparison to EV-transduced cells. Collectively, these analyses confirmed 
Figure 8 Expression kinetic of c-MYC-ERTAM and H-RASV12-ERTAM chimeric proteins in RPE-1 cells. 
(a) and (b) RPE-1 cells were transduced with vectors encoding c-MYC-ER and H-RASV12 -ER and treated with 
4-OHT for indicated time points.  Cytoplasmic and nuclear proteins from these cells were isolated and 
subjected to SDS-PAGE using specific antibodies against c-MYC and H-RAS. GAPDH, RPA and TFIIH 
were detected as fractionation controls.  (c) and (d) The cells were treated as in (a) and (b) and analyzed by 
IF to determine the subcellular localization. γH2AX was used as functional readout.    
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that ERTAM - 4-OHT is not a suitable experimental system for precise temporal controls of the 
gene expression.  
Because the IF analysis at time point 0h of 4-OHT showed a mixed population of cells expressing 
different levels of c-MYC, we diluted the bulk population and isolated single cell-derived clones to 
possibly select for the cells that did not show high basal levels of c-MYC expression (Figure 9 c). 
However, FACS analysis performed on each isolated clone showed elevated amount of c-MYC 
expression in the absence of the intracellular ligand 4-OHT.  
Although we were not able to precisely control the expression of c-MYC, we sought that this 
system could allow us to obtain insights in c-MYC induced replication stress. We treated RPE-1 
cells harboring c-MYC-ERTAM by increasing time exposure of 4-OHT, and analyzed the rate of 
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Figure 9 Analysis of C-MYC-ERTAM overexpression in RPE-1 cells. (a) FACS-based quantification of c-
MYC staining in RPE-1-c-MYC-ERTAM cells and RPE-1-EV treated with 4-OHT for indicated time points. (b) 
RPE-1-c-MYC-ERTAM and RPE-1-EV cells were treated with 4-OHT for indicated time points. Total RNAs 
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DNA synthesis by measuring EdU incorporation and the activation of DDR via γH2AX staining 
(Figure 9 d). C-MYC overexpression induced a burst of DNA replication, as detected by higher 
EdU incorporation compared to EV-cells. Moreover, we could observe marked increase of γH2AX 
in cells approaching completion of DNA replication (late S phase): these cells likely accumulated 
more damage during replication. These are important observations, as they - in line with previous 
reports - suggest that c-MYC overexpression increases replication origin activity – or transiently 
accelerates replication forks - leading to subsequent replication stress and DDR activation32.  
 
3.1.4. BRCA2 depletion causes reduced DNA replication and G1 arrest 
 
In another line of investigation, I focused my attention on the functions of BRCA2 during 
replication stress and investigated the consequences on replication dynamics upon its loss. 
Efficient downregulation of BRCA2 after more than 3d in U2OS cells (Figure 10 a) resulted in a 
marked reduction in replication fork speed, measured by DNA fiber spreading compared with 
control (siLuc) cells (Figure 10 b). Reduced fork progression rate was also observed by FACS 
analysis, where we monitored a reduced EdU incorporation upon BRCA2 loss. The under-
replicated DNA in BRCA2-deficient cells resulted in phosphorylation of H2AX histone variant, 
indicative of DDR activation, after more than 3 cell cycles (Figure 10 c). The unresolved damage 
induced these cells to stall in G1 phase (5d - 7d). Interestingly, these observations have been 
recently reported in a recent publication from Maria Jasin lab: they showed that BRCA2 loss 
leads to replication stress that is transmitted to the next cell cycle through DNA under-replication, 
which causes mitotic abnormalities, 53BP1 nuclear bodies and G1 arrest108. This represents an 
independent validation of the experimental set-up tested in this study. 
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3.1.5. BRCA2 suppresses re-replication in oncogene overexpressing cells 
 
The results described above, provided the impetus to investigate BRCA2 function in oncogene-
induced replication stress. As the construction of a suitable system to overexpress c-MYC and H-
RAS was still in progress (see section 3.1.3), I exploited a series of reagents already present in 
the lab, allowing a finely-tuned tetracycline-dependent CYCE overexpression in U2OS. We 
downregulated BRCA2 for 3 days in U2OS, and induced CYCE overexpression at different time 
points (Figure 11 a). We assessed the DNA replication dynamics by analyzing single DNA fibers 
as done in Figure 4 b, in combination with FACS analysis (Figure 11 b,c). In line with previous 
experiments25, the control CYCE overexpression sample was associated with a significant 
replication fork slowdown assessed by DNA fibers. FACS analysis, however, displayed a high 
EdU incorporation, suggesting that while individual forks slowed down, the global replication rate 
appeared to be higher, likely because of increased origin firing. Moreover, DDR activation (i.e. 
γH2AX) upon prolonged CYCE overexpression was mainly present in cells accumulating in S/G2 
or attempting re-replication at later time points (Figure 11 c). The observed replication stress was 
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Figure 10 BRCA2 depletion causes reduced DNA replication rate and G1 arrest. (a) Western blot 
analysis of BRCA2 levels in mock-depleted (siLuc) and BRCA2-depleted (siBRCA2) U2OS, 3 days, 5 
days and 7 days after siRNA transfection. TFIIH is used as loading control. (b) DNA fiber spreading of 
mock (siLuc) and BRCA2-depleted cells (siBRCA2). As shown in the scheme, CldU/IdU-containing 
tracts were immunostained in red and green for 20 min, respectively. Representative fibers are shown 
for each sample. The IdU replicate tracks are plotted. Horizontal lines indicate the median value. One 
hundred replication forks were analyzed for each condition. Statistical analysis: Mann-Whitney test; ns, 
not significant; ****, P< 0.0001. (c) FACS analysis for DNA synthesis (EdU incorporation), DNA content 
(DAPI) and DDR activation (γH2AX) in siLuc and siBRCA2 U2OS cells. Plots depict EdU incorporation 
versus DAPI. γH2AX positive cells are depicted in red.  
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increased upon BRCA2 downregulation. Unexpectedly, already before CYCE overexpression, Figure 11  BRCA2 suppresses -replicaton in oncogene overexpressi n cells. (a) and (c) We tern
blot analysis of BRCA2 and CYCE levels in mock-depleted (siLuc) and BRCA2-depleted (siBRCA2) U2OS 
cells overexpressing CYCE for indicated time points. TFIIH is used as loading control. (b) Analysis of DNA 
replication progression of samples from (a) by fiber spreading like in Figure 4 b. The IdU replicate tracks are 
plotted. Horizontal lines indicate the median value. One hundred replication forks were analyzed for each 
condition. Statistical analysis: Mann-Whitney test; ns, not significant; ****, P< 0.0001. (c) and (e) FACS 
analysis for DNA synthesis (EdU incorporation), DNA content (DAPI) and DDR activation (γH2AX) in siLuc 
and siBRCA2 U2OS cells overexpressing CYCE for 0 days, 8hours, 1 day, 3 days and 7days. Plots depict 
EdU incorporation versus DAPI. γH2AX positive cells are depicted in red. 	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DNA Fiber experiments showed faster fork progression after BRCA2 downregulation, which is 
only marginally affected by CYCE overexpression (Figure 11 b). This is not in line with the 
observed decrease of global DNA synthesis rate as assessed by EdU incorporation after CYCE 
overexpression (Figure 11 c). We do not currently have a clear explanation for this discrepancy. 
Additional experiments will be performed to validate this observation. However, these preliminary 
results suggest that BRCA2 depletion induced lower rate of DNA replication, which is associated 
with re-replication and DDR activation.  
Interestingly, when we downregulated BRCA2 for longer time (7 days) while overexpressing 
CYCE, we observed that the cells initially stalled in G1, were then pushed toward the S phase (1 
day) (Figure 11 d, e). Subsequently, they experienced major replication stress shown by 
compromised EdU incorporation (day 3), intermediate DNA content and extensive re-replication 
events (7d). Consistent with our results, it has been reported that DNA re-replication caused by 
deregulating origin firing, for example by CDT1 overexpression109 or geminin inactivation110, 
results in replication fork stalling and DSBs. Interestingly, HR-mediated repair is a primary 
mechanism to repair re-replication-induced DSBs111. Many models have been proposed to 
explain the formation and processing of DSBs at re-replicated DNA: (i) replication of gapped DNA 
templates that are accumulated during re-replication26 (ii) head-to-tail collision of re-replication 
and replication forks112; (iii) stalling and collapse of re-replication forks111; (iv) re-replication forks 
might be processed by endonucleases activity111; (v) stalled re-replicated DNA could be resected 
by exonucleases111. However, the underlying mechanisms are still under investigation as they 
represent a new and interesting biological question.   
 
 
Conclusive remarks 
Our results suggest that ERTAM-4-OHT system is not suitable to activate C-MYC and H-RAS 
activity in a precise controlled manner. A possible solution we set out to establish the same 
system that has been previously used for CYCE and CDC25A, namely tetracycline-controlled 
transcriptional activation (in place of the ER-mediated conditional protein translocation). The 
generation of the stable cell line with tetracycline-inducible c-MYC and H-RAS expression will be 
not described in this thesis as it is an unfinished ongoing effort in our laboratory.   
While we generate the stable cell line with tetracycline-inducible c-MYC and H-RAS expression, 
we decided to study the BRCA2 function in fork remodeling and stability upon different source of 
replication stress, such as TOP1 inhibition (CPT) and nucleotide depletion (HU).  
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3.2 Replication fork reversal triggers fork degradation in BRCA2-defective 
cells 
 
Manuscript accepted in Nature Communications 
Bellow I attached the complete manuscript in which we investigate the role of BRCA2 in 
remodeling and stability of the replication forks. This work is currently in press in Nature 
Communications. 
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Abstract 
 
Besides its role in homologous recombination (HR), the tumor suppressor BRCA2 protects stalled 
replication forks from nucleolytic degradation. Defective fork stability contributes to 
chemotherapeutic sensitivity of BRCA2-defective tumors by yet-elusive mechanisms. Using DNA 
fiber spreading and direct visualization of replication intermediates, we report that reversed 
replication forks are entry points for fork degradation in BRCA2-defective cells. Besides MRE11 
and PTIP, we show that RAD52 promotes stalled fork degradation and chromosomal breakage in 
BRCA2-defective cells. Inactivation of these factors restores reversed fork frequency and 
chromosome integrity in BRCA2-defective cells. Conversely, impairing fork reversal prevents fork 
degradation, but increases chromosomal breakage, uncoupling fork protection and chromosome 
stability. We propose that BRCA2 is dispensable for RAD51-mediated fork reversal, but 
assembles stable RAD51 nucleofilaments on regressed arms, to protect them from degradation. 
Our data uncover the physio-pathological relevance of fork reversal and illuminate a complex 
interplay of HR factors in fork remodeling and stability.  
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Introduction 
BRCA1 and BRCA2 genes represent paradigmatic examples of tumour suppressors, linking 
genome instability and cancer susceptibility1. Although several nuclear and cytoplasmic functions 
have been described for these proteins, mutations predisposing to cancer predominantly affect 
their common function in HR. BRCA2 biochemical function in HR has been linked to the 
replacement of the main ssDNA-binding protein RPA with the central recombination factor 
RAD51, which channels extended ssDNA regions for strand exchange reactions1,2. The HR 
function of BRCA2 has been mostly studied in response to double-strand breaks (DSBs). As a 
result, both the cancer predisposition and the effectiveness of certain chemotherapeutic drugs 
associated with BRCA2 deficiencies have long been linked to the DSB-repair defect3. However, 
recent work has uncovered a second, genetically separable function for BRCA2 in protecting 
stalled replication forks from extensive nucleolytic degradation4. This concept was later extended 
to several additional HR factors, as well as factors mutated in the cancer predisposition syndrome 
Fanconi anemia (FA)5. While controlled nucleolytic degradation of stalled replication forks likely 
plays a physiological role to tolerate replication stress, uncontrolled fork degradation upon HR/FA 
defects is detrimental for genome stability and affects cellular resistance to replication inhibitors4,6-
8. Most recently, this uncontrolled fork degradation – as opposed to the classical DSB repair 
defect - was linked both to the lethality of BRCA2-defective embryonic stem cells and to the 
exquisite sensitivity of BRCA-defective cells to certain chemotherapeutic treatments, elucidating a 
novel crucial mechanism of therapy resistance of BRCA-defective tumours9. It is thus of clinical 
relevance to investigate the detailed molecular mechanisms mediating or limiting fork degradation 
in response to chemotherapeutic treatments. 
Recent visualization of replication intermediates in human cells has revealed replication fork 
reversal – i.e. the conversion of replication forks into four way junctions by strand exchange 
reactions – as a global, evolutionary conserved cellular response to various conditions of 
replication stress, such as oncogene activation, chemotherapeutic treatments and replication of 
genomic sequences intrinsically prone to form secondary structures10-13. Reversed forks were 
also recently shown to protect genome integrity in unperturbed embryonic stem cells (ESCs), 
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which experience endogenous replication stress as a consequence of their accelerated cell cycle 
progression14. Fork reversal was shown to require the central recombinase RAD5111, suggesting 
that classical HR factors mediate strand exchange reactions at replication forks. Furthermore, 
reversed forks can be restarted by RECQ1-dependent branch migration15, but can also undergo 
controlled resection by DNA2/WRN7. The involvement of HR factors in reversed fork formation 
and processing suggests that fork reversal might be mechanistically linked to the extensive fork 
degradation observed in BRCA2-defective cells.  
Here we show that replication fork reversal is required for fork degradation in BRCA2-defective 
cells, as regressed arms act as entry points for MRE11-dependent degradation. Furthermore, we 
clarify the differential contribution of RAD51 and RAD52 in different steps of fork remodelling and 
protection. Finally, we provide evidence that, albeit priming fork degradation, reversal of stalled 
forks is essential to prevent excessive chromosomal breakage in BRCA2-defective tumour cells. 
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Results 
Unstable reversed forks and extended ssDNA upon BRCA2 defects 
To assess replication fork architecture during fork degradation in BRCA2-defective cells, we 
visualized replication intermediates in vivo by an established electron microscopy (EM) method16. 
We treated untransformed human retinal pigmented epithelial (RPE-1) cells with hydroxyurea 
(HU) to deplete nucleotides and stall replication forks. As previously shown11, the HU treatment 
led to significant accumulation (20%) of reversed replication forks, but their frequency was 
decreased 2-fold upon BRCA2 depletion by siRNA (Fig. 1a-b; Supplementary Table 1). MRE11 
inhibition by mirin17 had no significant effect on reversed fork frequency in untreated cells or in 
HU-treated wild type cells, but restored full fork reversal levels in BRCA2-depleted HU-treated 
cells (Fig. 1b; Supplementary Table 1). Thus, replication forks can be effectively reversed upon 
HU treatment also in the absence of BRCA2, but they are targeted by MRE11-dependent 
degradation. Although we did not detect a specific accumulation of ssDNA on regressed arms in 
HU-treated BRCA2-defective cells (Supplementary Fig. 1a), extended ssDNA stretches were 
observed upon BRCA2 downregulation at standard three-way fork junctions and were 
suppressed by mirin treatment in HU-treated cells (Fig. 1c-d). Shorter HU treatments also led to 
reduced reversed fork frequency in BRCA2-defective cells, but did not reveal increased ssDNA at 
fork junctions or regressed arms (Supplementary Fig. 1b-c, Supplementary Table 2). Taken 
together, these data suggest that nucleolytic processing in HU-treated BRCA2-defective RPE-1 
cells rapidly degrades regressed arms and, upon prolonged treatments, continues on newly 
synthesized DNA behind the fork. Whether or not transient accumulation and/or partial resection 
of reversed forks is visible by EM upon short genotoxic treatments in BRCA2-defective cells likely 
reflects different kinetics of fork reversal and processing in different cell lines18. These data 
highlight the different resolution and limitations of DNA fiber assays and EM visualization of fork 
remodeling and degradation, as recently discussed19.  
As PTIP depletion in mouse B cells was recently reported to suppress fork degradation in 
BRCA2-defective cells by limiting MRE11 recruitment at stalled forks9, we identified conditions to 
downregulate PTIP by two different siRNAs in RPE-1 cells, preceding long-term effects on cell 
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cycle progression (Supplementary Fig. 2a-b)20, and monitored fork degradation by DNA fibers. As 
reported4,9, HU-treated BRCA2-defective cells displayed marked degradation of nascent DNA, 
also by a labeling scheme that excludes shortening of replicated tracts by fork breakage 
(Supplementary Fig. 2c-d). In these conditions, similarly to mirin, PTIP downregulation 
suppressed fork degradation (Supplementary Fig. 2c) and restored wild type levels of reversed 
forks and ssDNA in BRCA2-defective HU-treated cells (Supplementary Fig. 2e-f and 
Supplementary Table 3). Thus, reversed forks appear as “entry points” for extensive MRE11-
dependent degradation of stalled forks in BRCA2-defective RPE-1 cells.  
Chinese Hamster BRCA2-defective cells (V-C8), previously reported to undergo fork degradation 
upon HU treatment4, also displayed reduced reversed fork levels and extended ssDNA stretches 
at forks (Fig. 2a, Supplementary Fig. 3a). Mirin treatment or complementation of these cells with 
WT BRCA2 restored high frequencies of reversed forks and short ssDNA stretches at forks. 
However, expression of the BRCA2 phosphorylation mutant S3291A – which causes a defect in 
fork integrity, but allows HR-mediated DSB repair4 – failed to complement either defect in V-C8 
cells (Fig. 2a, Supplementary Table 4 and Supplementary Fig. 3a), further linking reversed fork 
instability and fork degradation upon BRCA2 defects. Notably, reduced reversed fork frequency 
and extended ssDNA stretches at forks – both effectively suppressed by MRE11 inhibition - were 
also observed in BRCA2-depleted cells upon short treatments with low dose (25 nM) of CPT (Fig. 
2b, Supplementary Table 5 and Supplementary Fig. 3b), which induces frequent fork reversal but 
does not completely arrest fork progression11,21. These data show that BRCA2 generally protects 
reversed forks from nucleolytic degradation also in conditions of mild replication interference, 
where fork degradation is difficult to monitor by DNA fiber assays. 
 
Replication fork reversal is required for fork degradation 
The role of BRCA2 in fork protection was previously linked to RAD51 chromatin loading5,22. 
However, RAD51 is also essential for the accumulation of reversed forks, which appear to be the 
substrate for degradation in BRCA2-defective cells (Figs. 1-2). To resolve this conundrum, we 
analyzed fork degradation upon effective RAD51 downregulation. In contrast to BRCA2 
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defects4,22, depletion of RAD51 by two different siRNA sequences in HU-treated cells did not lead 
to fork degradation and surprisingly suppressed fork degradation in BRCA2-depleted cells (Fig. 
3a, Supplementary Fig. 4a). This data suggests that preventing fork reversal by RAD51 
inactivation prevents fork degradation in BRCA2-defective cells. Indeed, in our EM analysis, 
RAD51 depletion abolished HU-induced fork reversal also in the presence of mirin and prevented 
mirin-dependent restoration of reversed fork levels in BRCA2-defective cells (Fig. 3b and 
Supplementary Table 6). Notably, a different genetic perturbation that was recently shown to 
affect reversed fork formation in vivo23 – i.e. depletion of the DNA translocase ZRANB324-26 – also 
completely suppressed fork degradation in BRCA2-defective cells (Fig. 3c). Reversed fork 
formation requires the helicase, but not the nuclease activity of ZRANB323,24,26. Accordingly, we 
found that cells expressing at endogenous levels23 helicase-defective – but not wild type or 
nuclease-defective – ZRANB3 are resistant to fork degradation upon BRCA2 downregulation 
(Fig. 3d). Furthermore, PARP inhibition prior to HU treatment, which was previously reported to 
prevent efficient fork reversal11, also suppressed fork degradation in BRCA2-depleted cells (Fig. 
3e). Interestingly, this effect was not reported when the PARP inhibitor was added concomitantly 
with HU27. The latter conditions are likely to be initially permissive for HU-dependent reversed fork 
accumulation and thus prime fork degradation before PARP inhibition results in RECQ1-
dependent reversed fork resolution11,15. Altogether, these results strongly support the notion that 
fork reversal triggers fork degradation in BRCA2-deficient cells. PARP inhibitor and cisplatin 
treatments were also recently used to link chemoresistance in BRCA2-defective cells with 
restored fork stability9,28. However, it should be noted that this outcome requires PARP inhibition 
or downregulation before BRCA2 inactivation9,28, under which conditions the efficiency of fork 
remodeling has not been directly tested. 
 
Fork reversal does not require stable RAD51 nucleofilaments 
In light of these data and previous reports4, RAD51 seems to be essential both for BRCA2-
independent reversed fork formation and for BRCA2-dependent protection of reversed forks from 
nucleolytic degradation. Thus, different genetic manipulations affecting RAD51 function may have 
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diverse effects on each step of fork remodeling, likely explaining the different fork degradation 
phenotypes reportedly associated with RAD51 defects4,22. A dominant RAD51 mutant allele, 
found in FA patients, i.e. RAD51-T131P, was recently reported to destabilize RAD51 
nucleofilaments, by constitutive activation of RAD51 ATPase activity, leading to ssDNA 
accumulation by nucleolytic processing of replicating DNA8. Upon HU treatment, these patient 
cells – similarly to BRCA2-deficient cells - displayed extensive fork degradation, which was 
suppressed by mirin treatment (Fig. 4a). EM analysis of RAD51-T131P cells revealed a marked 
reduction in reversed fork levels, compared to wild-type counterparts, which was also suppressed 
by MRE11 inhibition (Fig. 4b and Supplementary Table 7). Together with our previous results, 
these data strongly suggest that unstable RAD51 filaments in RAD51-T131P cells are still 
capable of driving fork reversal, but fail to protect reversed forks from nucleolytic degradation, 
uncoupling RAD51 functions in fork remodeling and stability.   
  
RAD52 promotes stalled fork degradation via MRE11 recruitment 
As RAD51-mediated fork reversal is BRCA2 independent, we next tested whether RAD52 - which 
was shown to play an essential role in the absence of BRCA2 and to assist HR mechanisms 
specifically upon replication stress29-31 - could assist RAD51 in reversed fork formation and 
mediate fork degradation upon BRCA2 deficiency. Besides its recently established role in mitotic 
DNA synthesis and upon breakage of persistently stalled forks31,32, RAD52 is also stably recruited 
to chromatin in unperturbed S phase32 and might thus participate in early events occurring at 
transiently stalled replication forks. Importantly, RAD52 depletion by two independent siRNA 
sequences - as well as treatment with a specific RAD52 inhibitor32,33 – completely abolished fork 
degradation in BRCA2-deficient cells (Fig. 5a), in conditions that do not drastically affect cell cycle 
progression (Supplementary Fig. 4b). However, differently from RAD51 depletion, RAD52 
depletion did not per se affect fork reversal, but rather restored normal reversed fork levels in HU-
treated BRCA2-defective cells (Fig. 5b and Supplementary Table 8). These effects are highly 
reminiscent of those observed for MRE11 inhibition or PTIP depletion (Supplementary Fig. 2)9 
and suggest a key role for RAD52 in driving MRE11-dependent reversed fork processing.  In line 
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with this interpretation, RAD52 inhibition significantly reduced recruitment of MRE11 to HU-stalled 
forks in BRCA2-defective cells, as monitored by iPOND (Fig. 5c). Furthermore, similarly to 
MRE11 inhibition and PTIP depletion9, RAD52 depletion markedly suppressed HU-induced 
chromosomal breakage associated with BRCA2 deficiency (Fig. 5d). Thus, RAD52 is required to 
prime MRE11-dependent stalled fork resection in BRCA2-defective cells. Whether the role of 
RAD52 in MRE11 recruitment and reversed fork resection reflects its strand exchange34,35, single-
strand annealing36, inverse RNA/DNA strand exchange37 or other yet uncharacterized 
biochemical activities will require further investigation. 
 
Fork reversal prevents chromosome breakage upon fork stalling 
Reversed forks were recently shown to protect against genome instability during accelerated 
proliferation in early embryogenesis14. We thus tested whether the reported rescue of viability of 
mouse Brca2-null embryonic stem cells (ESCs) by PTIP depletion9 was also related to the 
protection of reversed forks from nucleolytic degradation. Upon transient downregulation of Brca2 
in unperturbed mouse embryonic stem cells (Supplementary Fig. 4c), we observed a decrease in 
the level of endogenous reversed forks, as compared to control cells. Notably, rescuing fork 
degradation by PTIP depletion restored normal frequencies of reversed forks in Brca2-null cells 
(Fig. 6a and Supplementary Table 9). These data further support a model where the essential 
role of key HR factors – e.g. RAD51 and BRCA2 - in early embryogenesis reflects their function in 
replication fork remodeling and protection9,14.  
Preventing MRE11-dependent degradation by mirin treatment, as well as PTIP or RAD52 
downregulation, suppressed the chromosomal breakage observed in HU-treated BRCA2-
defective cells (Figs. 5d and 6b)9. However, preventing fork reversal – e.g. by ZRANB3 
inactivation - also suppressed nucleolytic degradation (Fig. 3c), but rather elevated chromosomal 
breakage in BRCA2-defective U2OS cells. Chromosomal breaks upon simultaneous inactivation 
of ZRANB3 and BRCA2 were not suppressed by mirin treatment or PTIP depletion, indicating that 
they are not directly associated with unscheduled fork degradation (Fig. 6b), but likely with 
defective HR-mediated repair of DSBs arising upon genotoxic stress in the absence of fork 
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reversal. Furthermore, PARP inhibition shortly before HU treatment – which is also preventing 
effective fork reversal11 – increased chromosomal breakage in BRCA2-defective cells, but did not 
further increase chromosome instability in ZRANB3-KO BRCA2-defective cells, showing epistatic 
effects of these two means of fork reversal impairment (Fig. 6c). Altogether, these data strongly 
suggest that preventing fork degradation by abolishing fork reversal is detrimental for genome 
stability in BRCA2-defective cells, as it likely results in replication fork collapse. Thus fork reversal 
limits chromosomal breakage and genome instability at stalled forks, providing additional 
evidence for the physiological role of this global DNA transaction occurring upon replication 
stress11,13. These data also support a recent alternative model for the specific toxicity of PARP 
inhibition in BRCA2-defective tumors, where fork reversal suppression by PARP inhibitors11,21 
underlies the observed increase in fork breakage, requiring BRCA2 classical function in DSB 
repair13. 
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Discussion 
Taken together, our data reveal a complex interplay of different HR factors in forming and 
processing reversed forks. We propose that the same apparatus which mediates controlled 
resection of reversed forks - to allow their effective restart - may become deregulated in BRCA2-
defective cells and mediate extensive degradation of reversed forks (Fig. 7). Importantly, we 
show that these processing events are primed by fork reversal and can potentially occur even 
upon genotoxic treatments that do not completely block replication fork progression (e.g. mild 
CPT treatments), which better reflect clinically relevant conditions of replication interference and 
are anyway strong inducers of fork reversal21. RAD51 is clearly involved both in the formation and 
in the protection of reversed forks. Therefore, the molecular consequences of specific RAD51 
mutations will likely depend on residual fork reversal and fork protection activities in each genetic 
background. Based on our data, stable RAD51 nucleofilaments are strictly required to protect 
regressed arms, but unstable filaments and/or inefficient loading of RAD51 on ssDNA - as in 
BRCA2-deficient or RAD51-T131P cells – would not impair strand exchange reactions at 
replication forks (i.e. fork reversal), probably because they do not imply extensive homology 
search at a distance. It is intriguing that BRCA2 defects and this specific RAD51 mutation are 
both associated with FA and it will be crucial to extend this molecular analysis to other FA 
mutations. 
An intriguing implication of our work is the BRCA2-independent role of RAD51 in promoting fork 
reversal. This is in principle surprising, as RPA is known to rapidly bind ssDNA generated at forks 
and BRCA2 has been clearly implicated in replacing RPA with RAD5138, in order to form a stable 
nucleofilament. However, previous reports have suggested BRCA2-independent RAD51 
chromatin loading upon replication stress9,39. We envision several non-mutually exclusive 
scenarios to explain this intriguing observation: 1) besides BRCA2-mediated RAD51 loading at 
DNA ends, alternative mediators may have evolved to assist RPA-RAD51 exchange specifically 
in the context of ssDNA accumulating at a fork junction; 2) direct displacement of ssDNA-bound 
RPA by RAD51 at replication forks may be assisted by local exhaustion of free RPA40 and/or 
reported direct interactions between RAD51 and the replicative helicase41; 3) as suggested by our 
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data on RAD51-T131P mutant cells, inefficient and partial replacement of RPA with short and 
unstable RAD51 filaments in the absence of BRCA2 may be sufficient to assist strand annealing 
at uncoupled forks and thus prime fork reversal, which is anyway assisted by other enzymatic 
activities23. Uncovering the specific regulation of RAD51 activity in fork remodeling will require 
extensive biochemical reconstitution and in vivo investigations on replication intermediates. 
Another important implication of our data is that not all genetic conditions suppressing fork 
nucleolytic degradation in BRCA2-defective cells are expected to rescue genome stability and 
survival to genotoxic treatments, which is relevant for informed predictions on chemoresistance of 
BRCA2-defective tumors. Based on these data, we would expect that only genetic alterations still 
allowing reversed fork formation, but preventing their degradation would truly result in resistance 
to classical chemotherapeutic treatments (Fig. 7). However, due to the involvement of several 
factors – such as MRE11 and, here, RAD52 - in both fork degradation and restart of collapsed 
forks31,42, a detectable decrease in chromosomal breakage due to limited fork resection may not 
per se predict better recovery and resistance to genotoxic treatments. Indeed, despite extensive 
resection, BRCA2-defective cells are able to restart stalled forks4,9 and a significant proportion of 
the observed chromosomal breaks may in fact reflect fork restart pathways contributing to cell 
survival18. This intricate series of events likely explains why suppression of fork degradation is 
observed upon transient RAD52 downregulation in BRCA2-defective cells, although inactivation 
of these genes is reportedly synthetically lethal29 and RAD52 is actively explored as potential 
therapeutic target in BRCA2-defective tumors43,44. 
In light of our data and of the structural resemblance of regressed arms to DSBs, it is tempting to 
speculate that other classical DSB processing and repair factors may play relevant roles in 
replication fork remodeling, protection and restart, thereby determining sensitivity or resistance to 
current chemotherapeutic treatments. 
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Methods 
 
Cells and cell culture 
Human osteosarcoma U2OS cells, retinal pigment epithelium RPE-1 cells and VC-8 hamster 
cells, V-C8 cells complemented with human BACs (V-C8+BRCA2 and V-C8+BRCA S3291A4 
were cultured in DMEM (41966-029, Life Technologies) supplemented with 10 % (v/v) FBS, 100 
U ml-1 penicillin, and 100 µg ml-1 streptomycin at 37 °C and 6 % CO2. Patient fibroblasts RAD51-
T131P and BJ foreskin fibroblasts (ATCC) were grown in DMEM (41965-039, Life Technologies) 
supplemented with 15% (v/v) FBS, 100 U ml-1 penicillin, and 100 µg ml-1 streptomycin at 37 °C 
and 6 % CO28. PL2F2 mouse ESCs were maintained in DMEM with 15 % fetal bovine serum, 
0.00072 % β-mercaptoethanol, 100   U ml-1 penicillin, 100   µg ml-1 streptomycin and 0.292 mg ml-1 
L-glutamine at 37 °C and 5 % CO29. ESCs were cultured on feeder cells (MEFs inactivated with 
10   mg   ml-1 mitomycin C) for two passages, after they were transferred to feeder-free, gelatinized 
tissue culture dishes (0.1 % Gelatin from porcine skin, Sigma).  
 
Transfections and treatments 
For knockdown experiments, cells were transfected 20–48   h (as indicated below) prior to sample 
collection with the indicated siRNA using RNAiMax transfection reagent (Life Technologies) 
according to the manufacturer’s instructions:  
siLuc (40  nM; 5′-CGUACGCGGAAUACUUCGATT-3′);  
siBRCA2 (48 h, 40 nM; 5'-UUGACUGAGGCUUGCUCAGUUTT-3');  
siRAD51#1 (24 h, 40 nM; 5'-GACUGCCAGGAUAAAGCUUTT-3'); 
siRAD51#2 (24h, 40 nM; 5'-GUGCUGCAGCCUAAUGAGA-3’);  
siPTIP#1 (20 h, 40 nM; 5'-AAGGAAGAAGAGGAAGAGGAATT-3'); 
siPTIP#2 (20h, 40 nM; 5' UGUUUGCAAUUGCGGAUUAUU-3’); 
siRAD52#1 (24 h,10 nM, ON-TARGETplus Human RAD52 (5893), Dharmacon); 
siRAD52#2 (48h, 10 nM, s11746 (4392420), Ambion). 
Mouse ESCs were passaged in feeder-free conditions and plated in 50 % standard culture 
medium and 50 % Opti-MEM (Thermo Fisher Scientific) containing RNAiMax transfection reagent 
(Life Technologies) with the mix of following siRNAs at final concentration of 60 nM for 48 h: 
siBrca2#1 (5'-UGUUAGGAGAUUCAUCUGGTT-3'); 
siBrca2#2 (5'-GGCCUAGUCUCAAGAACUCTT-3'); 
siBrca2#3 (5'-GGAAUUGUAAGGUAGGCUCTT-3'). 
BRCA2 conditional knockout cells with shRNAs against Ptip mRNA ESCs were provided by the 
lab of A. Nussenzweig9. 
The following reagents were used to treat the cells for the indicated time at the indicated final 
concentrations before collection: HU (H8627, Sigma-Aldrich) was prepared in double-distilled 
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H2O to obtain a 100 mM (7.6 mg ml-1) stock (freshly made); Mirin (M9948, Sigma-Aldrich) was 
dissolved in DMSO to yield a 50 mM stock, and aliquots were stored at −80 °C; CPT (C9911, 
Sigma-Aldrich) was dissolved in DMSO to yield a 20 mM (7 mg ml-1) stock (freshly made); 
Nocodazole (M1404, Sigma-Aldrich) was prepared in DMSO at the final concentration of 1 mg ml-
1, aliquoted and stored at −80 °C. The Rad52 inhibitor (AICAR, A9978, Sigma-Aldrich) was 
dissolved in H2O to a final concentration of 40 mM and stored at -20 °C. The PARP inhibitor 
Olaparib (AZD2281, Ku-0059436; S1060, Selleckchem) was prepared in DMSO to obtain the 
concentration of 20mM, aliquoted and stored at -20°C. 
 
Western blotting 
Cells were collected using trypsin, immediately lysed using SDS buffer (0.16 M Tris-HCl pH 6.8, 4 
% SDS, 20 % glycerol, 100 mM DTT and 0.01 % bromophenol blue) and sonicated by Bioruptor 
(Diagenode) at 4 °C with the highest setting for 10 min (30 s on and 30 s off cycles). The lysates 
were incubated at 70 °C for 10 min and centrifuged at 13000 rpm for 7 min. Protein concentration 
in samples was measured using Nanodrop (A280). Equal amounts of protein (50–100 µg) were 
loaded on a NuPAGE-Novex 3–8 % Tris-Acetate or NuPAGE-Novex 10 % Bis-Tris gels (Life 
Technologies) and ran for 1 h, 180 V at room temperature. Proteins were blotted for 100 min (30 
V, room temperature) on Amersham Protran 0.2 mm NC (GE Healthcare). Membranes were 
blocked in 5 % milk in 0.1 % TBST (1 × TBS supplemented with 0.1 % Tween 20) for at least 
30  min and incubated in 2 % BSA with primary antibodies overnight at 4 °C. Membranes were 
probed for BRCA2 (1:500, Ab-1, OP 95, EMD Millipore); RAD51 (1:1000, H-92, sc-8349, Santa 
Cruz Biotechnology); RAD52 (1:1000, F-7, sc-365341, Santa Cruz Biotechnology); PTIP (1:500, 
ab214732, Abcam); ZRANB3 (1:1000, 23111-1-AP, ProteinTech); TFIIH (1:2000, S-19, sc-293, 
Santa Cruz Biotechnology). Secondary antibodies were added for 1 h at room temperature (in 
blocking solution). Membranes were washed three times with 0.1% TBST, 10 min each, after 
primary and secondary antibody incubations and detected with ECL detection reagent (GE 
healthcare). Uncropped blots for each western blot figure are provided in Supplementary Fig. 5. 
 
Electron microscopy analysis 
The procedure was performed as recently described16, with minor modifications described below. 
Following the depletion of the protein of interest, asynchronous subconfluent cells were treated 
with 25 nM CPT for 1 h or 4 mM HU for 5 h. Where indicated, cells were pretreated with 50 mM 
Mirin for 1h. Cells were collected, resuspended in PBS and crosslinked with 4,5', 8-
trimethylpsoralen (10 µg ml-1 final concentration), followed by irradiation pulses with UV 365 nm 
monochromatic light (UV Stratalinker 1800; Agilent Technologies). For DNA extraction, cells were 
lysed (1.28 M sucrose, 40 mM Tris-HCl [pH 7.5], 20 mM MgCl2, and 4 % Triton X-100; Qiagen) 
and digested (800 mM guanidine–HCl, 30 mM Tris–HCl [pH 8.0], 30 mM EDTA [pH 8.0], 5 % 
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Tween-20, and 0.5 % Triton X-100) at 50 °C for 2 h in presence of 1 mg ml-1 proteinase K. The 
DNA was purified using chloroform/isoamylalcohol (24:1) and precipitated in 0.7 volume of 
isopropanol. Finally, the DNA was washed with 70 % EtOH and resuspended in 200 µl TE (Tris-
EDTA) buffer. 100 U of restriction enzyme (PvuII high fidelity, New England Biolabs) were used to 
digest 12 µg of mammalian genomic DNA for 4-5 h. Replication intermediates enrichment was 
performed by QIAGEN Plasmid Mini Kit columns. The QIAGEN-tip 20 surface tension was 
reduced by applying 1 ml QBT buffer. The columns were washed and equilibrated with 10 mM 
Tris-HCl (pH 8.0), 1 M NaCl, followed by 10 mM Tris-HCl (pH 8.0), 300 mM NaCl, respectively. 
DNA was then loaded onto the columns. The columns were then washed with high NaCl solution 
(10 mM Tris-HCl [pH 8.0] and 900 mM NaCl) and eluted in caffeine solution (10 mM Tris-HCl [pH 
8.0], 1 M NaCl, and 1.8 % [w/v] caffeine). To purify and concentrate the DNA an Amicon size-
exclusion column was used. DNA was then resuspended in TE buffer. The 
Benzyldimethylalkylammonium chloride (BAC) method was used to spread the DNA on the water 
surface and then load it on carbon-coated 400-mesh copper grids. Subsequently, DNA was 
coated with platinum using a High Vacuum Evaporator MED 020 (BalTec). Microscopy was 
performed with a transmission electron microscope (Tecnai G2 Spirit; FEI; LaB6 filament; high 
tension ≤ 120 kV) and picture acquisition with a side mount charge-coupled device camera (2,600 
× 4,000 pixels; Orius 1000; Gatan, Inc.). For each experimental condition at least 70 replication 
fork molecules were analyzed. DigitalMicrograph version 1.83.842 (Gatan, Inc.) and ImageJ 
(National Institutes of Health) were used to process and analyze the images. 
 
DNA fibre analysis 
Following the depletion of proteins of interest, cells were sequentially pulse-labelled with 30 µM 
CldU (c6891, Sigma-Aldrich) and 250 µM IdU (I0050000, European Pharmacopoeia) for 20 min 
and treated with hydroxyurea (4 mM) for 5 h. The cells were collected and resuspended in PBS at 
2.5 × 105 cells ml-1. The labeled cells were diluted 1:5 (v/v) with unlabeled cells, and 2.5 µl of cells 
were mixed with 7.5 µl of lysis buffer (200 mM Tris-HCl, pH 7.5, 50 mM EDTA, and 0.5 % [w/v] 
SDS) on a glass slide. After 9 min, the slides were tilted at 15–45°, and the resulting DNA 
spreads were air dried, fixed in 3:1 methanol/acetic acid overnight at 4 °C. The fibers were 
denatured with 2.5 M HCl for 1 h, washed with PBS and blocked with 0.2 % Tween 20 in 1 % 
BSA/PBS for 40 min. The newly replicated CldU and IdU tracks were labeled (for 2.5 h in the 
dark, at RT) with anti-BrdU antibodies recognizing CldU (1:500, ab6326; Abcam) and IdU (1:100, 
B44, 347580; BD), followed by 1 h incubation with secondary antibodies at RT in the dark: anti–
mouse Alexa Fluor 488 (1:300, A11001, Invitrogen) and anti–rat Cy3 (1:150, 712-166-153, 
Jackson ImmunoResearch Laboratories, Inc.). Fibers were visualized (IX81; Olympus; objective 
lenses: LC Plan Fluor 60×, 1.42 NA oil Olympus BX60 microscope) and analyzed using ImageJ 
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software. The Mann–Whitney test was applied for statistical analysis using Prism (GraphPad 
Software).  
 
Isolation of proteins on nascent DNA or iPOND 
iPOND was performed essentially as described45. At least 1.0 x 108 of HEK293T cells were used 
per sample. BRCA2 depletion was performed 2 days before EdU labelling. The RAD52 inhibitor 
(AICAR, 40 µM) was optionally added 2 h before 10 µM EdU labeling (15 min), followed by 5 h 4 
mM HU treatment (HU) or by 2 h 10 µM thymidine chase (Thy-chase). Cells were cross-linked 
with 1% formaldehyde for 12 min at room temperature, quenched with 0.125 M glycine and 
collected by scraping. The cells were washed with PBS three times and permeabilized with 
0.25% Triton X-100/ PBS at room temperature for 30 min. Before the click reaction, samples were 
washed once in 0.5% BSA/PBS and once in PBS.  
For the conjugation of EdU with biotin azide (Vanderbilt University, Chemical Synthesis Core), 
cells were incubated with click reaction buffer (10 mM sodium-L-ascorbate, 10 µM biotin azide 
and 2 mM CuSO4) for 2 h at room temperature. Following the click reaction, cells were washed 
once in 0.5% BSA/PBS and once in PBS. Cells were then resuspended in lysis buffer (50 mM 
Tris-HCl, pH 8.0, and 1% SDS) supplemented with protease inhibitors (Roche), and chromatin 
was solubilized by sonication in a Bioruptor (Diagenode) at 4 °C for 20 min (20 sec pulse/40 sec 
pause). After centrifugation at 16,100 g for 10 min, clarified supernatants were collected and 
diluted 1:1 (v/v) with PBS containing proteinase inhibitor. To capture biotin-tagged nascent DNA, 
each sample was incubated at 4 °C o/n in the dark with streptavidin-agarose beads (Novagen, 
D00148073). 200 µL of bead slurry was used per 1x108 cells. After binding, beads were washed 
with lysis buffer, followed by one time wash with 1 M NaCl and two times with lysis buffer. 
Captured proteins were eluted by boiling beads in 2 × SDS Laemmli Sample Buffer (0.4 g SDS, 2 
ml 100% Glycerol, 1.25 mL 1 M Tris pH 6.8, and 0.01 g Bromophenol blue in 8 mL H2O) for 25 
min at 95 °C. Proteins were resolved by electrophoresis using Mini-PROTEAN TGXTM gels 
(BioRad) and detected by western blotting with the indicated antibodies: MRE11 (1:2000, NB100-
142, Novusbio); PCNA (1:1000, PC10, sc-56) and H3 (1:2000, Ab1791, Abcam).  
 
Analysis of chromosome spreads 
After the transfection with specific siRNAs, cells were treated with 4 mM HU for 5 h. The 
genotoxic agent was removed by washing 3 times with 1× PBS and the cells were then released 
into fresh medium containing 200 ng ml-1 nocodazole for 16 h. Cells were harvested and swollen 
with 75 mM KCl for 20 min at 37 °C. Swollen mitotic cells were collected and fixed with 
methanol:acetic acid (3:1). The fixing step was repeated 2 times. Cells were then dropped onto 
pre-hydrated glass slides and air-dried overnight. The following day, slides were mounted with 
Vectashield medium containing DAPI. Images were acquired with a microscope (model DMRB; 
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Leica) equipped with a camera (model DFC360 FX; Leica) and visible chromatid breaks/ gaps 
were counted.  
 
Flow cytometry 
For flow cytometric analysis of EdU/DAPI, cells were labelled for 30 min with 10   µM EdU, 
harvested and fixed for 15   min with 4 % formaldehyde/PBS. Cells were washed with 1 % 
BSA/PBS, pH 7.4 and permeabilized with 0.5% saponin/1 % PBS. Incorporated EdU was labelled 
according to the manufacturer’s instructions (#C-10425; Life Technologies). DNA was stained 
with 1 µg ml-1 DAPI. Samples were measured on a Cyan ADP and ATTUNE NXT flow cytometer 
(Beckman Coulter) and analyzed by the FlowJo software. 
 
Quantitative RT-PCR 
Total RNA was isolated from cells using the Oligotex mRNA Mini Kit (Qiagen). 500 ng of RNA 
was used for cDNA synthesis using Transcriptor First Strand cDNA Synthesis Kit (Roche). 
Quantitative real-time SYBR-Green-based PCR reactions were performed in triplicate and 
monitored with the Light Cycler 480 (Roche) system. The following primer pairs were used to 
determine BRCA2 mRNA levels: forward 5'-CACCTCTGGAGCGGACTTATT-3'; reverse 5'-
GCTTTGTTGCAGCGTGTCTT-3'.  
The housekeeping gene GAPDH, used as a control, was amplified with the following primers: 
forward 5'-GACATTGTTGCCATCAACGACC-3'; reverse 5'-CCCGTTGATGACCAGCTTCC-3'. 
 
Data availability 
The authors declare that all relevant data supporting the findings of this study are available within 
the article and its Supplementary Information files, or from the corresponding author upon 
reasonable request. 
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Figure Legends 
 
Figure 1. Stalled replication forks can reverse in the absence of BRCA2, but are targeted 
by nucleolytic degradation. (a, c) Electron micrographs of representative replication forks from 
RPE-1 cells: parental (P) and daughter (D) duplexes. (a) The black arrow indicates the regressed 
arm (R); the four-way junction at the reversed fork is magnified in the inset. (c) The white arrow 
points to a ssDNA region at the fork. Scale bar, 200 nm (= 460 bp), 40 nm (= 92 bp) in the 
inset. (b) Left panel: frequency of reversed replication forks isolated from mock-depleted (siLuc) 
and BRCA2-depleted (siBRCA2) RPE-1 cells upon optional 5 h treatment with 4 mM HU; where 
indicated 50 mM mirin was added 1h before HU treatment (6 h total treatment). The number of 
replication intermediates analyzed is indicated in parentheses. The graph depicts mean and 
standard deviations from three independent EM experiments, blinded to the investigator. The 
results of the individual biological replicates are in Supplementary Table 1.  Right panel: western 
blot analysis of BRCA2 levels in siLuc and siBRCA2 RPE-1 cells, 48 h after transfection. TFIIH, 
loading control. (d) Graphical distribution of ssDNA length at the junction (white arrow in Fig. 1c) 
in siLuc and siBRCA2 RPE-1 cells optionally treated with 4mM of HU for 5 h and 50 mM of mirin 
for 6 h. Only molecules with detectable ssDNA stretches are included in the analysis. The lines 
show the median length of ssDNA regions at the fork in the specific set of analyzed molecules. 
Statistical analysis: Mann-Whitney test; ns, not significant; **, P< 0.01; ***, P< 0.001; ****, P< 
0.0001. The number of analyzed molecules is in brackets. 
 
Figure 2. BRCA2 maintains reversed fork stability in different cell lines and upon different 
genotoxic treatments. (a) Top: schematic representation of BRCA2 protein. Green boxes: 
RAD51-binding BRC repeats; Black box: DBD, DNA binding domain; C-ter, yellow bar: RAD51-
biding c-terminal region. Blue arrows indicate truncations in V-C8 cells; the S3291A mutation is 
marked in red. Bottom: frequency of reversed replication forks isolated from VC-8 cells and V-C8 
cells stably expressing full-length BRCA2 or BRCA2 containing the S3291A mutation, treated as 
in Fig. 1 (4 mM HU for 5 h; 50 mM mirin for 6 h). The number of analyzed molecules is indicated 
in brackets. Results of two independent EM experiments are in Supplementary Table 4. Right: 
western blot analysis of BRCA2 levels in V-C8 and complemented cells. TFIIH, loading control. 
(b) EM-based analysis of reversed replication forks isolated from siLuc and siBRCA2 (48 h) RPE-
1 cells treated with 25 nM CPT for 1h; where indicated 50 mM mirin was added 1h before CPT 
treatment (2h total treatment). In brackets the total number of analyzed molecules. Results of two 
independent EM experiments are in Supplementary Table 5. 
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Figure 3. Impairing replication fork reversal prevents fork degradation in BRCA2-defective 
cells. (a) RPE-1 cells were transfected with siRNA before CldU (red) and IdU (green) labeling 
(siBRCA2, 48 h; siRAD51, 24 h), followed by treatment with 4 mM HU for 5 h. Left panel: levels of 
indicated proteins, assessed by western blot. TFIIH, loading control. Middle panel: a 
representative set of DNA fibers from each condition is shown. Right panel: IdU/CIdU tract length 
ratio is plotted. Horizontal lines and the numbers indicate the median value. Whiskers indicate the 
10-90 percentiles. At least one hundred replication forks were analyzed for each condition. 
Statistical analysis: Mann-Whitney test; ns, not significant; ****, P< 0.0001.  See also 
Supplementary Fig. 4a. (b) Frequency of reversed replication forks isolated from siLuc, siBRCA2 
(48 h) and siRAD51 (24 h) RPE-1 cells treated as in Fig. 1 (4 mM HU for 5 h; 50 mM mirin for 6 
h). In brackets the total number of analyzed molecules. Results of two independent EM 
experiments are in Supplementary Table 6. (c) The indicated U2OS-based cell lines were 
transfected with siRNA before CldU (red) and IdU (green) labeling (siBRCA2, 48 h; siRAD51, 24 
h), followed by treatment with 4 mM HU for 5 h and DNA fibre spreading. Left panel: levels of 
indicated proteins, assessed by western blot. TFIIH, loading control. Right panel: IdU/CIdU tract 
length ratio is plotted. Track length analysis and statistics as in Fig. 3a. (d) Stable derivatives of 
ZRANB3-KO U2OS cells, expressing wild type (WT), helicase-dead (HD) or nuclease-dead (ND) 
ZRANB3 at endogenous levels were transfected with siRNA for BRCA2 48h before CldU (red) 
and IdU (green) labeling, followed by treatment with 4 mM HU for 5 h. Track length analysis and 
statistics as in Fig. 3a. (e) U2OS cells were transfected with the indicated siRNAs 48h before 
CldU (red) and IdU (green) labeling, followed by treatment with 4 mM HU for 5 h. The PARP 
inhibitor olaparib (10 mM) was optionally added 2h before CldU addition. Track length analysis 
and statistics as in Fig. 3a. 
 
 
Figure 4. Stable RAD51 nucleofilaments are required not to form, but rather to protect 
reversed forks from nucleolytic degradation.   (a) Control (BJ) or RAD51-T131P fibroblasts 
were labeled with CldU (red) and IdU (green), followed by treatment with 4 mM HU for 5 h and 50 
mM mirin for 6 h, as indicated. A set of representative DNA fibers from each condition is shown. 
Ratios of IdU versus CldU tracts are plotted. Track length analysis and statistics as in Fig. 3a. (b) 
EM-based assessment of the frequency of reversed replication forks isolated from BJ and T131P 
treated as indicated (4 mM HU for 5 h; 50 mM mirin for 6 h). In brackets the total number of 
analyzed molecules. Results of two independent EM experiments are in Supplementary Table 7.  
 
Figure 5. RAD52 promotes stalled fork degradation in BRCA2-defective cells   (a) U2OS 
cells were transfected with siRNA before labeling (siBRCA2, 48 h; siRAD52, 24 h) with CldU (red) 
and IdU (green), followed by treatment with 4 mM HU for 5 h. The RAD52 inhibitor (AICAR 40 
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mM) was optionally added 2h before CldU labelling. Left: levels of indicated proteins, assessed 
by western blot. TFIIH, loading control. Middle panel: a representative set of DNA fibers from 
each condition is shown. Right: ratios of IdU versus CldU tracts are plotted. Track length analysis 
and statistics as in Fig. 3a. (b) EM-based assessment of the frequency of reversed replication 
forks isolated from U2OS cells transfected with control and siRNA against BRCA2 (48 h) and/or 
RAD52 (24 h). Cells were treated with 4 mM HU for 5 h and 50 mM mirin for 6 h, as indicated. In 
brackets, the total number of analyzed molecules. Results of two independent EM experiments 
are in Supplementary Table 8. (c) HEK293T cells were transfected by the indicated siRNAs 48 h 
before the EdU-labelling for 15 min and then treated with HU 4 mM for 5 h. AICAR 40 mM 
(RAD52 inhibitor) was optionally added 2 h before EdU labelling and retained throughout the 
experiment. Proteins associated with nascent DNA were isolated by iPOND (see Methods) and 
detected with the indicated antibodies. For the thymidine chase experiment (Thy-chase) 10 mM 
thymidine was added for 2 h directly after the EdU labelling. In the control experiment (no EdU), 
the click reaction is performed using DMSO instead of biotin azide. The graph represents average 
and standard deviations (error bars) of quantified of MRE11 capture signals from three 
independent experiments. (d) Chromosomal breakage quantification after HU and mirin treatment 
(4 mM HU for 5 h; 50 mM mirin for 6 h) of U2OS cells after depletion of BRCA2 (48 h) and/or 
RAD52 (24 h). One hundred cells in pro-metaphase were analyzed. Similar results were obtained 
in two biological replicates. 
 
Figure 6. Fork reversal impairment suppresses fork degradation, but increases 
chromosomal breakage in BRCA2-defective cells. (a) Frequency of reversed replication forks 
isolated from unperturbed mouse ESCs – transfected with siLuc or siBrca2 (48 h) - and from 
Brca2−/− shPtip ESCs. In brackets the total number of analyzed molecules. Results of two 
independent EM experiments are in Supplementary Table 9. (b) Representative count of 
chromatid breaks upon 5 h treatment with HU 4 mM in control and ZRANB3 knockout (KO) U2OS 
cells; where indicated, 50 mM mirin was added 1h before HU treatment (6h total treatment), and 
siRNA transfection was performed 48 h (BRCA2) or 20 h (PTIP) before HU treatment. The 
number of chromatid breaks per chromosome spread was plotted. At least 150 chromosome 
spreads were analyzed. Error bars represent SEM. A representative DAPI stained chromosome 
spread is shown. Inset 1 and 2 show intact chromosomes while 3 and 4 display chromosomal 
breaks. (c) Chromosomal breakage quantification of HU treated (4 mM HU, 5 h) U2OS after 
optional depletion of BRCA2 (48 h) and/or PARP inhibition (Olaparib 10mM, added 2h before 
HU). At least 180 cells in pro-metaphase were analyzed. The number of chromatid breaks per 
chromosome spread was plotted. Error bars represent SEM. Similar results were obtained in 
three biological replicates.  
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Figure 7. Model for the role of different HR factors in stalled fork remodeling and 
protection. With the help of ZRANB3 and PARP activity, RAD51 promotes efficient reversal of 
stalled replication forks independently of BRCA2. Upon initial resection of reversed forks, RAD51 
is efficiently loaded by BRCA2 on regressed arms to limit MRE11/PTIP/RAD52-dependent 
nucleolytic degradation and promote efficient fork restart. In BRCA2-defective cells, deregulated 
MRE11-dependent degradation of reversed forks leads to ssDNA accumulation and 
chromosomal breaks. Limiting reversed fork degradation restores fork integrity and prevents 
chromosomal breakage. Preventing fork reversal also restores fork integrity in BRCA2-defective 
cells - by reduced availability of degradation substrates – but leads to increased chromosomal 
breakage, and is thus detrimental for genome stability.  
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Replication fork reversal triggers  
fork degradation in BRCA2-defective cells 
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Supplementary Table 1. Electron microscopy data for Figure 1b. Percentage of observed reversed 
forks (% RF) in three independent EM experiments for samples in Figure 1b. Number of analyzed 
molecules is indicated in brackets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2. Electron microscopy data for Supplementary Figure 1b. Percentage of 
observed reversed forks (% RF) in two independent EM experiments for samples in Supplementary 
Figure 1b. Number of analyzed molecules is indicated in brackets. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Supplementary Table 3. Electron microscopy data for Supplementary Figure 2e. Percentage of 
observed reversed forks (% RF) in two independent EM experiments for samples in Supplementary 
Figure 2e. Number of analyzed molecules is indicated in brackets. 
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Supplementary Table 4. Electron microscopy data for Figure 2a. Percentage of observed reversed 
forks (% RF) in two independent EM experiments for samples in Figure 2a. Number of analyzed 
molecules is indicated in brackets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 5. Electron microscopy data for Figure 2b. Percentage of observed reversed 
forks (% RF) in two independent EM experiments for samples in Figure 2b. Number of analyzed 
molecules is indicated in brackets. 
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Supplementary Table 6. Electron microscopy data for Figure 3b. Percentage of observed reversed 
forks (% RF) in two independent EM experiments for samples in Figure 3b. Number of analyzed 
molecules is indicated in brackets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 7. Electron microscopy data for Figure 4b. Percentage of observed reversed 
forks (% RF) in two independent EM experiments for samples in Figure 4b. Number of analyzed 
molecules is indicated in brackets. 
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Supplementary Table 8. Electron microscopy data for Figure 5b. Percentage of observed reversed 
forks (% RF) in two independent EM experiments for samples in Figure 5b. Number of analyzed 
molecules is indicated in brackets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 9. Electron microscopy data for Figure 6a. Percentage of observed reversed 
forks (% RF) in two independent EM experiments for samples in Figure 6a. Number of analyzed 
molecules is indicated in brackets. 
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Supplementary figures 
 
 
 
Supplementary Figure 1. ssDNA detection at stalled and reversed replication forks in BRCA2-defective cells. (a) 
Distribution of the reversed forks scored in Fig. 1b among different categories, based on the presence of detectable ssDNA 
stretches on the regressed arm. “dsDNA” represents reversed forks where no ssDNA is detected, while “ssDNA” represents 
regressed arms that are entirely single-stranded. (b) Frequency of reversed forks scored in siLuc and siBRCA2 RPE-1 
treated with 4mM of HU for the indicated time. Different reversed fork categories are represented, as in panel (a). The total 
frequency of reversed forks is indicated above the bars. The total number of replication intermediates analyzed is indicated 
in parentheses. Results of two independent EM experiments are in Supplementary Table 2. (c) Graphical distribution of 
ssDNA length at the junction for the samples in (b). Only molecules with detectable ssDNA stretches are included in the 
analysis. The lines show the median length of ssDNA regions at the fork in the specific set of analyzed molecules. 
Statistical analysis: Mann-Whitney test; ns, not significant; **, P< 0.01. The number of analyzed molecules is in brackets.  
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 Supplementary Figure 2. PTIP depletion suppresses reversed fork processing in HU-treated BRCA2-defective 
RPE-1 cells (a) Western blot analysis of PTIP levels and (b) FACS analysis for DNA synthesis (EdU incorporation) and 
DNA content (DAPI) in mock-depleted and PTIP-depleted RPE-1 cells 16h, 24h and 48h after siRNA transfection. Top 
right: gating strategy to identify intact cells (SSC/FSC) and exclude doublets (DAPI-A/DAPI-H). Overall, roughly 80% of 
the 20’000 analyzed cells is scored for EdU/DAPI analysis in each samples. At 48 h, PTIP depleted cells undergo cell cycle 
arrest in G1 phase, while no such effect is observed shortly after protein depletion. (c) RPE-1 cells were transfected with 
siRNA before CldU (red) and IdU (green) labeling (siBRCA2, 48 h; siPTIP, 20 h), followed by treatment with 4 mM HU 
for 5 h, as indicated in the scheme. IdU/CIdU ratio is plotted. Horizontal lines and the numbers indicate the median value. 
Whiskers indicate the 10-90 percentiles. At least one hundred replication forks were analyzed for each condition. Statistical 
analysis: Mann-Whitney test; ns, not significant; ****, P< 0.0001. (d) Schematic of the alternative labeling protocol for 
single-molecule DNA fiber tract analysis and representative images of control and BRCA2-defective U2OS cells. U2OS 
cells were transfected with siRNA before CldU labeling (red) and IdU labeling (green) concomitantly with 4mM HU 
treatment as indicated. Size distribution of IdU tract length is plotted. Horizontal lines and the numbers indicate the median 
value. Whiskers indicate the 10-90 percentiles. At least one hundred replication forks were analyzed for each condition. 
Statistical analysis: Mann-Whitney test; ns, not significant; ****, P< 0.0001. (e) Frequency of reversed replication forks 
isolated from siLuc, siBRCA2 (48 h) and siPTIP#1 (20 h) RPE-1 cells upon 5 h treatment with 4 mM HU. The number of 
replication intermediates analyzed is indicated in parentheses. Results of two independent EM experiments are in 
Supplementary Table 3. (f) Graphical distribution of ssDNA length at the junction in siBRCA2 (48 h) and/or siPTIP#1 (20 
h) RPE-1 cells treated with 4 mM of HU for 5 h. Only molecules with detectable ssDNA stretches are included in the 
analysis. The lines show the median length of ssDNA regions at the fork in the specific set of analyzed molecules. 
Statistical analysis: Mann-Whitney test; ns, not significant; ***, P< 0.001. The number of analyzed molecules is in 
brackets. 
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Supplementary Figure 3. ssDNA accumulation upon BRCA2 defects in HU-treated V-C8 cells and CPT-treated 
U2OS cells (a) Graphical distribution of ssDNA length at the junction found in VC-8 cells and V-C8 cells stably 
expressing a full-length or mutated variant of BRCA2 (S3291A) treated with 4mM of HU for 5 h and 50 µM of mirin for 6 
h. (b) Graphical distribution of ssDNA length at the junction in siLuc and siBRCA2 (48 h) RPE-1 cells treated with 25 nM 
of CPT for 1 h and 50 µM of mirin for 2 h. For both panels, only the molecules with detectable ssDNA stretches are 
included in the analysis. The lines show the median length of ssDNA regions at the fork. Statistical analysis: Mann-
Whitney test; ns, not significant; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. 
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Supplementary Figure 4. Control experiments for the effects of RAD51 and RAD52 downregulations in RPE-1 cells 
and for BRCA2 downregulation in ESCs. (a) RPE-1 cells were transfected with the indicated siRNAs before CldU (red) 
and IdU (green) labeling, followed by treatment with 4 mM HU for 5 h. Left: levels of indicated proteins, assessed by 
western blot. TFIIH, loading control. Right panel: IdU/CIdU tract length ratio is plotted. Track length analysis and statistics 
as in Fig. 3d. (b) FACS analysis for DNA synthesis (EdU incorporation) and DNA content (DAPI) in U2OS cells after 
transfection with siRNA targeting BRCA2 (48h) and/or RAD52 (24h). No obvious defect in cell cycle progression is 
induced by downregulation of these proteins in the experimental conditions of Fig. 5a-b. (c) Time course for Brca2 mRNA 
abundance measured by quantitative RT-PCR in mouse embryonic stem cells transfected with siLuc or siBrca2. The 
increase of Brca2 mRNA at 72h is most likely due to selective elimination of ESCs effectively depleted of Brca2 and 
overgrowth of cells that were not transfected by the siRNA. 
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Supplementary Figure 5. Uncropped western blots. (a) Figure 1b, (b) Figure 2a, (c) Figure 3a, (d) 
Figure 3c, (e) Figure 5a, (f) Figure 5c. 
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3.3 Personal contribution in other projects  
3.3.1 Deregulated origin licensing leads to chromosomal breaks by 
rereplication of a gapped DNA template 	  
I started my PhD training in the lab of Massimo Lopes working on an advanced project whose aim 
was to unravel new mechanistic insights of DNA rereplication, a notorious causative factor of 
genome instability. We showed that origin firing deregulation by EMI1 depletion leads to rapid 
origin reactivation and checkpoint-blind ssDNA gaps. These gaps persist in the template and are 
converted to DSBs due to uncontrolled reactivation of replication origins. 
 
My contribution consisted in performing the experiments shown in the following figures: FACS 
analysis in Fig 1, Fig 2, Fig S1, Fig S2, Fig S3; Western blot in Fig 1, Fig 2, Fig S1, Fig S4; Fibers 
analysis Fig 3.  
 
In addition to allow me to become a contributing author to the final publication, this initial period 
was fundamental for introducing me in the use of the majority of the techniques I exploited in the 
other studies presented in this thesis. 
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leads to chromosomal breaks
by rereplication of a gapped
DNA template
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Kingdom
Deregulated origin licensing and rereplication promote
genome instability and tumorigenesis by largely elusive
mechanisms. Investigating the consequences of Early
mitotic inhibitor 1 (Emi1) depletion in human cells,
previously associated with rereplication, we show by
DNA fiber labeling that origin reactivation occurs rap-
idly, well before accumulation of cells with >4N DNA,
and is associated with checkpoint-blind ssDNA gaps and
replication fork reversal. Massive RPA chromatin load-
ing, formation of small chromosomal fragments, and
checkpoint activation occur only later, once cells com-
plete bulk DNA replication. We propose that deregulated
origin firing leads to undetected discontinuities on newly
replicated DNA, which ultimately cause breakage of
rereplicating forks.
Supplemental material is available for this article.
Received July 12, 2013; revised version accepted October 30,
2013.
The activation of DNA replication origins is a tightly
regulated mechanism, entailing two main steps: (1) ‘‘or-
igin licensing,’’ restricted to late mitosis and early G1,
when essential replication initiation proteins (ORC1,
Cdc6, Cdt1, and Mcm2–7) are sequentially loaded on
origin DNA sequences, forming the ‘‘prereplicative com-
plex’’ (preRC), and (2) ‘‘origin firing,’’ occurring through-
out S phase, when additional proteins are recruited to the
preRC and start unwinding andDNA synthesis (Arias and
Walter 2007). As relicensing and thus rereplication are
detrimental to genome stability, several cyclin-dependent
kinase (CDK)-dependent and -independent mechanisms
have evolved to coordinate these steps with cell cycle
progression (Blow and Dutta 2005; Arias and Walter
2007).
Although several preRC components are targets of
regulation, the major mechanism by which metazoans
prevent origin licensing during S phase is inactivation of
Cdt1 by ubiquitin-mediated degradation or binding to its
inhibitor Geminin. Cdt1 proteolysis is tightly linked to
the cell cycle, as ubiquitylation requires CDK-dependent
phosphorylation (Li et al. 2003; Sugimoto et al. 2004;
Nishitani et al. 2006). Moreover, CUL4/DDB1-mediated
ubiquitylation of Cdt1 occurs in S phase or in response to
DNA damage (Arias and Walter 2006; Nishitani et al.
2006; Senga et al. 2006). Geminin exerts its inhibitory
function on Cdt1 in S, G2, and early M phase and is
inactivated in late M phase by anaphase-promoting com-
plex (APC/C)-dependent polyubiquitylation, leading to
reactivation of origin licensing (McGarry and Kirschner
1998; Wohlschlegel et al. 2000; Tada et al. 2001; Li and
Blow2004). Accordingly,Geminin depletion induces rerep-
lication and activation of the DNA damage response
(DDR) (Melixetian et al. 2004; Zhu et al. 2004).
By direct control of Geminin and indirect control of
Cdt1 proteolysis via regulation of CycA–CDK activity,
APC/C plays a pivotal role coordinating origin licensing
with cell cycle progression (Hook et al. 2007). APC/C
activity is inhibited by Early mitotic inhibitor 1 (Emi1)
(Wang and Kirschner 2013), which thereby stabilizes
APC/C substrates like Geminin and Cyclin A (Di Fiore
and Pines 2007). Thus, inactivation of Emi1 leads to
degradation of both inhibitors of Cdt1 activity, resulting
in massive rereplication and DDR activation (Machida
and Dutta 2007).
As many origin licensing genes are overexpressed in
cancer cells and several oncogenes are known to affect
origin licensing, it is suspected that deregulated licensing
contributes to genome instability and tumorigenesis
(Hook et al. 2007; Blow and Gillespie 2008). However,
our understanding of how rereplication challenges ge-
nome stability is very limited. Studies with Xenopus
laevis egg extracts provided the first insight into the
effects of rereplication. Addition of recombinant Cdt1 to
G2-arrested egg extracts was shown to trigger DNA
breaks, proposed to arise from head-to-tail collision of
rereplicating forks (Davidson et al. 2006). However, little
information is available on the mechanisms leading
to DNA damage and DDR activation in rereplicating
human cells.
We combined cell/molecular biology and in vivo single-
molecule approaches to investigate how deregulated
origin licensing by Emi1 depletion affects replicating
chromosomes. We show that cells experience mild DNA
replication stress and ssDNA accumulation during the
first replication round upon licensing deregulation, which
may act as precursor for DNA breaks, when rereplicating
forks approach ssDNA gaps on the template. Extending
the analysis to other experimental systems of deregulated
! 2013 Neelsen et al. This article is distributed exclusively by Cold
Spring Harbor Laboratory Press for the first six months after the full-issue
publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After
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licenses/by-nc/3.0/.
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licensing (Geminin depletion and Cdt1 addition in
X. laevis extracts), we propose a new model for rerepli-
cation-induced chromosomal breakage, which may con-
tribute to cancer-relevant genome rearrangements.
Results and Discussion
Emi1 depletion affects DNA synthesis prior
to accumulation of >4N DNA, chromosomal breakage,
and checkpoint activation
To gain mechanistic insight into how deregulated origin
licensing affects the replication process, leading to DNA
breaks and DDR activation, we depleted Emi1 in U2OS
cells, a condition previously associated with rereplication
and DNA damage (Machida and Dutta 2007). Using flow
cytometry, we monitored cell cycle progression (DNA
content), DNA synthesis (EdU incorporation), and DDR
activation (phosphorylation of H2AX [gH2AX]) (Supple-
mental Fig. S1) after Emi1 depletion. Sixteen hours to 24 h
after siEmi1 transfection, we noticed accumulation of
cells in S phase and a reduced incorporation rate in mid–
late S phase (Fig. 1A). In synchronized cells, the impact of
deregulated origin licensing on DNA synthesis was
detected from the onset of the first S phase (Supplemental
Fig. S2). At these time points, gH2AX was only detected
in cells close to having completed a first round of bulk
DNA replication (Fig. 1A,B). Later (32–40 h), gH2AX and
a markedly reduced rate of DNA synthesis were detected
in cells displaying >4N DNA, a commonly used readout
for rereplication (Fig. 1A,C). Only at 32–40 h did cells
accumulate detectable levels of double-strand breaks
(DSB) and display activation of ATM and ATR pathways
(phosphorylation of KAP1/RPA2-S4/S8 and CHK1/RPA2-
S33, respectively), as expected for DSB-induced DDR (Fig.
1D,E). A relevant fraction of chromosomal fragments
induced by Emi1 depletion is significantly smaller (20–
100 kb) than camptothecin-induced DSB (0.5–2 Mb) (Fig.
1E; Supplemental Fig. S1B; Hanada et al. 2007), suggesting
that rereplication-induced DSBs are clustered. DNA
breakage at 32–40 h was also confirmed by colocalization
of gH2AX and 53BP1, particularly evident in cells with
‘‘giant nuclei,’’ a sign of extensive rereplication (Supple-
mental Fig. S1C–E; Zhu et al. 2004). Altogether, these
data indicate that mild replication stress during the first
S phase after Emi1 depletion precedes cell cycle arrest,
DNA breakage, and DDR activation, which are coupled
to overt rereplication (DNA content >4N). Similar obser-
vations were made in untransformed human epithelial
cells (RPE-1) (Supplemental Fig. S3), showing that the
stepwise impact on DNA replication and genome stabil-
ity is a general consequence of Emi1 depletion.
Progressive RPA accumulation on chromatin precedes
rereplication-associated DNA damage
To further characterize DNA replication stress early after
Emi1 depletion, we monitored chromatin loading of the
human ssDNA-binding protein (RPA) (Forment et al.
2012). Limited amounts of ssDNA are present during
DNA replication, leading to RPA chromatin loading in
S phase (Fig. 2A; Supplemental Fig. S4A; Forment et al.
2012). While this signal is rapidly lost as control cells
complete S phase, Emi1 depletion leads to progressive
accumulation of RPA on chromatin and unusually high
RPA levels in mid–late S-phase cells (Fig. 2A). RPA foci
colocalized with gH2AX foci at late time points (32–40 h)
(Supplemental Fig. S4A), presumably marking processing
of the detected DSBs (Fig. 1E; Supplemental Fig. S1C,D).
However, in both U2OS and RPE-1 cells, some RPA ac-
cumulation was already observed at earlier time points
Figure 1. Emi1 depletion causes DNA replication stress in S phase
and DDR activation and DNA breakage in cells with $4 DNA. (A)
FACS analysis of DNA synthesis (EdU), DNA content (DAPI), and
DDR activation (gH2AX) after mock (siLUC) or Emi1 depletion in
U2OS cells using two different siRNAs. gH2AX+ cells are in red (see
also Supplemental Fig. S1A). Yellow arrowheads indicate cells with
compromised DNA synthesis. gH2AX+ cells (B) and cells with >4N
DNA (C) after mock (siLUC) or Emi1 depletion quantified by FACS.
Mean + SEM; n = 3. (D) ATR (pCHK1), ATM (pKAP1) activation, RPA
phosphorylation (RPA2 pS4/S8 and pS33), and total DDR proteins
(CHK1, KAP1, and RPA2) assessed by Western blot upon Emi1
depletion. (TFIIH) Loading control. (E) DNA breakage after mock
(siLUC) or Emi1 depletion monitored by pulse-field gel electropho-
resis. The solid and dashed lines indicate large (0.5- to 2-Mb) and
smaller (20- to 100-kb) chromosomal fragments, respectively. The
molecular size markers are based on data in Supplemental Figure
S1B. Four-hour treatment with 1 mM camptothecin (CPT) served as
a positive control for DSB.
Neelsen et al.
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(16–24 h), when it was largely uncoupled from DDR
activation, extensive rereplication (measured by flow
cytometry), and DNA breaks (Figs. 1, 2A; Supplemental
Fig. S3D). Furthermore, even at later time points ($24 h)
after Emi1 depletion, when gH2AX is clearly detectable
in the population, our FACS experiments identified a
cell population with unusually high RPA content in the
absence of gH2AX (Fig. 2B, yellow dots, RPA++ gH2AX!).
These data suggest that Emi1 depletion progressively
induces ssDNA accumulation, which goes undetected
by the DDR and precedes rereplication-associated DNA
breaks. Importantly, PCNA ubiquitylation, a sensitive
marker of replication-associated ssDNA gaps (for re-
view, see Chen et al. 2011), was detectable within 24 h
(Fig. 2C) and thus earlier than other DDR markers
(Fig. 1D).
Emi1 depletion does not detectably impair fork
progression but induces refiring of clustered origins
before accumulation of >4N DNA content
We next monitored the effect of Emi1 depletion on fork
progression by DNA fiber spreading (Jackson and Pombo
1998). Ongoing forks were identified by a red–green
pattern (Supplemental Fig. S5A). Fork progression ap-
peared unaffected by Emi1 depletion when we used a
10-min labeling time (Fig. 3A). However, in Emi1-
depleted cells, tract length increased more markedly
than in control cells with longer labeling times (Fig. 3A;
Supplemental Fig. S5C,D). This suggests that Emi1 de-
pletion does not affect progression of individual forks but
that deregulated activation of clustered replication ori-
gins leads to more frequent fork fusion and thus longer
tracts. We then adapted the labeling protocol to detect
DNA rereplication events, modifying a published pro-
tocol (Dorn et al. 2009). A 120-min CldU pulse followed
by a 30-min IdU pulse allowed us to follow fork pro-
gression and reactivation of replication origins in pre-
viously replicated tracts (Supplemental Fig. S5A). ‘‘Rerep-
Figure 2. siEmi1-induced deregulation of origin licensing promotes
RPA chromatin binding and ubiquitylation of PCNA from the first
S phase. (A) FACS analysis of chromatin-bound RPA and DNA
content (DAPI) after mock (siLuc) or Emi1 depletion in U2OS cells.
(B) gH2AX/RPA levels in samples in A. Black, green, and yellow
regions identify RPA negative cells (!), cells with S-phase RPA levels
(+), and cells with elevated RPA (++), respectively. The red region
identifies gH2AX+ cells. See Supplemental Figure S4B for Emi1
levels. (C) Analysis of PCNA ubiquitylation in mock-transfected
cells (siLuc) and at the indicated time points after Emi1 depletion
(siEmi1 #1). The dotted line indicates ubiquitylated PCNA. UV-
irradiated cells served as positive control. (TFIIH) Loading control.
Figure 3. Rereplication is detectable by a DNA fiber-spreading
assay before completion of bulk DNA synthesis. (A) Length of newly
replicated tracts (IdU; green) in mock-depleted U2OS cells (siLuc)
and after Emi1 depletion (siEmi1 #1), using 10-min or 20-min
labeling pulses. (B,C) Representative DNA tracts labeled with CldU
for 2 h and IdU for 30 min to identify termination and rereplication
events. (B) A replication ‘‘termination’’ event. (C) Two ‘‘rereplica-
tion’’ events in close proximity. (D) Quantification of rereplication/
termination events as shown in B and C after mock (siLuc) or Emi1
depletion. The percentage indicated represents the fraction of
rereplication events in the total population of ‘‘red–green–red’’ tracts
analyzed. (Whiskers) 10–90 percentile; (***) P < 0.0001; (**) P <
0.005; (ns) not significant, Mann-Whitney test; n = 100 in A. Bar, 10
mm. See Supplemental Figure S5, A and B, for Emi1 levels and
labeling protocols to study fork progression (A) and rereplication
events (B,C).
Rereplicating fork breakage on a gapped template
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lication’’ events during the second labeling should appear
as green signals embedded in a longer red tract. A similar
pattern is expected for physiological fork fusion events
during the second label (‘‘termination’’), but rereplication
events can be distinguished by the substantial overlap of
red and green signals (Fig. 3B,C). As expected, in control
cells, virtually all green signals identified within red
tracts displayed a termination pattern (‘‘red–green–red’’)
(Fig. 3B,D). In contrast, Emi1-depleted cells showed
rereplication events (‘‘red–yellow–red’’), often coupled to
further progression of the first set of forks during the
second labeling period (Fig. 3C, note the distal green
tracts). Surprisingly, these ‘‘rereplication’’ events were
almost as frequent as ‘‘termination’’ events already 20 h
after siRNA transfection (Fig. 3D). At 40 h, when rerepli-
cation has led to >4N DNA content (Fig. 1A,C), rerepli-
cation events were more frequent than fork fusions and
were occasionally clustered on the same DNA fiber (Fig.
3C,D). These data demonstrate that origin reactivation
can be detected by DNA fiber spreading before it is
detectable by flow cytometry and that refiring of clus-
tered origins occurs already during a first round of rep-
lication with deregulated origin licensing.
Deregulation of origin licensing induces ssDNA gaps
on replicated duplexes, which can be template
for rereplication
To gain additional insight into themolecular consequences
of deregulated origin licensing, we investigated in vivo
replication fork structure by electron microscopy (EM)
(Neelsen et al. 2014). Already 20 h after siRNA trans-
fection, several marks of replication stress were detect-
able (Fig. 4). Small (<1-kb) replication bubbles were over-
represented upon Emi1 depletion (9%–10% compared
with 1%–2% in control U2OS cells), suggesting that
deregulated firing is accompanied by reduced fork pro-
gression from the origin. These replicated tracts would be
too small for detection in DNA fiber assays, which may
explain why the reduced EdU incorporation after Emi1
depletion (Fig. 1A) is not accompanied by detectable
reduction in fork progression (Fig. 3A). As implied by
RPA chromatin loading and PCNA ubiquitylation (Fig.
2A,C), 11% of forks exposed ssDNA gaps 20 h after
siEmi1 transfection compared with 1% of forks in control
cells (Fig. 4A,B; Supplemental Fig. S6A). Furthermore,
;13% of the replication forks had undergone reversal
(Supplemental Fig. S6B,C). The latter two features closely
resemble the effects of oncogene activation (Neelsen
et al. 2013) and thus most likely reflect the licensing
defects common to these genetic conditions (Hook et al.
2007; Blow and Gillespie 2008) and their consequences in
terms of nucleotide depletion (Bester et al. 2011) and/or
interference with transcription (Jones et al. 2013). Al-
though ssDNA sensors (e.g., RPA chromatin loading and
PCNA ubiquitylation) (Fig. 2A,C) detected these changes
in the architecture of replication intermediates, they are
‘‘checkpoint-blind’’ (i.e., not associated per se with DDR
activation) (Fig. 1A,D), as already shown for CycE over-
expression (Neelsen et al. 2013). The proportion of forks
displaying ssDNA gaps increases from 11% to 37%
between 20 and 40 h, when rereplication andDSB become
detectable by flow cytometry and PFGE, respectively
(Figs. 1A,C,E, 4B). Intriguingly, a significant proportion
of the observed ssDNA gaps were located on template
DNA ahead of the replication forks (Fig. 4B,C; Supple-
mental Fig. S6D). At 40 h, when all cells completed a first
round of replication and the relative proportion of rerep-
licating forks in our EM samples is expected to increase,
20% of the ssDNA gaps (n = 6 of 22) were detected on
template DNA ahead of the replication forks (Fig. 4B).
Figure 4. Emi1 depletion leads to ssDNA gaps on the replicated
duplex, which persist as a template for rereplicating forks. (A,C)
Electron micrographs of representative replication forks from U2OS
cells 40 h after transfection with siEmi1. Black arrows indicate
ssDNA gaps. The insets show magnified ssDNA gaps and schemes
of fork structure, indicating parental (P) and replicated (R) duplexes.
Gaps are on a replicated duplex in A and on the parental duplex in C.
Black and gray lines describe parental and newly synthesized DNA
strands in the replicated duplexes, respectively. Bars: 100 nm (250
base pairs [bp]); inset, 50 nm. (B) Frequency of replication forks with
ssDNA gaps in mock-depleted cells (siLuc) and after Emi1 depletion
(siEmi1 #1). #RI is the number of analyzed replication intermediates.
(D) Sperm nuclei replication assays in Xenopus interphase extracts.
For S-phase experiments, extracts were optionally supplemented
with 10 ng/mL Cdt1 at the time of sperm and [a-32P]dATP addition
and incubated for 60 min. For G2 experiments, Cdt1 was optionally
added with [a-32P]dATP 90 min after sperm addition and incubated
for a further 60 min. After incubation, DNA was isolated, separated
by neutral agarose gel electrophoresis, and autoradiographed. The
dashed line indicates sperm DNA fragmentation. The asterisk
indicates branched replicating DNA molecules retained in the well.
(E) Frequency of replication forks with ssDNA gaps recovered after
sperm nuclei incubation in S-phase or G2-phase extracts (see D),
with optional addition of Cdt1. # RI is the number of analyzed
replication intermediates. (F) Model for the formation of chromo-
somal breaks upon deregulation of origin licensing by Emi1 de-
pletion. Excessive firing of clustered origins leads to replication
stress during the first S phase and accumulation of ssDNA gaps.
Uncontrolled reactivation of replication origins in this context
triggers chromosomal breakage by replication of a discontinuous
template.
Neelsen et al.
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These data strongly suggest that gaps accumulating
during the first round of replication after Emi1 depletion
persist and present a damaged template for new replica-
tion rounds.
To further test this hypothesis, we analyzed by EM a
different experimental system associated with rereplication
and DNA breakage; i.e., addition of Cdt1 to replication
sperm nuclei in X. laevis egg extracts (Davidson et al.
2006). In line with published results, addition of Cdt1
(Ferenbach et al. 2005) induced [a-32P]dATP incorporation
in G2 extracts, particularly visible on branched DNA
molecules retained in the well (Fig. 4D; Supplemental
Fig. S6E). Moreover, rereplication was associated with
DNA breakage when Cdt1 was added to S-phase and G2
extracts (Fig. 4D). The analysis of replication intermedi-
ates confirmed an accumulation of ssDNA gaps upon
Cdt1 addition, particularly marked in G2 extracts (Fig.
4E) where multiple rounds of rereplication have been
reported (Davidson et al. 2006). Similar to Emi1 deple-
tion, ssDNA gaps were also observed ahead of the rep-
lication forks, showing that rereplication was impaired
by template discontinuities (Fig. 4E).
A new model for chromosomal breakage associated
with deregulated origin licensing and rereplication
Our data strongly suggest that deregulated origin firing
rapidly induces ssDNA gaps during DNA replication and
that these persist in the template, where they cause
stalling and eventually breakage of rereplicating forks
(Fig. 4F). Rereplicating forks could break by simply
impacting ssDNA gaps on the template (‘‘runoff’’). Alter-
natively, they could stall upstream of the gap and later be
resolved into DSBs by slow ‘‘runoff,’’ nucleolytic process-
ing, or head-to-tail collision with forks generated in
following rounds of rereplication. In support of transient
stalling and remodeling, small replication bubbles accu-
mulated upon Emi1 depletion, indicative of early fork
stalling from reactivated origins. Moreover, the frequency
of reversed forks remained high 40 h after Emi1 depletion,
when rereplicating forks are overrepresented in our EM
samples (Fig. 3D; Supplemental Fig. S6C). Fork reversal
was associated with fork slowing during replication of
a nicked template, thereby protecting forks from break-
age (Ray Chaudhuri et al. 2012). Thus, rereplicating forks
could transiently arrest and reverse at ssDNA gaps before
eventually undergoing breakage.
A prediction of our model is that the genotoxicity of
rereplication correlates with the extent of origin firing
deregulation in the previous replication round, as this
creates the template discontinuities for rereplication. We
tested this hypothesis by comparing the described effects
for Emi1 depletion with Geminin depletion, a genetic
condition associated with mild overreplication (Melixetian
et al. 2004; Zhu et al. 2004), in which CDK-dependent
Cdt1 inactivation partially restrains deregulated origin
firing (Hook et al. 2007; Machida and Dutta 2007). In line
with a recent study (Klotz-Noack et al. 2012), Geminin-
depleted cells showed unperturbed EdU incorporation
and progression in the first S phase, indicating marginal
replication stress (Supplemental Fig. S7A). Accordingly,
Geminin-depleted cells undergoing overt rereplication
(>4N DNA content) displayed gH2AX only after comple-
tion of the first S phase and transition into a mitotic state
(H3 phosphorylation) (Supplemental Fig. S7B). In line
with our model, rereplication induced by Geminin de-
pletion is associated with higher EdU incorporation and
less DNA damage than Emi1 depletion, indicated by
reduced gH2AX in cells with >4N DNA content (40 h)
(Supplemental Fig. S7A,C). Intriguingly, if deregulation of
origin licensing is induced after S-phase completion,
DNA breakage requires at least two rounds of rereplica-
tion, as observed with Cdt1 addition to sperm nuclei in
G2-arrested X. laevis extracts (Davidson et al. 2006),
reinforcing the conclusions of this study. In this view,
fork breakage during rereplication would not require
head-to-tail fork collision (Davidson et al. 2006) but
would rather occur as forks approach ssDNA gaps in
close proximity to the origin, resulting in the observed
release of small DNA fragments (Figs. 1E, 4F; Davidson
et al. 2006). Accordingly, even in experimental conditions
where rereplicating forks should represent a substantial
fraction of total replication intermediates (siEmi1 40 h,
Cdt1 addition in G2 extracts), we could never identify by
EM a replicating and a rereplicating fork on the same
DNA fragment.
The molecular mechanisms characterized here under
conditions of severe rereplication could also be relevant
for milder deregulation of origin licensing, associated
with genome evolution and tumorigenesis (Hook et al.
2007; Green et al. 2010). As mild oncogene-induced
replication stress can go undetected by cell cycle check-
points (Fig. 1D; Neelsen et al. 2013), reactivation of
specific replication origins in the presence of unrepaired
ssDNA gaps may compromise chromosome integrity. In-
triguingly, complex rearrangements in tumors have been
recently associated with replication errors and copy
number changes (Liu et al. 2011), which could result
from breakage and repair of overreplicating chromosomes
by mechanisms similar to those described here.
Materials and methods
Cell culture and transfections
U2OS and hTERT RPE-1 retinal pigmented epithelial cells were grown in
DMEM + 10% FCS. Cells were transfected with the indicated siRNAs
using RNAiMAX (Invitrogen) according to the manufacturer’s instruc-
tions: siLuc (10 nM; 59-GGUACGCGGAAUACUUCGAdTdT-39), siEmi1
#1 (10 nM; 59-GAUUGUGAUCUCUUAUUAAdTdT-39), siEmi1 #2 (10
nM; 59-GAGAAUUUCGGUGACAGUCUAdTdT-39), and siGeminin (20
nM; 59- UGCCAACUCUGGAAUCAAAdTdT-39).
Methods
Flow cytometry was essentially performed as described previously for
gH2AX/EdU/DAPI in Neelsen et al. (2013) and for gH2AX/RPA/DAPI in
Forment et al. (2012). DNA fiber spreadings were performed according to
Ray Chaudhuri et al. (2012) with the modifications outlined in the text.
Pulse-field gel electrophoresis, immunofluorescence, and sample prepa-
ration for EM have been described in Neelsen et al. (2013, 2014). Protocols
for Cdt1 purification, replication assays in X. laevis egg extracts, and
isolation of genomic DNA for electron microscopic analysis can be found
in the Supplemental Material. Detailed protocols for all other methods
and a list of antibodies are included in the Supplemental Material.
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Supplemental Methods 
Flow cytometry 
Flow cytometric analysis for γH2AX/EdU/DAPI and H3-pS10/EdU/DAPI was carried 
out as described previously. Briefly, cells were labeled with EdU, harvested and fixed 
for 10 min with 4% formaldehyde/PBS. Cells were washed with 1% BSA/PBS pH 
7.4, permeabilized with 0.5% saponin/1% BSA/PBS and stained with anti-γH2AX 
antibody (Millipore, # 05-636) or anti-H3-pS10 (Millipore, # 06-570), followed by 
incubation with a suitable secondary antibody. Incorporated EdU was labeled 
according to the manufacturer’s instructions (Invitrogen, # C35002). For flow 
cytometric analysis for γH2AX/RPA/DAPI, non-chromatin bound proteins were pre-
extracted with 0.2% Triton X-100/PBS for 10 minutes on ice, fixed as above and 
stained with antibodies against γH2AX (Cell Signaling, #9718) and RPA 
(Calbiochem, NA19L) and suitable secondary antibodies. In both assays, DNA was 
stained with 1 µg/ml DAPI, samples were measured on a Cyan ADP flow cytometer 
(Beckman Coulter) and analyzed with Summit software v4.3. 
 
Pulse field gel electrophoresis, single cell microscopy and antibodies 
Pulse-field gel electrophoresis and was performed as reported previously. Briefly, 
cells were embedded in a 0.8% agarose plug (2.5×105 cells/plug), digested in lysis 
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buffer (100 mM EDTA, 1% (w/v) sodium lauryl sarcosyne, 0.2% (w/v) sodium 
deoxycholate, 1 mg/ml proteinase K) at 37 °C for 48 h and washed in 10 mM TrisHCl 
pH8.0, 100 mM EDTA. Electrophoresis was performed at 14 °C in 0.9% (w/v) Pulse 
Field Certified Agarose (BioRad) containing Tris-borate/EDTA buffer in a BioRad 
CHEF DR III apparatus (9 h, 120°, 5.5 V/cm, 30 – 18 s switch time, 6 h, 117°, 4.5 
V/cm, 18 – 9 s switch time, 6 h, 112°, 4 V/cm, 9 – 5 s switch time). Lambda Ladder 
(Biorad, #170-3635) was run as size standard. The gel was stained with ethidium 
bromide and imaged on an Alpha Innotech Imager. For single cell immunostaining, 
cells were pre-extracted with 0.5% Triton X-100/PBS for 5 minutes on ice, stained 
with indicated antibodies and mounted with Vectashield (Vector Laboratories). 
Images were acquired on a Leica CLSM SP2 microscope (Leica Microsystems) 
equipped with a HCX PL APO CS 63x objective. The following antibodies were used:  
γH2AX (Millipore, # 05-636), 53BP1 (Santa Cruz, sc-22760), CHK1 pS345 (Cell 
Signaling, #2348), CHK1 (Santa Cruz, sc-8408), EMI1 (Invitrogen, 38-5000), 
Geminin (Santa Cruz, sc-13015), KAP1-pS824 (Bethyl, A300-767A), KAP1 (Bethyl, 
A300-274A), PCNA (PC10, Santa Cruz, sc-56), RPA2 (Calbiochem NA19L), RPA2 
(RPA32)-pS4/S8 (Bethyl, A300-245A), RPA2 (RPA32)-pS33 (Bethyl, A300-246A), 
TFIIH (Santa Cruz, sc-293). Secondary antibodies were Alexa Fluor-conjugates 
(Alexa Fluor-488, -594 and -647, Invitrogen). 
 
Chromatin enrichment 
For detection of ubiquitylated PCNA, cells were washed with ice-cold PBS and pre-
extraction buffer containing 25mM Hepes 7.4, 50mM NaCl, 1mM EDTA, 3mM 
MgCl2, 300mM sucrose and 0.5% Triton X-100. Cells were then incubated in fresh 
pre-extraction buffer for 10 min on ice, washed with cold pre-extraction buffer and 
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PBS and collected by scraping in Laemmli buffer. Samples were boiled, sonicated and 
analysed by SDS-PAGE. PCNA protein was detected using Thermo Scientific 
SuperSignal West Femto Chemiluminescent Substrate. 
 
DNA fiber spreadings 
Cells were sequentially pulse labeled with 30 µM IdU and 250 µM CldU for the 
indicated times and harvested. Cells were then lysed and DNA fibers stretched onto 
glass slides, as described. Briefly, the fibers were denatured with 2.5 M HCl for 1 h, 
washed with PBS and blocked with 0.2% Tween 20 in 2% BSA/PBS. CldU and IdU 
tracks were revealed with anti-BrdU antibodies recognizing CldU (Abcam, ab6326) 
and IdU (BD, 347580), respectively, and appropriate secondary antibodies. Images 
were acquired with an Olympus IX81 microscope, CellR software (Olympus) and an 
Orca camera (Hamamatsu). Statistical analysis was carried out using GraphPad Prism. 
 
Electron microscopic analysis of genomic DNA 
In vivo psoralen cross-linking, isolation of total genomic DNA, enrichment of the 
replication intermediates and their EM visualization were carried out as described. 
Briefly, cells were harvested, genomic DNA was crosslinked by two rounds of 
incubation in 10 µM 4,5',8-Trimethylpsoralen and two minutes of irradiation with 366 
nm UV light. Cells were lysed, genomic DNA was isolated from the nuclei by 
proteinase K digestion and phenol-chloroform extraction. Purified DNA was digested 
with PvuII and replication intermediates were enriched on a BND cellulose column. 
EM samples were prepared by spreading the DNA on carbon-coated grids and 
visualized by platinum rotary-shadowing. Images were acquired on a FEI Tecnai G2 
Spirit microscope and analysed with ImageJ. 
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Cell synchronisation 
For synchronization, 50% confluent U2OS cells were treated with 2 mM thymidine 
for 24 h, washed three times with PBS buffer and released into fresh media for 3 h. 
This was followed by nocodazole treatment for 12 h (75 ng/ml). The cells were again 
washed three times with PBS and incubated in fresh media for siRNA transfection. At 
the indicated times, samples were taken and processed for western blots and FACS 
analysis. 
 
Cdt1 purification 
His-Cdt1 was purified as described (Ferenbach et al. 2005). Briefly, His-tagged Cdt1 
was expressed in E. coli, and solubilized from inclusion in 8 M urea and purified on 
Ni-NTA agarose beads. Urea was removed from protein eluate by dialysis in THED 
200 (0.03% Triton, 20 mM HEPES, pH 8, 20% ethylene glycol, 1 mM DTT and 200 
mM KCl). 
 
X. laevis interphase egg extract preparation, replication assays and extraction of 
genomic DNA 
X. laevis eggs were dejelled in buffer (20 mM Tris, pH 8.5, 110 mM NaCl, 5 mM 
DTT) for 5 min, washed with ¼ Marc's modified Ringer (MMR) (5 MMR: 100 mM 
HEPES, pH 7.5, 2 M NaCl, 10 mM KCl, 5 mM MgSO4, 10 mM CaCl2, 0.5 mM 
EDTA) and activated with 1 µg/ml calcium ionophore A23187 in MMR for 5 min. 
The activated eggs were washed with ¼ MMR and then washed three times with ice-
cold S-buffer (50 mM HEPES–KOH, pH 7.5, 0.25 M sucrose, 50 mM KCl, 2.5 mM 
MgCl2, 2 mM β-mercaptoethanol, 15 µg/ml leupeptin). The eggs were packed by 
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spinning and then crushed at 20000 g for 15 min. The cytoplasmic fraction between 
lipid cap and pellet was collected, supplemented with cytochalasin B (40 µg/ml final 
concentration) and centrifuged at 220000 g for 15 min to remove residual debris. The 
cytosolic and membrane fractions were collected and supplemented with 30 mM 
creatine phosphate and 150 mg/ml creatine phosphokinase. Extracts were snap-frozen 
with 3% glycerol in aliquots of 20 µl. For titration experiments (Supplemental Fig. 
S6E) demembranated sperm nuclei (4,000 /μl) were incubated in 20 µl of egg extract 
for 90 min at 23°C. At this time point, 0, 2.5 or 10 ng/µl Cdt1243-620 was added to the 
extracts and incubated for another 90 min in the presence of [α-32P]dATP at 23°C.  
The extracts were then diluted with 20 volumes of EB buffer (50 mM HEPES-KOH, 
pH 7.5, 100 mM KCl, 2.5 mM MgCl2) containing 0.2% (v/v) Triton X-100 to stop 
replication. DNA was digested with 1 mg/ml proteinase K for 2 hours and the DNA 
was extracted with phenol/chloroform and electrophoresed on 0.8% agarose gel. For 
EM sample preparation, demembranated sperm nuclei (4,000 /μl) were incubated in 
300 µl of egg extract for 60 min (with or without Cdt1243-620) for studying re-
replication in 1st S-phase or 150 min (addition of Cdt1243-620 after 90 min) to study Re-
replication in G2. The extracts were diluted with 1 ml of EB buffer, layered onto 1ml 
of EB buffer plus 30% (w/v) sucrose and centrifuged at 3000 g for 10 min at 4 °C. 
The pellets were resuspended in 300 μl of EB buffer, transferred to a 96-well plate 
(100 μl/well), and crosslinked with four cycles of incubation with 10 μg/ml 10 
4,5 ,8-Trimethylpsoralen (TMP) for 5 min on ice in the dark followed by irradiation 
with 366 nm light for 3 min. Genomic DNA was purified by proteinase K and RNase 
A treatment, phenol-chloroform extraction and isopropanol precipitation. The purified 
DNA (20 μg) was digested with NdeI endonuclease, and the replication intermediates 
were enriched on a BND cellulose column before processing for EM.  
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Supplemental Figures 
 
Supplemental Figure S1. Activation of the DNA damage response in Emi1-depleted cells upon completion of 
bulk DNA replication. (A) γH2AX levels in samples in Fig. 1A. Dashed line indicates threshold for γH2AX 
positivity, determined by single cell immunofluorescence staining (Neelsen et al. 2013). (B) Lambda Ladder 
(Biorad, #170-3635) was run along with a positive control for chromosomal breakage (CPT 1mM, 4 h) and with 
one of the samples from Fig. 1E, in identical electrophoretic conditions as in Fig. 1E, to determine the range of 
molecular size of the chromosomal fragments observed. A shorter and a longer exposure are shown. (C) Single cell 
immunofluorescence staining for γH2AX and 53BP1 in samples as in (A). Scale bar: 5 µm. (D) Quantification of 
γH2AX+/53BP1- (grey) and γH2AX+/53BP1+ (black) cells after mock- (siLuc) or Emi1 depletion. Cells with >3 
53BP1 foci and >5 γH2AX foci were scored as positive. (E) Emi1 levels in samples in (C). TFIIH as loading 
control, molecular weight in kDa of nearest protein size marker is indicated. 
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Supplemental Figure S2. Emi1-depletion in U2OS synchronised cells. (A) Emi1 levels in samples in (B, C). 
TFIIH as loading control, molecular weight in kDa of nearest protein size marker is indicated. (B) FACS analysis 
of DNA content (DAPI) of cells at indicated stages of the synchronisation procedure outlined in (C). (C) FACS 
analysis of DNA synthesis (EdU), DNA content (DAPI) and DDR activation (γH2AX) after mock- (siLuc) or 
Emi1 depletion at the indicated time points in synchronised U2OS cells. γH2AX-positive cells in red. The yellow 
and red arrowheads indicate cells with compromised DNA synthesis, and cells arrested after Nocodazole treatment 
with elevated levels of γH2AX, respectively. The presence of this subpopulation of cells that do not recover from 
Nocodazole arrest and display active DDR (red arrowheads) is a side-effect of the synchronization procedure 
coupled with siRNA transfection and impairs the assessment of DDR activation specifically induced by Emi1 
depletion.  
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Supplemental Figure S3. Emi1-depletion in untransformed RPE-1 cells induces checkpoint activation and 
promotes RPA chromatin binding. (A) FACS analysis of DNA synthesis (EdU), DNA content (DAPI) and DDR 
activation (γH2AX) after mock- (siLuc) or Emi1 depletion at the indicated time points in RPE cells. γH2AX-
positive cells in red. The yellow arrowheads indicate cells with compromised DNA synthesis in mid-late S-phase. 
(B) γH2AX levels in samples in (A). Dashed line indicates threshold for γH2AX positivity. (C) ATR- (pCHK1) 
and ATM- (pKAP1) activation, and RPA phosphorylation (RPA2 pS4/S8 and pS33) and total DDR proteins 
(CHK1, KAP1, RPA2) assessed by western blot upon Emi1-depletion. TFIIH as loading control. Molecular weight 
in kDa of nearest protein size marker is indicated. (D) FACS analysis of chromatin-bound RPA and DNA content 
(DAPI) after mock- (siLuc) or Emi1 depletion in RPE cells. 
 
	   92 
   
 
 
Supplemental Figure S4. Accumulation of chromatin-bound RPA in Emi1-depleted U2OS cells. (A) Single 
cell immunofluorescence staining for γH2AX and RPA2 in samples from Fig. 2A and B. The long exposure allows 
detection of physiological chromatin-bound RPA levels in S phase unperturbed cells. (B) Emi1 levels in samples 
in Fig. 2A, B and Supplemental Fig. 4A. 
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Supplemental Figure S5. Depletion of Emi1 promotes frequent fork fusion, but does not detectably interfere 
with the progression of individual replication forks. (A) Labelling protocols for assessment of replication fork 
progression (top, Fig. 3A and Supplemental Fig. S5C, D) and detection of re-replication events (bottom, Fig. 3B–
D) by DNA fiber spreading. (B) Emi1 levels in samples in Fig. 3 and Supplemental Fig. S5C, D. (C) Mean length 
of newly replicated DNA tracts after indicated labelling pulses in mock-depleted cells (siLuc, circles) and 20 h 
after Emi1 depletion (siEmi1 #1, squares). (D) Length of newly replicated tracts in mock-depleted cells (siLuc) 
and 20 h after Emi1 depletion (siEmi1 #1) after indicated labelling pulses as shown in (A). Whiskers: 10-90 
percentile, n = 100. 
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Supplemental Figure S6. Emi1-depletion leads to replication fork reversal. (A, D) Electron micrographs of 
representative replication forks from U2OS cells, 40 h after transfection with siEmi1. Black arrows indicate 
ssDNA gaps. Insets show magnified ssDNA gaps and schemes of fork structure, indicating parental (P) and 
replicated (R) duplexes. Gaps are in (A) on a replicated duplex and in (D) on the parental duplex. (B) Electron 
micrograph of a representative reversed replication fork from U2OS cells, 40 h after transfection with siEmi1. 
Insets show magnified junction and fork structure. In (A, B, D) black and grey lines describe parental and newly 
synthesized DNA strands in the replicated duplexes, respectively. Scale bar: 100nm (= 250bp), 50nm in inset. (C) 
Frequency of reversed replication forks in mock-depleted cells (siLuc) and at the indicated time points after Emi1 
depletion (siEmi1 #1). # RI is the number of analysed replication intermediates. (E) Sperm nuclei re-replication 
assay in Xenopus interphase extracts in G2. The indicated concentrations of Cdt1 were added along with 
[α32P]dATP  90 min after sperm addition (G2) and incubated for further 90 min. After incubation, DNA was 
isolated, separated by neutral agarose gel electrophoresis, and autoradiographed. As control, [α32P]dATP was 
added along with the sperm, and DNA was isolated after 60 min (S). The grey line indicates a cropped lane in the 
gel. 
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Supplemental Figure S7. Geminin-depletion does not visibly interfere with first S-phase completion and 
leads to reduced DNA damage during re-replication. (A) FACS analysis of DNA synthesis (EdU), DNA content 
(DAPI) and DDR activation (γH2AX) after mock- (siLuc) or Geminin depletion at the indicated time points in 
U2OS cells, using identical settings as in Fig. 1A. γH2AX-positive cells in red. (A) FACS analysis of DNA 
synthesis (EdU), DNA content (DAPI) and mitotic marker (H3-pS10) after mock- (siLuc) or Geminin depletion at 
the indicated time points in U2OS cells. H3-pS10-positive cells in cyan. (C) FACS analysis of DDR activation 
(γH2AX) after mock- (siLuc), Geminin- or Emi1 depletion at 40h. Cell cycle distribution (DNA content) at this 
time point can be seen in (B). 
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4. Discussion 
 
Relevance of the biological question 
The main aim of the work presented here is to understand, at a molecular level, how the cell 
deals with obstacles that impair its ability to efficiently and faithfully replicate their genome. DNA 
replication is, in fact, a crucial process, which involves the accurate duplication of the entire 
genetic information. As described in the introduction, numerous impediments may hinder DNA 
replication fork progression, leading to replication stress. In the last two decades, great attention 
has been given to replication stress, as this is regarded as an early, primary cause of 
tumorigenesis, and can be already frequently detected in hyper-proliferative pre-cancerous 
lesions. A second - perhaps counterintuitive - reason why it is of primary importance 
understanding how replication forks deal with genotoxic stress, is that interfering with DNA 
replication is a widely used strategy in cancer treatment, but the molecular mechanisms 
underlying sensitivity or resistance to these treatments are largely elusive.  
Our lab, including the efforts presented in this thesis, has pioneered the use of single-molecule 
analysis of the replication process and the in vivo visualization of replication intermediates, to 
possibly improve our mechanistic understanding of replication stress. The microscopy-based 
techniques we exploited allowed us to study the replication dynamics and DNA structures forming 
during cancer-relevant replication stress. Data from our lab suggest that different chemical insults 
or the activation of proto-oncogenes, lead to stall of the replication fork, and the subsequent 
formation of a four-way junction structure - the reversed fork. This is relevant, as a 
comprehensive understanding of the factors involved in fork remodeling and metabolism, as well 
as their time and modes of action, can be instrumental to design better diagnostic and perhaps 
therapeutic approaches in the coming years. 
 
Oncogene-induced replication stress 
The initial part of this thesis was inspired by previous work published by our lab25, showing that 
overexpressing CYCE or CDC25A in U2OS cells leads to frequent formation of reversed 
replication forks, which are processed by endonucleases MUS81/EME1 into DSB upon cell cycle 
checkpoint deregulation. This is as an important mechanistic aspect that may contribute to 
chromosomal instability in oncogene overexpressing cells and prompted us to extend our studies 
to other proto-oncogenes, in order to find the 'common denominator' that underlies oncogene-
induced replication stress.  
We thus decided to study aberrant activation of c-MYC and H-RAS, two well-studied oncogenes 
clearly contributing to tumourigenesis. Both of them are centrally positioned in the molecular 
circuitry regulating cell growth and as such they have very potent oncogenic activity.  
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To determine whether formation and endonucleolytic processing of reversed forks is a shared 
trait also by these two aggressive proto-oncogenes, we selected two highly proliferative cellular 
systems, U2OS and h-TERT immortalized RPE-1 cell lines. The first is a tumor cell line and as it 
has been used in CYCE and CDC25A overexpression, will serve as control to exclude cellular 
specific effects of replication stress. The second cell line is a primary cell line and represents a 
more physiological context to study the outbreak of tumorigenesis.  
To overexpress c-MYC and H-RAS we explored transient transfection and transduction, two 
techniques that offer the relevant advantage of extending our studies to different kinds of cells. 
Although faster and simpler, transient transfection showed low efficiency of gene uptake and, 
since we want to investigate the early events of oncogene activation, it generally does not allow a 
controlled expression of the genes of interest. Therefore, we decided to stably integrate our 
genes of interest exploiting retroviral transduction. Once the retroviruses carrying the gene of 
interest have been produced, they were used to easily infect different target cells lines. To 
achieve a temporal control of c-MYC and H-RAS activity we used ERTAM- 4-OHT system. Here, 
the gene is highly expressed under the control of the retroviral 5’LTR, but the protein translocates 
to the nucleus and is active only when the cells are exposed to 4-OHT. We characterized the 
efficiency and the fidelity of ERTAM- 4-OHT system by analyzing mainly the activity of c-MYC-
ERTAM in RPE-1 cell line. Time-course immunofluorescence and quantitative real-time RT-PCR 
analysis revealed a significant increase of c-MYC-ERTAM localization and activity in the nucleus 
compared to the EV control, even in the absence of 4-OHT, implying a technical defect of the 
ERTAM system. The 'leakiness' in the nuclear translocation might arise from traces of estrogens in 
the reagents used to grow and manipulate the cells (e.g. traces of phenol red or inefficient 
removal of estrogens from serum). Another possibility is that the concentration of c-MYC-ERTAM 
exceeds the one of HSP90, leaving many fusion proteins free to translocate in the nucleus. 
Collectively, these analyses showed that ERTAM - 4-OHT is not a suitable experimental system for 
precise temporal control of the gene expression.  
To overcome these technical drawbacks, we plan to exploit new overexpression methods. An 
attractive alternative could be tetracycline inducible expression, which has been shown to be very 
effective for CYCE and CDC25A expression25. One of the major benefits of the Tet-inducible 
system is that it allows a varied expression levels of the transgene and offers the possibility to 
rapidly and reversibly switch the transgene on or off at any time point. Another alternative could 
be the use of already existing human cancers that 'naturally' overexpress c-MYC or H-RAS. 
Despite appealing, however, this approach lacks the substantial advantage of inducing oncogene 
activation in a time-controlled manner, and thus to study early effects on DNA replication. 
We plan to resume this part of the thesis as part of a new PhD project. In combination with our 
recent findings discussed bellow, we will investigate replication fork reversal and stability as 
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possible 'common denominator' mechanisms underlying replication stress by different 
oncogenes. 
 
Function of HR factors at replication fork reversal 
The second part of the thesis, recently accepted for publication in Nature Communications113, 
focuses on the events occurring at the replication fork, when DNA replication is stalled by 
nucleotide depletion, leading to reversed fork formation and, in specific genetic background, to 
degradation of newly synthesized strands. 
Our focus has been on the action of BRCA2, RAD51 and MRE11, recognized players of DSBs 
repair via HR. DSB repair requires end-processing and the formation of 3' ssDNA overhangs, for 
which MRE11 nuclease has been implicated. BRCA2 is recruited at sites of DSBs and stimulates 
the loading of RAD51 recombinase on ssDNA, thus initiating homology search. Recent studies 
revealed that these key HR factors play an unexpected function at forks experiencing replication 
stress upon nucleotide depletion: BRCA2 loads and stabilizes RAD51 filaments at stalled forks to 
protect the newly synthesized DNA from MRE11-mediated degradation39,40. This new function 
appears to be essential to ensure correct progression of DNA replication and maintain genome 
stability. Indeed, uncontrolled fork degradation leads to chromosomal instability and has been 
linked to lethality in BRCA2-defective mESCs, as well to sensitivity to chemotherapeutic 
treatments of BRCA-tumors that have bypassed the requirement for HR101,102,108.  
These discoveries, derived from the work of many different laboratories, inspired us to 
hypothesize that reversed forks, which accumulate in response to replication interference and 
very much resemble DSBs, might be the target of nucleolytic degradation in BRCA2-deficient 
cells. 
Our data reveal that these previously reported fork resection events are indeed triggered by fork 
reversal, as - in the absence of BRCA2 protein - the unprotected regressed arms of reversed 
forks act as the entry point for MRE11 degradation. Importantly, we show that this processing 
occurs even in conditions of replication interference that do not completely stall replication fork 
progression (i.e. mild CPT treatments), which better reflect clinically relevant conditions of 
genotoxic stress. Three additional studies performed in different human cell lines (e.g. ovarian 
cancer cells PEO1 and FA cell line EUFA423) and in Xenopus laevis egg extracts using a wide 
range of genotoxic treatments (e.g. CPT, HU, aphidicolin) confirmed this key finding98,114,115. 
Altogether these studies identify the protection of reversed forks by BRCA2 and RAD51 
nucleofilaments as a central and conserved mechanism to prevent unscheduled fork processing 
upon replication stress.  
BRCA2 has been extensively described to act in complex with RAD51. The role of BRCA2 in fork 
protection was previously linked to loading and stabilization of RAD51 on the DNA. We now show 
that, differently from BRCA2, RAD51 is essential for the formation of reversed forks. In line with 
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this finding, depletion of RAD51 did not lead to fork degradation, but surprisingly abolished the 
degradation observed in BRCA2 deficient cells. These data suggest a dual role for RAD51 at 
stalled fork: first, RAD51 mediates the formation of reversed forks in a BRCA2-independent 
manner; subsequently, in complex with BRCA2, it protects these structures from deregulated 
nucleolytic processing. We were able to genetically separate these two RAD51 functions by 
studying fork remodeling in FA patient cells carrying the RAD51T131P mutation. RAD51T131P cannot 
form stable RAD51 filaments as it has deregulated ATPase activity97. Our data suggest that 
stable RAD51 nucleofilaments are required for the protection of reversed forks, but not for their 
formation, as RAD51T131P cells can mediate fork reversal, but are unable to protect them from 
MRE11-dependent degradation. How these unstable RAD51 filaments can drive fork remodeling 
in a BRCA2-independent manner will need further in vivo and biochemical investigations. We 
hypothesize that RAD51 might be loaded on the DNA by other mediators, such as RAD51 
paralogs, which regulate HR by protecting RAD51 filaments against antirecombinase activity116 
and remodel the filaments to stimulate strand exchange117. Intriguingly, these factors have been 
recently implicated in stalled replication fork stability91, but their potential role in fork remodeling 
remains to be tested. Alternatively, this step might be carried out without any mediator, by only 
partial displacement of RPA with short and unstable RAD51 filamente, which may be sufficient to 
prime fork reversal. This hypothesis is supported by ssDNA curtain studies showing that RPA is 
in dynamic equilibrium between free and bound states and few RAD51 nucleation events can 
occur without any mediator resulting in filaments formation118. Moreover, based on data from our 
lab and others, the step of reversed fork formation is assisted by the combined activity of different 
fork remodeling factors, like ZRANB355,115, SMARCAL152,114,115 and HLTF53,115, which might 
facilitate RPA displacement. Last but not least, previous studies have reported two distinct 
pathways of RAD51 assembly at the chromatin: BRCA2-independent during S-phase and 
BRCA2-dependent after IR119. Supported by our findings on the different nature of RAD51 
filaments formed at the fork before fork reversal and on the regressed arm, it is conceivable that 
in the first step RAD51 does not strictly require a loader, because of the reported direct 
interaction with replication apparatus120. Conversely, at DSBs induced by IR and at regressed 
arms - which structurally resemble a DSB - de novo loading of RAD51 may strictly require 
BRCA2.  
 
Similarities and differences between DSBs and regressed arms 
It is possible that the MRN complex-dependent resection that typically occurs on DSB ends also 
takes place at regressed arm. A recent report showed in vivo that - as for DSBs - CtIP is  required 
to initiate the MRE11-dependent degradation of the unprotected regressed arms and, because of 
its limited processivity,  EXO1 contributes to extended fork degradation in BRCA-deficient cells. 
The role of DNA2 in this context seems somewhat limited but may deserve further investigation98. 
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In the absence of RECQ1 - a fork remodeling enzyme which specifically restores normal forks 
from reversed ones58 - the nucleolytic resection of regressed arms is mediated by the combined 
activity of WRN and DNA2, independently from CtIP, MRE11 or EXO157. BOD1L loss is yet 
another condition where the uncontrolled resection of damaged forks and increased genomic 
instability is DNA2, but not MRE11 dependent.93 Moreover, our fiber assay and EM experiments 
show that FA cells carryng RAD51T131P show both MRE11- and DNA2-dependent degradation 
reversed forks (data not shown). Molecular determinants that channel the pathway towards one 
or the other processing pathway are not yet clear. The presence of ssDNA at the regressed arm, 
specific chromatin marks, or proteins bound to the end of the regressed arms - such as Ku70/80 - 
might influence the rate of resection and the type of nuclease recruited, similarly to what 
observed at DSBs80.  
In the context of replication fork stalling, similar to BRCA2, BRCA1 prevents MRE11-mediated 
degradation of reversed forks98,115. However, upon DSBs formation, BRCA1 is well-known to 
promote CtIP- and MRN-dependent resection to initiate HR121. BRCA1 plays a crucial role also in 
the pathway choice between HR and NHEJ, but the loss of the two antagonists in this decision, 
namely 53BP1 or RIF1 in BRCA1-/- cells did not limit the degradation of nascent strand by MRE11 
upon HU fork stalling, suggesting a role for BRCA1 at stalled forks different from the one 
observed at DSB102.  Further investigations are required to clarify the exact role and the dynamics 
of BRCA1 and other proteins shown to be required in stabilization of stalled forks, such as 
FANCD240,90, BOD1L93 and WRNIP189. 
 
Physiological relevance of fork reversal 
The degradation of stalled forks in BRCA2 deficient cells has been shown to cause chromosomal 
instability. Preventing the degradation by inhibiting the activity of MRE11 or impairing its 
recruitment to the fork by PTIP or CHD4 downregulation rescues the chromosomal instability 
detected in HU-treated BRCA2-defective cells. Consistent with published data, we observe an 
increase of breaks and gaps when we treat BRCA2-deficient cells with HU, which decreases 
when MRE11 activity is inhibited or its recruitment is impaired by PTIP or, as we showed now, 
RAD52 downregulation. Surprisingly, however, if we prevent fork degradation by impairing fork 
reversal (e.g. ZRANB3 inactivation) we observed a further increase of chromosomal breakage in 
BRCA2-defective cells, which persisted also when inhibiting MRE11 activity or its recruitment by 
PTIP depletion. These data suggest that this chromosomal instability is not associated with forks 
resection, but most likely with defective repair of DSBs arising upon genotoxic stress in the 
absence of fork reversal. Thus, not all systems that prevent fork degradation in BRCA2-defective 
cells restore genome stability; in fact, we show that abolishing fork reversal during replication 
stress is detrimental for genome stability in BRCA2-defective cells.  
PARP inhibitiors have long been known to aggravate chemosensitivity and genome instability of 
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BRCA-defective cells, mainly by exploiting their DSB repair defect50 and are now either used in 
the clinic or are in the final phases of clinical trials for BRCA2 mutated breast 
(https://www.breastcancertrials.org) and ovarian cancer treatment. Recent reports showed that 
PARP inhibition or its depletion can also suppress the observed fork degradation in BRCA-
defective cells101,102 and the acquisition of PARP inhibitors and cisplatin resistance was 
associated with replication fork protection in Brca2-deficient tumor cells that do not develop Brca2 
reversion mutations.  
PARP inhibition was shown to lower the frequency of reversed forks by deregulating the RECQ1 
activity and to promote replication-dependent chromosomal breakage in combination with 
genotoxic treatment (CPT). Consistent with the requirement of fork reversal to observe fork 
degradation (this thesis), we found that PARP inhibition also prevents fork degradation in BRCA2-
depleted cells upon replication fork stalling, similar to RAD51 or ZRANB3 loss. We next assessed 
chromosomal instability by treating BRCA2-deficient cells with PARP inhibitors and HU and, as 
for ZRANB3 inactivation, we observed a further increase in genome instability compared to 
BRCA2-defective cells treated with HU only. Additional ZRANB3 loss in these conditions did not 
further increase chromosomal breaks, suggesting an epistatic relationship between these two 
ways of fork reversal impairment. Taken together these data strongly suggest that the synthetic 
lethality of PARP inhibition and BRCA2 defects upon replication stress reflects defective fork 
remodeling induced by PARP inhibition. These results provide additional evidence for the 
physiological role of global fork reversal and indicate the factors mediating the formation or 
stabilization of reversed forks as potential therapeutic targets against HR-defective tumors. 
 
Connecting the dots 
Initially we planned to study the role of HR factors in fork remodeling in the context of oncogene-
induced replication stress. As the construction of a suitable system to overexpress c-MYC and H-
RAS was still in progress, we exploited a series of reagents already present in the lab, allowing a 
finely-tuned tetracycline-dependent CYCE overexpression in U2OS. Preliminary experiments 
suggest that prolonged downregulation of BRCA2 per se resulted in reduced fork progression 
rate and DDR activation. In line with a recent report from Maria Jasin lab108, accumulating DNA 
damage in these cells lead them to stall in G1 phase. Interestingly, when we activated the 
oncogene CYCE in BRCA2 downregulated cells, the G1 block was abolished and S phase cells 
displayed impaired DNA replication – as seen by compromised EdU incorporation, impaired 
completion of bulk DNA replication or extensive re-replication. I find these preliminary 
observations intriguing, especially in light of the recently published work. In my opinion these data 
would deserve attention and further investigation, in order to possibly link mechanistically the 
following series of recent observations: 
 
	   102 
(i) Reversed forks are formed in response to CYCE overexpression, as well as upon induction of 
re-replication events caused by origin licensing deregulation25,26. Preliminary experiments 
discussed in this thesis suggest that BRCA2 in these cells limits re-replication and replication 
stress.  
 
(ii) Cyclin E overexpression has been shown to increase replication initiation and conflicts with 
transcription resulting in DNA damage that activates RAD51-mediated recombination23. 
 
(iii) It has been reported that DNA re-replication caused by deregulated origin firing, for example 
by CDT1 overexpression109 or geminin inactivation110, results in replication fork stalling and DSBs 
for which HR is a primary mechanism of repair111.  
 
 (iv) The lab of Thanos Halazonetis has performed a screen in order to select factors implicated in 
DNA synthesis specifically in cells overexpressing CYCE and identified POLD3, a subunit of DNA 
polymerase delta, as well as HR factors, as strictly necessary for cell cycle progression and 
processive DNA synthesis. They propose that BIR repair of damaged replication forks observed 
in CYCE overexpressing cells results in segmental genomic duplication (particularly tandem 
head-to-tail duplications, which is frequently found in breast and ovarian cancer)122. Following up 
on this report, they found that RAD52 is required for G1-to-S-phase transition to facilitate the 
restart of collapsed forks in CYCE-overexpressing cells and propose that RAD52, together with 
POLD3, participates in BIR. Additionally, they identified MUS81, SLX4 and SMARCAL1 – fork 
remodeling and processing enzymes – as being required for S-phase progression in cyclin-E-
overexpressing cells123.  
 
(v) Finally, as discussed above, we report that BRCA2 and RAD51 protect reversed forks from 
extensive nucleolytic degradation. Moreover, we found that RAD52 interacts with MRE11 to 
promote stalled fork degradation and chromosomal breakage in HU treated BRCA2-defective 
cells. Additionally, Alessandro Vindigni lab reported that the resection of the regressed arms 
establishes the substrate for MUS81 cleavage of the stalled forks in BRCA2-deficient cells to 
promote POLD3-dependent fork rescue.   
 
Taken together, these data suggest that nucleotide depletion, replication/transcription conflicts, 
re-replication and/or increased DNA torsional stress induced by genotoxic treatments or 
oncogenes activation lead to the formation of reversed forks by the action of SMARCAL1, 
ZRANB3, HLTF and RAD51. Once formed, reversed forks are protected by BRCA2- and RAD51 
to limit chromosomal instability. Loss of these factors will lead to RAD52-dependent recruitment 
of MRE11 at regressed arm, which is processed by MUS81 and SLX4 into DSB for a BIR repair 
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of the collapsed forks. In order to test this unified hypothesis we could assess resection of the 
stalled forks and DSB formation in CYCE overexpressing cells upon BRCA2 loss. The resection 
and chromatin instability should be rescued by mirin treatment.  
If this is true, unscheduled processing of reversed forks could be proposed as 'common 
denominator' mechanism of tumorigenesis and as such, factors involved in its formation, 
stabilization and processing could represent new potential targets for therapeutic intervention in 
cancer cells that experience replication stress.  
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5. Materials and Methods 	  
Oncogene-induced replication stress 
 
Cell culture, treatments, and transfections  
Human osteosarcoma (U2OS)-derived clones carrying inducible copies of CYCE and CDC25A 
were grown in DMEM supplemented with 10% FCS and 4 µg/ml tetracycline (Sigma-Aldrich, 
T7660). The overexpression of the oncogenes was induced by washing off tetracycline. Retinal 
pigment epithelium (RPE-1) cells were grown in DMEM and 10% FCS, while BJ foreskin 
fibroblasts (kindly provided by Fabrizio d'Adda di Fagagna, IFOM-IEO Campus, Milan, Italy) were 
maintained in MEM medium supplemented with 10% FCS, 10 mM NEAA, 1mM NaPyruvate and 
2 mM Glutamine. During the retroviral transduction Phoenix-AMPHO cells and later U2OS and 
RPE-1 cells carrying c-Myc-ERTAM or H-Ras-ERTAM were grown in phenol free DMEM (Life 
Technologies, 21063-045) supplemented with 10% charcoal stripped FCS (Sigma-Aldrich, 
F6765). Where indicated the cells were treated with 100 nM 4-OHT (Sigma-Aldrich, T5648). The 
treatments was refreshed every day. Treatments with CPT (Sigma-Aldrich, C9911) were carried 
out at the final concentration of 25 nM. 
 
Transient transfection and retrovirus transduction 
For transient oncogene overexpression in U2OS cells, cells were transfected with pBabe (empty 
vector) or plasmid encoding Cdc25A (kindly provided by J. Lukas, Center for Protein Research, 
Copenhagen, Denmark) 24h before collection using FuGENE6 (Promega, E2313) according to 
the manufacturer’s instructions. For depletion experiments, cells were transfected at indicated 
time points before oncogene induction with the indicated siRNA using Lipofectamine RNAiMax 
(Invitrogen, 13778-150) according to the manufacturer’s instructions: 
siLuc   (40 nM; 5′-CGUACGCGGAAUACUUCGATT-3′);  
siBRCA2  (48 h, 40 nM; 5′-UUGACUGAGGCUUGCUCAGUUTT-3′). 
For virus production, about 1.5x106 Phoenix packaging cells were plated 2 days before 
transfection. The cells were transfected with 10 µg of pBabe (empty vector) and pBabe-puro-Myc-
ER (kindly provided by Carla Grandori, Fred Hutchinson Cancer Research Center, Seattle, USA), 
pLNCX2 (empty vector) and pLNCX2-neo-RASV12-ER (kindly provided by Fabrizio d'Adda di 
Fagagna, IFOM-IEO Campus, Milan, Italy) and pLTR-CMV-GFP-puro (kindly provided by 
Raffaella Santoro, Department of Molecular Mechanisms of Disease, University of Zurich, Zurich, 
Switzerland) using the calcium phosphate coprecipitation method. For a 10 cm plate 438 µl of 
H2O, 10 µg of DNA and 61 µl of 2 M CaCl2 were mixed and added dropwise to 500 µl 2xHBS. 
The solution was incubated for 5 min added to the cells. The medium was refreshed 8h and 24h 
after the transfection. Two days after the transfection, the retrovirus-containing supernatants were 
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filtered through 0.45 µm syringe filters and used to infect U2OS and RPE-1 cells. For a more 
efficient infection, 8 mg/ml of polybrene was added to the filtered supernatant. The infection was 
repeated 3h after the first infection. Two rounds of infection were repeated on the next day. The 
cells were selected with 3 µg/ml puromycin (InvivoGen, ant-pr-1) or 3 mg/ml G418 (InvivoGen, 
ant-gn-1). For single clone isolation the cells were highly diluted, plated on a 10 cm dish and 
picked using cloning cylinders.  
 
Western blotting 
Cells were collected and lysed using 2x Laemmli buffer or NP-40 lysis buffer (HEPES 50 mM, 
NaCl 250 mM, EDTA 5 mM, NP-40 1%, DTT 1 mM, proteinase inhibitors (Roche)) for BRCA2 
extraction. Protein amounts were normalized using known concentrations of BSA and protein 
absorbance was measured using Nanodrop technology. Precast gradient 4-15% SDS-gels were 
run at 180 V and proteins were either wet-blotted overnight (30 V, 4 °C) or for 2 h (100 V, 4 °C) at 
room temperature on Nitrocellulose blotting membranes (GE Healthcare). Membranes were 
blocked in 2% ECL (GE Healthcare) in 0.1% TBST (1xTBS supplemented with 0.1% Tween-20) 
for at least 30 min and incubated with primary antibodies over night at 4 °C or at room 
temperature for 4 h in blocking solution and secondary antibodies were added for 1 h at room 
temperature (in blocking solution). Membranes were washed 3 times with 0.1% TBST after 
primary and secondary antibody incubations and detected with ECL detection reagent (GE 
healthcare). Antibodies: c-MYC (Santa Cruz Biotechnology, N-262, sc-764, 1:500); H-RAS (Santa 
Cruz Biotechnology, C-20, sc-520, 1:500); BRCA2 (EMD Millipore, Ab-1, OP 95, 1:500); CycE 
(Santa Cruz Biotechnology, C-19, sc-198; 1:500); RPA2 (Calbiochem, NA19L, 1:1000); TFIIH 
(Santa Cruz Biotechnology, S-19, sc-293, 1:2000), GAPDH (Millipore, MAB374, 1:2000). 
 
 
Extraction of cytoplasmic and nuclear proteins  
Cells were collected (ca 5-10x106 cells) by trypsinization procedure and washed three times with 
ice cold PBS. The cells were centrifuged at 6000 rpm for 5 min at 4°C and 5x packed cell volume 
of cytoplasmic extract buffer (HEPES 10 mM pH 7.9, KCl 10 mM, EDTA 0.1 mM) was added to 
the pellet. The cells were incubated on ice for 5 min and then centrifuged at 3000 rpm for 5 min. 
The supernatant, which correspond to cytoplasmic extract, was collected. The pellet was 
resuspended in 100 µl of cytoplasmic buffer without NP-40 and centrifuged at 3000 rpm for 5 min. 
This procedure was repeated two times. A volume of nuclear buffer (HEPES 20 mM pH 7.9, NaCl 
0.4 M, EDTA 1 mM, Glycerol 25%, Protease Inhibitors (Roche)) equal to volume of the pellet was 
added to the pellet and incubated on ice for 10 min. After the centrifugation at 14000 rpm for 5 
min at 4°C, the supernatant (nuclear extract) was collected. Equal amount of cytoplasmic and 
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nuclear proteins were resolved by electrophoresis using SDS-PAGE electrophorisis and detected 
by western blotting with the indicated antibodies.  
 
Quantitative real-time PCR 
Total RNA was isolated from cells using the Oligotex mRNA Mini Kit (Qiagen). RNA of 500 ng 
was used for complementary DNA (cDNA) synthesis using Transcriptor First Strand cDNA 
Synthesis Kit (Roche). Quantitative real-time SYBR-Green-based PCR reactions were performed 
in triplicate and monitored with the Light Cycler 480 (Roche) system. The following primer pairs 
were used: 
eIF4E:   forward 5' GATGGTATTGAGCCTATGTGG 3'; 
  reverse 5' CAATAAGGCACAGAAGTGTCTC 3'. 
Nucleolin: forward 5' AGAGCAATCAGGCTGGAGTTG 3'; 
  reverse 5' TTCAGTGGTATCCTCAGACAGGC 3'. 
β-actin:  forward 5' CCAACCGCGAGAAGATGA 3'; 
  reverse 5' CCAGAGGCGTACAGGGATAG 3'. 
 
Immunofluorescence and Flow cytometry  
For single-cell immunostaining, cells were treated fixed with 4% formaldehyde/PBS for 15 min at 
room temperature (RT), permeabilized in 0.5% Triton X-100 for 10 min and stained for γH2AX 
(Millipore, Ser139, 05-636, 1:300), CDC25A (Santa Cruz Biotechnology, sc-7389, F-6, 1:300), c-
Myc (Santa Cruz Biotechnology, N-262, sc-764, 1:100) and H-Ras (BD Transduction 
Laboratories, 610001, 1:100), detected by appropriate secondary antibodies, and mounted with 
Vectashield (Vector Laboratories). Cells were imaged using a microscope (model DMRB; Leica) 
equipped with a camera (model DFC360 FX; Leica). Images were taken at 60x, using Leica 
Application Suite 3.3.0.  
For cell cycle analysis by propidium iodide staining cells were washed three times with ice-cold 
PBS (5 min, 400g, 4°C) and fixed with ice-cold 70% ethanol for 30 min. Subsequently the cells 
were washed with PBS, and the DNA was stained with 25 µg/ml propidium iodide (Sigma-Aldrich, 
81845) and 100 µg/ml RNase A (Invitrogen, C35002) at RT for 1h. For flow cytometric analysis of 
γH2AX/EdU/DAPI, cells were labeled for 30 min with 10 µM EdU, harvested, and fixed for 15 min 
with 4% formaldehyde/ PBS. Cells were washed with 1% BSA/PBS, pH 7.4, permeabilized in 
0.5% saponin/1% BSA/PBS and stained with anti- γH2AX antibody for 2h (Millipore, Ser139, 05-
636, 1:500), followed by incubation with a suitable secondary antibody for 30 min. Incorporated 
EdU was labeled according to the manufacturer’s instructions (Life Technologies, #C35002). For 
flow cytometric analysis for c-Myc/DAPI, prior the fixation, the cells were pre-extracted with 0.5% 
TritonX-100 for 10 min on ice. The cells were then fixed for 15 min with 4% formaldehyde/ PBS, 
washed with 1% BSA/PBS, pH 7.4, permeabilized with 0.5% saponin/1% BSA/PBS and stained 
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with anti-c-Myc antibody for 2h (Santa Cruz Biotechnology, N-262, sc-764, 1:125). In both assays 
the DNA was stained with 1 µg/ml DAPI. Samples were measured on a Cyan ADP flow cytometer 
(Beckman Coulter) and analyzed with Summit software v4.3 (Beckman Coulter). 
 
DNA fiber spreading 
Following the depletion of proteins of interest, cells were sequentially pulse-labeled with 30 µM 
CldU (c6891, Sigma-Aldrich) and 250 µM IdU (I0050000, European Pharmacopoeia) for 20 min 
each. The cells were collected and resuspended in PBS at 2.5 × 105 cells per ml. The labeled 
cells were diluted 1:5 (v/v) with unlabeled cells, and 2.5 µl of cells were mixed with 7.5 µl of lysis 
buffer (200 mM Tris-HCl, pH 7.5, 50 mM EDTA, and 0.5% (w/v) SDS) on a glass slide. After 9 
min, the slides were tilted at 15–45°, and the resulting DNA spreads were air dried, fixed in 3:1 
methanol/acetic acid overnight at 4 °C. The fibers were denatured with 2.5 M HCl for 1 h, washed 
with PBS (2x 3 min) and blocked with 0.2% Tween 20 in 1% BSA/PBS for 40 min. The newly 
replicated CldU and IdU tracks were labeled (for 2.5 h in the dark, at RT) with anti-BrdU 
antibodies recognizing CldU (Abcam, ab6326, 1:500) and IdU (BD, B44, 347580, 1:100), followed 
by 1 h incubation with secondary antibodies at RT in the dark: anti–mouse Alexa Fluor 488 
(Invitrogen, A11001, 1:300) and anti–rat Cy3 (Jackson ImmunoResearch Laboratories, Inc., 712-
166-153,1:150,). Images were acquired (IX81; Olympus; objective lenses: LC Plan Fluor 60x, 
1.42 NA oil Olympus BX60 microscope) and analyzed using ImageJ software. The Mann–
Whitney test was applied for statistical analysis using Prism (GraphPad Software). 
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